U.S. patent application number 11/004706 was filed with the patent office on 2005-07-14 for heterocyclic anti-migraine agents.
Invention is credited to Chaturvedula, Prasad V., Chen, Ling, Degnan, Andrew P., Dubowchik, Gene M., Luo, Guanglin, Macor, John E., Tora, George O..
Application Number | 20050153959 11/004706 |
Document ID | / |
Family ID | 34680800 |
Filed Date | 2005-07-14 |
United States Patent
Application |
20050153959 |
Kind Code |
A1 |
Luo, Guanglin ; et
al. |
July 14, 2005 |
Heterocyclic anti-migraine agents
Abstract
The present invention relates to compounds of Formula (I) 1 as
antagonists of calcitonin gene-related peptide receptors
("CGRP-receptor"), pharmaceutical compositions comprising them,
methods for identifying them, methods of treatment using them and
their use in therapy for treatment of neurogenic vasodilation,
neurogenic inflammation, migraine and other headaches, thermal
injury, circulatory shock, flushing associated with menopause,
airway inflammatory diseases, such as asthma and chronic
obstructive pulmonary disease (COPD), and other conditions the
treatment of which can be effected by the antagonism of
CGRP-receptors.
Inventors: |
Luo, Guanglin; (Madison,
CT) ; Chen, Ling; (Middletown, CT) ; Degnan,
Andrew P.; (New Haven, CT) ; Dubowchik, Gene M.;
(Middlefield, CT) ; Macor, John E.; (Guilford,
CT) ; Tora, George O.; (Meriden, CT) ;
Chaturvedula, Prasad V.; (Cheshire, CT) |
Correspondence
Address: |
STEPHEN B. DAVIS
BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT
P O BOX 4000
PRINCETON
NJ
08543-4000
US
|
Family ID: |
34680800 |
Appl. No.: |
11/004706 |
Filed: |
December 3, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60527438 |
Dec 5, 2003 |
|
|
|
Current U.S.
Class: |
514/227.5 ;
514/235.2; 514/235.5; 514/241; 514/252.02; 514/252.03; 514/252.05;
514/252.11; 514/253.01; 514/254.02; 514/318; 514/326; 544/114;
544/124; 544/209; 544/238; 544/295; 544/360; 544/372; 544/405;
544/60; 546/207 |
Current CPC
Class: |
A61P 9/08 20180101; A61P
43/00 20180101; C07D 471/10 20130101; A61P 17/02 20180101; A61P
25/06 20180101; A61P 11/00 20180101; C07D 413/14 20130101; A61P
11/06 20180101; C07D 401/14 20130101; A61P 29/00 20180101 |
Class at
Publication: |
514/227.5 ;
514/252.02; 514/252.03; 514/252.11; 514/253.01; 514/254.02;
514/252.05; 514/318; 514/326; 514/235.2; 514/235.5; 514/241;
544/060; 544/114; 544/124; 544/238; 544/209; 544/295; 544/360;
544/372; 544/405; 546/207 |
International
Class: |
C07D 417/02; C07D
413/02; C07D 049/02; C07D 043/02; A61K 031/541 |
Claims
What is claimed is:
1. A compound of Formula (I) 297or a pharmaceutically acceptable
salt or solvate thereof wherein V is a 5-membered ring selected
from the group consisting of imidazolyl, pyrazolyl, thiazolyl,
isothiazolyl, oxazolyl, furanyl, isoxazolyl, oxadiazolyl,
triazolyl, thiadiazolyl and tetrazolyl; or a 6-membered ring
selected from the group consisting of pyridyl, pyrimidinyl,
triazinyl, pyrazinyl, pyridazinyl and tetrazinyl; or a fused
bicyclic ring system selected from the group consisting of indolyl,
isoindolyl, indazolyl, benzimidazolyl, benzythiazolyl,
triazolopyridinyl, imidazopyridinyl, quinolinyl, isoquinolinyl,
cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl and
benzfuranyl; wherein V is optionally substituted with one to three
of the same or different substituents selected from the group
consisting of C.sub.1-4alkyl, C.sub.1-4alkoxy,
C.sub.1-4hydroxyalkyl, C(O)OC.sub.2-3alkyl, C.sub.1-4alkylcarbonyl,
carboxy, C.sub.1-4alkylcarboxy, trifluoromethyl, halo, cyano,
amino, amido, nitro, carbamoyl, ureido, C.sub.1-4alkylamino,
C.sub.1-4dialkylamino, C.sub.1-4dialkylaminoC.sub.1-2alkyl,
sulphonamide and sulphonyl; and V optionally contains 1 or 2
carbonyls; provided that if t is 1, then V is optionally
substituted with one of the substitutents selected from the group
consisting of halo, C.sub.1-4alkyl, C.sub.1-4alkylidine,
.sub.4alkylidine, C.sub.1-4alkoxy, C.sub.1-4hydroxyalkyl,
C.sub.1-4alkylcarbonyl, trifluoromethyl, halo and cyano; and V
optionally contains 1 or 2 carbonyls; (V').sub.t wherein t is 0 or
1; and V' is selected from the group consisting of
C.sub.3-7cycloalkyl, phenyl, adamantyl, quinuclidyl,
azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl,
dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,
pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,
pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,
pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,
piperidinyl, piperazinyl, morpholino, thiomorpholino and
dioxolanyl; and wherein V' is optionally substituted with 1 or 2 of
the same or different substituents selected from the group
consisting of halo, cyano, C.sub.1-4alkyl, C.sub.1-4haloalkyl,
C.sub.1-4alkoxy, hydroxy, amino, C.sub.3-7cycloalkyl,
C.sub.1-4alkylamino, C.sub.1-4dialkylamino,
(C.sub.1-3alkyl).sub.0-2ureid- o, C(O)OC.sub.2-3alkyl, carboxy,
amido, nitro, phenyl and benzyl; and wherein V' optionally contains
1 or 2 carbonyls; and V and V' are optionally interrupted by
C.sub.1-3alkylene, O, --(CH.sub.2).sub.0-2C(O)--
-(CH.sub.2).sub.0-2--; or --N--C.sub.1-4alkyl, said
C.sub.1-3alkylene being optionally interrupted by or having
attached thereto O, N or S; U is CH.sub.2, O, or NH; Q is
(S.sup.y).sub.sR.sup.3; wherein S.sup.y is C.sub.1-3alkylene or
C.sub.1-3alkylidene and s is 0 or 1; R.sup.3 is R.sup.3a or
R.sup.3b wherein R.sup.3a is (i) a heterocycle having two fused
rings with 5 to 7 members in each of said rings, said heterocycle
containing one to five of the same or different heteroatoms
selected from the group consisting of O, N and S and said
heterocycle optionally containing 1 or 2 carbonyls wherein the
carbon atom of said carbonyl is a member of said fused rings; (ii)
a 4 to 6 membered heterocycle containing one to three of the same
or different heteroatoms selected from the group consisting of O, N
and S, optionally containing 1 to 2 carbonyls, wherein the carbon
atom of said carbonyl is a member of said 4 to 6 membered
heterocycle; (iii) C.sub.3-7cycloalkyl; (iv) carbazolyl, fluorenyl,
phenyl, --O-phenyl, --O--C.sub.1-4alklylene-phenyl, or napthyl; or
(v) C.sub.1-8alkyl, C.sub.2-7alkenyl, --C(O)R.sup.3',
CHC(O)O--R.sup.3', CH(CH.sub.3)C(O)O--R.sup.3', --C(O)O--R.sup.3'
or C.sub.2-7alkynyl; and wherein R.sup.3a is optionally substituted
with 1 to 3 of the same or different substituents selected from the
group consisting of benzyl, phenyl, --O-phenyl,
--O--C.sub.1-3alkylenephenyl, --C.sub.1-3alkylene-OC(- O)-phenyl,
cyano, amino, nitro, halo, C.sub.1-6alkyl,
C.sub.1-3mono-bi-tri-haloalkyl, C.sub.1-3mono-bi-tri-haloalkyloxy,
(C.sub.1-3alkyl).sub.1-2amine, --OR.sup.3', --C(O)R.sup.3',
--C(O)O--R.sup.3', --O--C(O)R.sup.3', --N(R.sup.3').sub.2,
--C(O)N(R.sup.3').sub.2, --N(R.sup.3')C(O)(R.sup.3').sub.2,
--N(R.sup.3')C(O)N(R.sup.3').sub.2, --N(R.sup.3')C(O)OR.sup.3',
--O--C(O)N(R.sup.3').sub.2, --N(R.sup.3')SO.sub.2R.sup.3',
--SO.sub.2N(R.sup.3').sub.2 and --SO.sub.2R.sup.3'; R.sup.3' is H
or --C.sub.1-6alkyl; R.sup.3b is R.sup.3a but is not said phenyl or
said substituted phenyl; provided that if V and V' together form
substitued or unsubstituted imidazol-2-yl or a substituted or
unsubstituted fused bicyclic system containing imidazol-2-yl, then
R.sup.3 is R.sup.3b; D is O, NCN or NSO.sub.2C.sub.1-3alkyl; A is
C, N or CH; m and n are independently 0, 1 or 2; provided that if m
and n are 0, then A is not N; if m is 2, then n is not 2; or if n
is 2, then m is not 2; E is N, CH or C; p is 0 or 1; if p is 1,
then G, J and E together form A.sup.x or A.sup.y; A.sup.x is a
fused heterocycle having two fused rings with 5 to 7 members in
each of said rings, said heterocycle containing one to four of the
same or different heteroatoms selected from the group consisting of
O, N and S; and optionally containing 1 or 2 carbonyls wherein the
carbon atom of said carbonyl is a member of said fused heterocycle;
A.sup.y is a 4 to 6 membered heterocycle containing one to three
heteroatoms selected from the group consisting of O, N and S; and
optionally containing 1 to 2 carbonyls, wherein the carbon atom of
said carbonyl is a member of said 4 to 6 membered heterocycle;
wherein A.sup.x and A.sup.y are optionally substituted with
C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-4haloalkyl, cyano,
C.sub.3-7cycloalkyl, phenyl, halophenyl, halo, furanyl, pyrrolyl,
pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,
piperidinyl, piperazinyl or morpholino; or if p is 0 such that G
and J are each attached to A, then A is C, and G, J and A together
form a spirocyclic ring system with said rings of said system
containing A and wherein GJA is A.sup.x or A.sup.y.
2. A compound according to claim 1 wherein m is 1 and n is 1.
3. A compound according to claim 1 wherein p is 1.
4. A compound according to claim 1 wherein p is 1 and E is N.
5. A compound according to claim 1 wherein p is 1 and E is C.
6. A compound according to claim 1 wherein p is 1 and E is CH.
7. A compound according to claim 1 wherein p is 1 and G, J and A
form a A.sup.x.
8. A compound according to claim 1 wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members.
9. A compound according to claim 1 wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
3,4-dihydro-1H-quinazolin-2-one.
10. A compound according to claim 1 wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
3,4-dihydro-1H-quinazolin-2-one optionally halogenated.
11. A compound according to claim 1 wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)- -yl.
12. A compound according to claim 1 wherein p is 0.
13. A compound according to claim 1 wherein p is 0 and G, J and A
form a A.sup.x.
14. A compound according to claim 1 wherein p is 0 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members and where said fused heterocycle
forms a spirocyclic ring system containing A.
15. A compound according to claim 1 wherein p is 0 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members, wherein one of said 6-membered
rings, which contains A, further contains a nitrogen and an oxygen
which are interrupted by a carbonyl said oxygen attached to A and
wherein said fused heterocycle forms a spirocyclic ring system
containing A.
16. A compound according to claim 1 wherein s is 1 and S.sup.y is
methylene.
17. A compound according to claim 1 wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a.
18. A compound according to claim 1 wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is a heterocycle
having two fused rings, one of said fused rings having six members
and being attached to S.sup.y and the other of said rings having 5
members and containing two nitrogens.
19. A compound according to claim 1 wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is
7-methyl-1H-indazol-5-yl.
20. A compound according to claim 1 wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is
7-ethyl-3-methyl-1H-indazol-5-yl.
21. A compound according to claim 1 wherein D is O and U is O.
22. A compound according to claim 1 wherein D is O and U is
CH.sub.2.
23. A compound according to claim 1 wherein D is O and U is NH.
24. A compound according to claim 1 wherein t is 0.
25. A compound according to claim 1 wherein t is 1.
26. A compound according to claim 1 wherein t is 1 and V' is
selected from the group consisting of C.sub.3-7cycloalkyl, phenyl,
tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrrolinyl,
pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,
pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,
pyridyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl,
morpholino and thiomorpholino and dioxolanyl.
27. A compound according to claim 1 wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl.
28. A compound according to claim 1 wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl and V' is substituted with 1 or 2 of the same or
different substituents selected from the group consisting of halo,
cyano, C.sub.1-4alkyl, C.sub.1-4haloalkyl, C.sub.1-4alkoxy,
hydroxy, amino, C.sub.3-7cycloalkyl, C.sub.4alkylamino,
C.sub.1-4dialkylamino, (C.sub.1-3alkyl).sub.0-2ureido,
C(O)OC.sub.2-3alkyl, carboxy, amido, nitro, phenyl and benzyl.
29. A compound according to claim 1 wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl and V' is substituted with 1 or 2 of the same or
different substituents selected from the group consisting of
C.sub.1-4dialkylamino, C(O)OC.sub.2-3alkyl, carboxy, amido, nitro
and phenyl.
30. A compound according to claim 1 wherein V is said 5-membered
ring.
31. A compound according to claim 1 wherein V is said 6-membered
ring.
32. A compound according to claim 1 wherein V is said fused
bicyclic ring system.
33. A compound according to claim 1 wherein V is furanyl,
imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine,
quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl,
triazolopyridinyl or imidazopyridinyl.
34. A compound according to claim 1 wherein V contains a
carbonyl.
35. A compound according to claim 1 wherein V is furanyl,
imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine,
quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl or
[1,2,4]Triazolo[4,3-a]pyrid- in-3-yl or
H-Imidazo[1,5-a]pyridin-3-yl).
36. A compound according to claim 1 wherein V and V' are
interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2--.
37. A compound according to claim 1 wherein V and V' are
interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2-- wherein said
interrupting substituents are unsubstituted.
38. A compound according to claim 1 wherein s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is an optionally
C.sub.1-3alkyl-substituted indazolyl; U is CH.sub.2, O, or NH; D is
O; A is CH; m and n are each 1; E is N; p is 1; and G, J and E
together form A.sup.x, wherein A.sup.x is an optionally halogenated
dihydroquinazolinone.
39. A compound according to claim 1 wherein V is furanyl,
imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine,
quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl,
triazolopyridinyl or imidazopyridinyl; t is 0 or 1; V' is selected
from the group consisting of phenyl, pyridyl and piperidinyl and V'
is substituted with 1 or 2 of the same or different substituents
selected from the group consisting of C.sub.1-4dialkylamino,
C(O)OC.sub.2-3alkyl, carboxy, amido, nitro and phenyl; wherein V
and V' are interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2-- wherein said
interrupting substituents are unsubstituted; s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is an optionally
C.sub.1-3alkyl-substituted indazolyl; U is CH.sub.2, O, or NH; D is
O; A is CH; m and n are each 1; E is N; p is 1; and G, J and E
together form A.sup.x, wherein A.sup.x is an optionally halogenated
dihydroquinazolinone.
40.
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-pipe-
ridin-4-yl}-3,4-dihydro-1H-quinazolin-2-one;
(.+-.)-3-{1-[3-(3-Benzyl-[1,2-
,4]oxadiazol-5-yl)-4-(7-methyl-1H-indazol-5-yl)-butyryl]-piperidin-4-yl}-3-
,4-dihydro-1H-quinazolin-2-one;
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)--
3-(3-piperidin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl}--
3,4-dihydro-1H-quinazolin-2-one;
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-
-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1-
H-quinazolin-2-one;
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-methyl--
[1,2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin--
2-one;
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-pyridin-4-ylmethyl-[-
1,2,4]oxadiazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-
-one;
(.+-.)-3-{1-[3-(3-Dimethylaminomethyl-[1,2,4]oxadiazol-5-yl)-4-(7-me-
thyl-1H-indazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-
-one;
(.+-.)-3-{1-[3-(3-Benzyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1H-indaz-
ol-5-yl)-butyryl]-4,4'-piperidinyl}-1',2'-dihydro-2'-oxospiro-[4H-3',1-ben-
zoxazine;
(.+-.)-3-{1-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1H-i-
ndazol-5-yl)-butyryl]-4,4'-piperidinyl}-1',2'-dihydro-2'-oxospiro-[4H-3',
1-benzoxazine;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-
-1-carboxylic acid
[1-(3-benzyl-[1,2,4]oxadiazol-5-yl)-2-(7-methyl-1H-inda-
zol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-pi-
peridine-1-carboxylic acid
[2-(7-methyl-1H-indazol-5-yl)-1-(3-methyl-[1,2,-
4]oxadiazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin--
3-yl)-piperidine-1-carboxylic acid
[2-(7-methyl-1H-indazol-5-yl)-1-(3-pyri-
din-4-ylmethyl-[1,2,4]oxadiazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid
[1-(3-dimethylaminomethyl-[1,2,4]oxadiazol-5-yl)-2-(7-methyl-1H-inda-
zol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-pi-
peridine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tet-
razol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)--
piperidine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(phen-
ethyl-1H-tetrazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quina-
zolin-3-yl)-piperidine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-indazol-5-
-yl)-1-(2-phenethyl-2H-tetrazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1-methyl-1H-tetrazol-5-yl)--
ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-
-carboxylic acid
[1-(1-benzyl-1H-tetrazol-5-yl)-2-(7-ethyl-3-methyl-1H-ind-
azol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-p-
iperidine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-pyridi- n-4-yl
methyl-1H-tetrazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro--
2H-quinazolin-3-yl)-piperidine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-i-
ndazol-5-yl)-1-(2-oxo-2Phenethyl-2H-tetrazol-5-yl)-ethyl]-amide;
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicac-
id
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-[1-(2-oxo-2-phenyl-ethyl)-1H-te-
trazol-5-yl)-ethyl]-amide;
(.+-.)-3-(1-(3-(4-Ethylpyridin-2-yl)-4-(7-methy-
l-1H-indazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one-
;
(.+-.)-8-Fluoro-3-(1-(4-(7-methyl-1H-indazol-5-yl)-3-(pyridin-2-yl)butan-
oyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(pyridin-2-yl)butanoyl)piperi-
din-4-yl)quinolin-2(1H)-one;
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(-
3-methylpyridin-2-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)--
one;
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(5-methylpyridin-2-yl)but-
anoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
(.+-.)-3-(1-(3-(5-(Hydroxymethyl)pyridin-2-yl)-4-(7-methyl-1H-indazol-5-y-
l)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
(.+-.)-6-(1-(7-Methyl-1H-indazol-5-yl)-4-oxo-4-(4-(2-oxo-1,2-dihydroquina-
zolin-3(4H)-yl)piperidin-1-yl)butan-2-yl)nicotinaldehyde;
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(5-(piperidin-1-ylmethyl)pyri-
din-2-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
(.+-.)-N-(1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl)-4-(2-oxo-1,-
2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(4-nitropyridin-2-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(4-Fluoropyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(-
2-oxo-1,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(quinolin-2-yl)ethyl)-4-(2-oxo-1-
,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-(7-methyl-1-
H-indazol-5-yl)-1-(quinolin-2-yl)ethyl)piperidine-1-carboxamide;
N-(1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-d-
ihydroquinolin-3-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-ind-
azol-5-yl)-1-(6-phenylpyridin-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3-
(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-
-(6-methylpyridin-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pipe-
ridine-1-carboxamide;
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazo-
l-5-yl)ethyl-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-
-carboxylate;
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)e-
thyl-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-1-(6-tert-Butoxypyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl-4--
(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-2-(7-Methyl-1H-indazol-5-yl)-1-(6-oxo-1,6-dihydropyridin-2-yl)ethy-
l 4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-1-(6-Isobutylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxylat- e;
(.+-.)-1-(6-(3,5-Difluorobenzyl)pyridin-2-yl)-2-(7-methyl-1H-indazol-5--
yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-car-
boxylate;
(.+-.)-1-(6-Cyanopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate-
;
(.+-.)-1-(4-(Hydroxymethyl)pyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)eth-
yl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-1-(4-Formylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-2-(2-(7-Methyl-1H-indazol-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazolin--
3(4H)-yl)piperidine-1-carbonyloxy)ethyl)isonicotinic acid;
(.+-.)-2-(7-Methyl-1H-indazol-5-yl)-1-(4-(piperidine-1-carbonyl)pyridin-2-
-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate- ;
N-(1-(isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2--
dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)-N-(1-(isoquinolin-3-yl-
)-2-(7-methyl-1H-indazol-5-yl)ethyl)piperidine-1-carboxamide;
1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate-
; 1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
2-(7-methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
2-(7-methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate-
; 1-(Furan-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroqui- nazolin-3(4H)-yl)piperidine-1-carboxylate;
2-(7-Methyl-1H-indazol-5-yl)-1-- (pyridin-4-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-c- arboxylate;
2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-3-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-3-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate-
; 1-(Furan-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-d-
ihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
2-(7-Methyl-1H-indazol-5-yl)-1-(quinolin-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3 (4H)-yl)piperidine-1-carboxylate;
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate;
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate-
; 1-(Benzofuran-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(.+-.)-N-(1-(1H-Imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-ox-
o-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(1-Methyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl-
)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(1-Benzyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl-
)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(1-(3-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol--
5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxam- ide;
(.+-.)-N-(1-(1-(3,5-Difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H--
indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-c-
arboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-phenethyl-1H-imida-
zol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbo-
xamide;
(.+-.)-N-(1-(1-(2-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-i-
ndazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-ca-
rboxamide;
(.+-.)-N-(1-(1-(4-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1-
H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-
-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(pyridin-4-ylmet-
hyl)-1H-imidazol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piper-
idine-1-carboxamide;
(.+-.)-N-(1-(1-(3-Cyanobenzyl)-1H-imidazol-2-yl)-2-(7-
-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pip-
eridine-1-carboxamide;
(.+-.)-N-(1-(1-(4-tert-Butylbenzyl)-1H-imidazol-2-y-
l)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide;
(.+-.)-3-((2-(2-(7-Methyl-1H-indazol-5--
yl)-1-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamido)et-
hyl)-1H-imidazol-1-yl)methyl)benzoic acid;
(.+-.)-N-(1-(1-(3-Carbamoylbenz-
yl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-(2-oxo-1,2-dihydr-
oquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(R)-1-(1-(3,5-difluorobenzy-
l)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(2-nitrophenyl)-1H-imidazol-2-
-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamid-
e;
(R)-1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol--
5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(2-nitrophenyl)-1H-imidazol-2-
-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamid-
e;
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3[4H]-yl)-N-(2{7-methyl--
1H-indazol-5-yl}-1-{1H-tetrazol-5-yl}ethyl)piperidin-1-carboxamide;
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-[7-methyl-1-
H-indazol-5-yl]-1-[1-(piperidin-4-ylmethyl)-1H-tetrazol-5-yl]ethyl)piperid-
in-1-carboxamide;
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-
-N-(2-[7-methyl-1H-indazol-5-yl]-1-[2-(piperidin-4-ylmethyl)-1H-tetrazol-5-
-yl]ethyl)piperidin-1-carboxamide;
(.+-.)-N-(1-([1,2,4]Triazolo[4,3-a]pyri-
din-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(8-fluoro-2-oxo-1,2-dihydro-
quinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-ind-
azol-5-yl)-1-(1-neopentyl-1H-tetrazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquin-
azolin-3(4H)-yl)piperidine-1-carboxamide;
(R)-N-(1-(H-Imidazo[1,5-a]pyridi-
n-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin--
3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(4-Bromo-1H-imidazol-2-yl)--
2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl-
)piperidine-1-carboxamide;
(.+-.)-N-(1-(4,5-Dibromo-1H-imidazol-2-yl)-2-(7-
-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pip-
eridine-1-carboxamide;
(.+-.)-N-(1-(1-(3,5-Difluorobenzyl)-5-bromo-1H-imid-
azol-2-yl)-2-(7-methyl-2H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazol-
in-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(1-(3-Fluorobenzyl)-4-me-
thyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dih-
ydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(4-Methyl-1H-
-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroqui-
nazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazo-
l-5-yl)-1-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-yl)ethyl)-4-(2-oxo-1,2-dih-
ydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-
-indazol-5-yl)-1-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-yl)ethyl)-4-(2-oxo--
1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide;
(.+-.)-N-(1-(1-((2-Chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)--
2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl-
)piperidine-1-carboxamide;
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-((2-
-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroqu-
inazolin-3(4H)-yl)piperidine-1-carboxamide;
3-(1-(3-(1-(4-tert-Butylbenzyl-
)-1H-imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-indazol-5-yl)butanoyl)pip-
eridin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
3-(1-(3-(1-(4-tert-Butylbenz-
yl)-1H-imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-indazol-5-yl)butanoyl)p-
iperidin-4-yl)-8-fluoro-3,4-dihydroquinazolin-2(1H)-one;
3-(1-(4-(7-Methyl-3a,7a-dihydro-1H-indazol-5-yl)-3-(1-(pyridin-4-ylmethyl-
)-1H-imidazol-2-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-on-
e;
3-(1-(3-(1H-Benzo[d]imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-indazol-
-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
3-(1-(3-(1-Ethyl-1H-benzo[d]imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-i-
ndazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one;
(R)-1-(3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-1H-indazol-5--
yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate;
(R)-2-(7-Methyl-1H-indazol-5-yl)-1-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl-
)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate;
(R)-2-(7-Methyl-1H-indazol-5-yl)-1-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl-
)ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate;
or
(R)-1-(3-(Ethoxycarbonyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-1H-indazol-5--
yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate; or a
pharmaceutically acceptable salt or solvate thereof.
41. A compound selected from the group consisting of Examples 1-103
having an IC50 of less than 10 nM.
42. A pharmaceutical composition comprising a compound according to
claim 1.
43. A method of treating migraine in a patient in need thereof
comprising the administration of an anti-migraine effective amount
of a pharmaceutical composition comprising a compound according to
claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a non-provisional application which claims the
benefit of U.S. Provisional Application No. 60/527,438 filed Dec.
5, 2003.
FIELD OF THE INVENTION
[0002] The present invention relates to novel small molecule
antagonists of calcitonin gene-related peptide receptors
("CGRP-receptor"), pharmaceutical compositions comprising them,
methods for identifying them, methods of treatment using them and
their use in therapy for treatment of neurogenic vasodilation,
neurogenic inflammation, migraine, cluster headache and other
headaches, thermal injury, circulatory shock, flushing associated
with menopause, airway inflammatory diseases, such as asthma and
chronic obstructive pulmonary disease (COPD), and other conditions
the treatment of which can be effected by the antagonism of
CGRP-receptors.
BACKGROUND OF THE INVENTION
[0003] Calcitonin gene-related peptide (CGRP) is a naturally
occurring 37-amino-acid peptide first identified in 1982 (Amara, S.
G. et al, Science 1982, 298, 240-244). Two forms of the peptide are
expressed (.alpha.CGRP and .beta.CGRP) which differ by one and
three amino acids in rats and humans, respectively. The peptide is
widely distributed in both the peripheral (PNS) and central nervous
system (CNS), principally localized in sensory afferent and central
neurons, and displays a number of biological effects, including
vasodilation.
[0004] When released from the cell, CGRP binds to specific cell
surface G protein-coupled receptors and exerts its biological
action predominantly by activation of intracellular adenylate
cyclase (Poyner, D. R. et al, Br J Pharmacol 1992, 105, 441-7; Van
Valen, F. et al, Neurosci Lett 1990, 119, 195-8.). Two classes of
CGRP receptors, CGRP.sub.1 and CGRP.sub.2, have been proposed based
on the antagonist properties of the peptide fragment CGRP (8-37)
and the ability of linear analogues of CGRP to activate CGRP.sub.2
receptors (Juaneda, C. et al. TiPS 2000, 21, 432-438). However,
there is lack of molecular evidence for the CGRP.sub.2 receptor
(Brain, S. D. et al, TiPS 2002, 23, 51-53). The CGRP.sub.1 receptor
has three components: (i) a 7 transmembrane calcitonin
receptor-like receptor (CRLR); (ii) the single transmembrane
receptor activity modifying protein type one (RAMP1); and (iii) the
intracellular receptor component protein (RCP) (Evans B. N. et al.,
J. Biol. Chem. 2000, 275, 31438-43). RAMP1 is required for
transport of CRLR to the plasma membrane and for ligand binding to
the CGRP-receptor (McLatchie, L. M. et al, Nature 1998, 393,
333-339). RCP is required for signal transduction (Evans B. N. et
al., J. Biol. Chem. 2000, 275, 31438-43). There are known
species-specific differences in binding of small molecule
antagonists to the CGRP-receptor with typically greater affinity
seen for antagonism of the human receptor than for other species
(Brain, S. D. et al, TiPS 2002, 23, 51-53). The amino acid sequence
of RAMP1 determines the species selectivity, in particular, the
amino acid residue Trp74 is responsible for the phenotype of the
human receptor (Mallee et al. J Biol Chem 2002, 277, 14294-8).
[0005] Inhibitors at the receptor level to CGRP are postulated to
be useful in pathophysiologic conditions where excessive CGRP
receptor activation has occurred. Some of these include neurogenic
vasodilation, neurogenic inflammation, migraine, cluster headache
and other headaches, thermal injury, circulatory shock, menopausal
flushing, and asthma. CGRP receptor activation has been implicated
in the pathogenesis of migraine headache (Edvinsson L. CNS Drugs
2001;15(10):745-53; Williamson, D. J. Microsc. Res. Tech. 2001, 53,
167-178; Grant, A. D. Brit. J. Pharmacol. 2002, 135, 356-362.).
Serum levels of CGRP are elevated during migraine (Goadsby P J, et
al. Ann Neurol 1990;28: 183-7) and treatment with anti-migraine
drugs returns CGRP levels to normal coincident with alleviation of
headache (Gallai V. et al. Cephalalgia 1995; 15: 384-90).
Migraineurs exhibit elevated basal CGRP levels compared to controls
(Ashina M, et al., Pain. 2000;86(1-2):133-8.2000). Intravenous CGRP
infusion produces lasting headache in migraineurs (Lassen L H, et
al. Cephalalgia. 2002 February;22(1):54-61). Preclinical studies in
dog and rat report that systemic CGRP blockade with the peptide
antagonist CGRP (8-37) does not alter resting systemic hemodynamics
nor regional blood flow (Shen, Y-T. et al, J Pharmacol Exp Ther
2001, 298, 551-8). Thus, CGRP-receptor antagonists may present a
novel treatment for migraine that avoids the cardiovascular
liabilities of active vasoconstriction associated with
non-selective 5-HT.sub.1B/1D agonists, `triptans` (e.g.,
sumatriptan). See Olesen, et al., New England Journal of Medicine,
2004, 350 (11), 1104-1110.
[0006] A number of non-peptidic, small molecule CGRP-receptor
antagonists have been recently reported. WO 97/09046 and
equivalents disclose inter alia quinine and quinidine related
compounds which are ligands, in particular antagonists, of
CGRP-receptor. WO 98/09630 and WO 98/56779 and equivalents disclose
inter alia variously substituted, nitrobenzamide compounds as
CGRP-receptor antagonists. WO 01/32649, WO 01/49676, and WO
01/32648 and equivalents disclose inter alia a series of
4-oxobutanamides and related cyclopropane derivatives as
CGRP-receptor antagonists. WO 00/18764, WO 98/11128 and WO 00/55154
and equivalents disclose inter alia benzimidazolinyl piperidines as
antagonists to CGRP-receptor. Unrelated to CGRP, a series of
somatostatin antagonists have been disclosed in WO 99/52875 and WO
01/25228 and equivalents. See also U.S. Pat. No. 6,344,449, U.S.
Pat. No. 6,313,097, U.S. Pat. No. 6,521,609, U.S. Pat. No.
6,552,043, U.S. 20030181462, U.S. 20030191068 and WO 03/076432 and
related applications. Yet other CGRP-receptor antagonist and
related applications include U.S. 20030139417A1, U.S. 20030181462,
U.S. 20030191068A1, U.S. 20030212057A1, U.S. 20030236282A1, U.S.
20040014679A1, U.S. 20040076587A1, U.S. 20040132716A1, U.S.
20040192729A1, WO2004082602A2, WO2004082605A2, WO2004082678A1,
WO2004083187A1, WO2004092168A1, WO2004092166A2 and WO2004091514A2.
A great need for the development of novel CGRP-receptor antagonists
effective for the treatment of neurogenic inflammation, migraine
and other disorders exists.
SUMMARY OF THE INVENTION
[0007] Thus according to a first embodiment of the first aspect of
the present invention are provided compounds of Formula (I) 2
[0008] or pharmaceutically acceptable salts or solvates thereof
wherein
[0009] V is
[0010] a 5-membered ring selected from the group consisting of
imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl,
isoxazolyl, oxadiazolyl, triazolyl, thiadiazolyl and tetrazolyl;
or
[0011] a 6-membered ring selected from the group consisting of
pyridyl, pyrimidinyl, triazinyl, pyrazinyl, pyridazinyl and
tetrazinyl; or
[0012] a fused bicyclic ring system selected from the group
consisting of indolyl, isoindolyl, indazolyl, benzimidazolyl,
benzythiazolyl, triazolopyridinyl, imidazopyridinyl, quinolinyl,
isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl
and benzfuranyl;
[0013] wherein V is optionally substituted with one to three of the
same or different substituents selected from the group consisting
of C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-4hydroxyalkyl,
C(O)OC.sub.2-3alkyl, C.sub.1-4alkylcarbonyl, carboxy,
C.sub.1-4alkylcarboxy, trifluoromethyl, halo, cyano, amino, amido,
nitro, carbamoyl, ureido, C.sub.1-4alkylamino,
C.sub.1-4dialkylamino, C.sub.1-4dialkylaminoC.sub.1-2alkyl,
sulphonamide and sulphonyl; and
[0014] V optionally contains 1 or 2 carbonyls;
[0015] provided that if t is 1, then V is optionally substituted
with one of the ubstitutents selected from the group consisting of
halo, C.sub.1-4alkyl, C.sub.1-4alkylidine, .sub.4alkylidine,
C.sub.1-4alkoxy, C.sub.1-4hydroxyalkyl, C.sub.1-4alkylcarbonyl,
trifluoromethyl, halo and cyano; and
[0016] V optionally contains 1 or 2 carbonyls;
[0017] (V').sub.t wherein t is 0 or 1; and
[0018] V' is selected from the group consisting of
C.sub.3-7cycloalkyl, phenyl, adamantyl, quinuclidyl,
azabicyclo[2.2.1]heptyl, azetidinyl, tetrahydrofuranyl, furanyl,
dioxolanyl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl,
pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,
pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,
pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,
piperidinyl, piperazinyl, morpholino, thiomorpholino and
dioxolanyl; and wherein
[0019] V' is optionally substituted with 1 or 2 of the same or
different substituents selected from the group consisting of halo,
cyano, C.sub.1-4alkyl, C.sub.1-4haloalkyl, C.sub.1-4alkoxy,
hydroxy, amino, C.sub.3-7cycloalkyl, C.sub.1-4alkylamino,
C.sub.1-4dialkylamino, (C.sub.1-3alkyl).sub.0-2ureido,
C(O)OC.sub.2-3alkyl, carboxy, amido, nitro, phenyl and benzyl; and
wherein
[0020] V' optionally contains 1 or 2 carbonyls; and
[0021] V and V' are optionally interrupted by C.sub.1-3alkylene, O,
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2--; or
--N--C.sub.1-4alkyl, said C.sub.1-3alkylene being optionally
interrupted by or having attached thereto O, N or S;
[0022] U is CH.sub.2, O, or NH;
[0023] Q is (S.sup.y).sub.sR.sup.3;
[0024] S.sup.y is C.sub.1-3alkylene or C.sub.1-3alkylidene and s is
0 or 1;
[0025] R.sup.3 is R.sup.3a or R.sup.3b
[0026] wherein
[0027] R.sup.3a is
[0028] (i) a heterocycle having two fused rings with 5 to 7 members
in each of said rings, said heterocycle containing one to five of
the same or different heteroatoms selected from the group
consisting of O, N and S and said heterocycle optionally containing
1 or 2 carbonyls wherein the carbon atom of said carbonyl is a
member of said fused rings;
[0029] (ii) a 4 to 6 membered heterocycle containing one to three
of the same or different heteroatoms selected from the group
consisting of O, N and S, optionally containing 1 to 2 carbonyls,
wherein the carbon atom of said carbonyl is a member of said 4 to 6
membered heterocycle;
[0030] (iii) C.sub.3-7cycloalkyl;
[0031] (iv) carbazolyl, fluorenyl, phenyl, --O-phenyl,
--O--C.sub.1-4alklylene-phenyl, or napthyl; or
[0032] (v) C.sub.1-8alkyl, C.sub.2-7alkenyl, --C(O)R.sup.3',
CHC(O)O--R.sup.3', CH(CH.sub.3)C(O)O--R.sup.3', --C(O)O--R.sup.3'
or C.sub.2-7alkynyl; and
[0033] wherein R.sup.3a is optionally substituted with 1 to 3 of
the same or different substituents selected from the group
consisting of benzyl, phenyl, --O-phenyl,
--O--C.sub.1-3alkylenephenyl, --C.sub.1-3alkylene-OC(- O)-phenyl,
cyano, amino, nitro, halo, C.sub.1-6alkyl,
C.sub.1-3mono-bi-tri-haloalkyl, C.sub.1-3mono-bi-tri-haloalkyloxy,
(C.sub.1-3alkyl).sub.1-2amine, --OR.sup.3', --C(O)R.sup.3',
--C(O)O--R.sup.3', --O--C(O)R.sup.3', --N(R.sup.3').sub.2,
--C(O)N(R.sup.3').sub.2, --N(R.sup.3')C(O)(R.sup.3').sub.2,
--N(R.sup.3')C(O)N(R.sup.3').sub.2, --N(R.sup.3')C(O)OR.sup.3',
--O--C(O)N(R.sup.3').sub.2, --N(R.sup.3')SO.sub.2R.sup.3',
--SO.sub.2N(R.sup.3').sub.2 and --SO.sub.2R.sup.3';
[0034] R.sup.3' is H or --C.sub.1-6alkyl;
[0035] R.sup.3b is R.sup.3a but is not said phenyl or said
substituted phenyl;
[0036] provided that if V and V' together form substitued or
unsubstituted imidazol-2-yl or a substituted or unsubstituted fused
bicyclic system containing imidazol-2-yl, then R.sup.3 is
R.sup.3b;
[0037] D is O, NCN or NSO.sub.2C.sub.1-3alkyl;
[0038] A is C, N or CH;
[0039] m and n are independently 0, 1 or 2;
[0040] provided that
[0041] if m and n are 0, then A is not N;
[0042] if m is 2, then n is not 2; or
[0043] if n is 2, then m is not 2;
[0044] E is N, CH or C;
[0045] p is 0 or 1;
[0046] if p is 1, then G, J and E together form A.sup.x or
A.sup.y;
[0047] A.sup.x is a fused heterocycle having two fused rings with 5
to 7 members in each of said rings, said heterocycle containing one
to four of the same or different heteroatoms selected from the
group consisting of O, N and S; and
[0048] optionally containing 1 or 2 carbonyls wherein the carbon
atom of said carbonyl is a member of said fused heterocycle;
[0049] A.sup.y is a 4 to 6 membered heterocycle containing one to
three heteroatoms selected from the group consisting of O, N and S;
and
[0050] optionally containing 1 to 2 carbonyls, wherein the carbon
atom of said carbonyl is a member of said 4 to 6 membered
heterocycle;
[0051] wherein A.sup.x and A.sup.y are optionally substituted with
C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-4haloalkyl, cyano,
C.sub.3-7cycloalkyl, phenyl, halophenyl, halo, furanyl, pyrrolyl,
pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,
piperidinyl, piperazinyl or morpholino; or
[0052] if p is 0 such that G and J are each attached to A, then A
is C, and G, J and A together form a spirocyclic ring system with
said rings of said system containing A and wherein GJA is A.sup.x
or A.sup.y.
[0053] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein m is 1 and n is 1.
[0054] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1.
[0055] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and E is N.
[0056] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and E is C.
[0057] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and E is
CH.
[0058] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and G, J and A
form a A.sup.x.
[0059] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members.
[0060] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
3,4-dihydro-1H-quinazolin-2-one.
[0061] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
3,4-dihydro-1H-quinazolin-2-one optionally halogenated.
[0062] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 1 and G, J and A
form a A.sup.x and wherein A.sup.x is
8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)- -yl.
[0063] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 0.
[0064] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 0 and G, J and A
form a A.sup.x.
[0065] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 0 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members and where said fused heterocycle
forms a spirocyclic ring system containing A.
[0066] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein p is 0 and G, J and A
form a A.sup.x and wherein A.sup.x is a fused heterocycle with two
fused rings each having 6 members, wherein one of said 6-membered
rings, which contains A, further contains a nitrogen and an oxygen
which are interrupted by a carbonyl said oxygen attached to A and
wherein said fused heterocycle forms a spirocyclic ring system
containing A.
[0067] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein is s is 1 and S.sup.y
is methylene.
[0068] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a.
[0069] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein is s is 1, S.sup.y is
methylene and R is R.sup.3a wherein R.sup.3a is a heterocycle
having two fused rings, one of said fused rings having six members
and being attached to S.sup.y and the other of said rings having 5
members and containing two nitrogens.
[0070] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is
7-methyl-1H-indazol-5-yl.
[0071] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein is s is 1, S.sup.y is
methylene and R.sup.3 is R.sup.3a wherein R.sup.3a is
7-ethyl-3-methyl-1H-indazol-5-yl.
[0072] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein D is O and U is O.
[0073] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein D is O and U is
CH.sub.2.
[0074] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein D is O and U is
NH.
[0075] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 0.
[0076] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 1.
[0077] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 1 and V' is
selected from the group consisting of C.sub.3-7cycloalkyl, phenyl,
tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrrolinyl,
pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl,
pyrazolinyl, pyrazolidinyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyranyl,
pyridyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl,
morpholino and thiomorpholino and dioxolanyl.
[0078] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl.
[0079] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl and V' is substituted with 1 or 2 of the same or
different substituents selected from the group consisting of halo,
cyano, C.sub.1-4alkyl, C.sub.1-4haloalkyl, C.sub.1-4alkoxy,
hydroxy, amino, C.sub.3-7cycloalkyl, C.sub.1-4alkylamino,
C.sub.1-4dialkylamino, (C.sub.1-3alkyl).sub.0-2ureid- o,
C(O)OC.sub.2-3alkyl, carboxy, amido, nitro, phenyl and benzyl.
[0080] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein t is 1 and V' is
selected from the group consisting of phenyl, pyridyl and
piperidinyl and V' is substituted with 1 or 2 of the same or
different substituents selected from the group consisting of
C.sub.1-4dialkylamino, C(O)OC.sub.2-3alkyl, carboxy, amido, nitro
and phenyl.
[0081] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V is said 5-membered
ring.
[0082] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V is said 6-membered
ring.
[0083] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V is said fused
bicyclic ring system.
[0084] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V is furanyl,
imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine,
quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl,
triazolopyridinyl or imidazopyridinyl.
[0085] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V contains a
carbonyl.
[0086] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V is furanyl,
imidazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidine,
quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl or
[1,2,4]Triazolo[4,3-a]pyrid- in-3-yl or
H-Imidazo[1,5-a]pyridin-3-yl).
[0087] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V and V' are
interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2--.
[0088] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein V and V' are
interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2-- wherein said
interrupting substituents are unsubstituted.
[0089] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein
[0090] s is 1, S.sup.y is methylene and R.sup.3 is R.sup.3a wherein
R.sup.3a is an optionally C.sub.1-3alkyl-substituted indazolyl;
[0091] U is CH.sub.2, O, or NH;
[0092] D is O;
[0093] A is CH;
[0094] m and n are each 1;
[0095] E is N;
[0096] p is 1; and
[0097] G, J and E together form A.sup.x, wherein A.sup.x is an
optionally halogenated dihydroquinazolinone.
[0098] According to a another emobdiment of the first aspect of the
present invention are compounds of Formula (I) or pharmaceutically
acceptable salts or solvates thereof wherein
[0099] V is furanyl, imidazolyl, oxadiazolyl, tetrazolyl, pyridyl,
pyrimidine, quinolinyl, C.sub.1-4alkylcarbonyl, carboxy, indazolyl,
triazolopyridinyl or imidazopyridinyl;
[0100] t is 0 or 1;
[0101] V' is selected from the group consisting of phenyl, pyridyl
and piperidinyl and V' is substituted with 1 or 2 of the same or
different substituents selected from the group consisting of
C.sub.1-4dialkylamino, C(O)OC.sub.2-3alkyl, carboxy, amido, nitro
and phenyl;
[0102] wherein V and V' are interrupted by methylene, ethylene and
--(CH.sub.2).sub.0-2C(O)--(CH.sub.2).sub.0-2-- wherein said
interrupting substituents are unsubstituted;
[0103] s is 1, S.sup.y is methylene and R.sup.3 is R.sup.3a wherein
R.sup.3a is an optionally C.sub.1-3alkyl-substituted indazolyl;
[0104] U is CH.sub.2, O, or NH;
[0105] D is O;
[0106] A is CH;
[0107] m and n are each 1;
[0108] E is N;
[0109] p is 1; and
[0110] G, J and E together form A.sup.x, wherein A.sup.x is an
optionally halogenated dihydroquinazolinone.
[0111] According to various embodiments of a second aspect of the
present invention are provided pharmaceutical compositions
comprising compounds of Formula (I) as defined herein.
[0112] According to various embodiments of a third aspect of the
present invention are provided methods of treating inflammation
(particularly neurogenic inflammation), headache (tension see U.S.
20040097562A1 and particularly migraine), pain, thermal injury,
psoriasis (see WO2004014351A2), circulatory shock, diabetes,
Reynaud's syndrome, peripheral arterial insufficiency,
subarachnoid/cranial hemorrhage, tumor growth, flushing associated
with menopause and other conditions the treatment of which can be
effected by the antagonism of the CGRP receptor by the
administration of pharmaceutical compositions comprising compounds
of Formula (I) as defined herein.
[0113] According to various embodiments of a fourth aspect of the
present invention are uses of the compounds of the present
invention selected from the group consisting of (a) immune
regulation in gut mucosa (b) protective effect against cardiac
anaphylactic injury (c) stimulating or preventing
interleukin-1b(IL-1b)-stimulation of bone resorption (d) modulating
expression of NK1 receptors in spinal neurons and (e) airway
inflammatory diseases and chronic obstructive pulmonary disease
including asthma. See (a) Calcitonin Receptor-Like Receptor Is
Expressed on Gastrointestinal Immune Cells. Hagner, et al.
Institute of Physiology, Philipps University, Marburg, Germany.
Digestion (2002), 66(4), 197-203; (b) Protective effects of
calcitonin gene-related peptide-mediated evodiamine on guinea-pig
cardiac anaphylaxis. Rang, et al. School of Pharmaceutical
Sciences, Department of Pharmacology, Central South University,
Xiang-Ya Road 88, Changsha, Hunan, Naunyn-Schmiedeberg's Archives
of Pharmacology (2003), 367(3), 306-311; (c) The experimental study
on the effect calcitonin gene-related peptide on bone resorption
mediated by interleukin-1. Lian, Kai; et al. Department of
Orthopedics, Xiehe Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, Peop. Rep. China.
Journal of Tongji Medical University (2001), 21(4), 304-307, (d)
Calcitonin gene-related Peptide regulates expression of neurokinin1
receptors by rat spinal neurons. Seybold V S, et al. J. Neurosci.
2003 23 (5): 1816-1824. Department of Neuroscience, University of
Minnesota, Minneapolis, Minn. 55455, and Department of
Pharmacology, Toxicology, and Therapeutics, University of Kansas
Medical Center, Kansas City, Kans. 66160 (e) Attenuation of
antigen-induced airway hyperresponsiveness in CGRP-deficient mice.
Aoki-Nagase, et al. Department of Geriatric Medicine, Graduate
School of Medicine, University of Tokyo, Tokyo, Japan. American
Journal of Physiology (2002), 283(5,Pt. 1), L963-L970; (f)
Calcitonin gene-related peptide as inflammatory mediator. Springer,
Jochen; et al. Charite Campus-Virchow, Department of Pediatric
Pneumology and Immunology, Division of Allergy Research,
Humboldt-University Berlin, Berlin, Germany. Pulmonary Pharmacology
& Therapeutics (2003), 16(3), 121-130; and (g) Pharmacological
targets for the inhibition of neurogenic inflammation. Helyes, et
al. Department of Pharmacology and Pharmacotherapy, Faculty of
Medicine, University of Pecs, Pecs, Hung. Current Medicinal
Chemistry: Anti-Inflammatory & Anti-Allergy Agents (2003),
2(2), 191-218 all incorporated by reference herein.
[0114] According to various embodiments of a fifth aspect of the
present invention are provided combinations of the compounds of the
present invention with one or more agents selected from the group
consisting of COX-2 inhibitors, NSAIDS, aspirin, acetaminophen,
triptans, ergotamine and caffeine for the treatment of
migraine.
[0115] Other embodiments of the present invention may comprise a
suitable combination of two or more of the embodiments and/or
aspects disclosed herein.
[0116] Yet other embodiments of the present invention may comprise
a suitable subset of an embodiment and/or aspect disclosed
herein.
[0117] Still yet other embodiments and aspects of the invention
will be apparent according to the description provided below.
DETAILED DESCRIPTION OF THE INVENTION
[0118] The description of the invention herein should be construed
in congruity with the laws and principals of chemical bonding. For
example, it may be necessary to remove a hydrogen atom in order
accommodate a substitutent at any given location.
[0119] As used herein, "heterocyclic" or "heterocycle" includes
cyclic moieties containing one or more heteroatoms, (e.g., O, N or
S) said heterocycles include those that are aromatic and those that
are not, i.e., "alicyclic", unless otherwise specified.
[0120] As used herein, the term "fused bicyclic system" when
describing for example a 5.6-fused bicyclic system containing 1 to
4 nitrogen atoms includes aromatic and alicyclic systems, e.g.
indolizine, indole, isoindole, 3H-indole, indoline, indazole or
benzimidazole.
[0121] If a substitutent is named generically, then any and all
species of that genus comprise that aspect of the invention. For
example, a substituent generically named as "pyrrolonyl" (the
radical of "pyrrolone", a pyrrole having a carbonyl) includes
pyrrol-2-onyls wherein the carbonyl is adjacent to the nitrogen and
pyrrol-3-onyls wherein the carbonyl and nitrogen have an
intervening methylene.
[0122] Similarly, the present invention comprises that a
substituent may be attached at any and all suitable points of
attachement on said substituent unless otherwise specified.
[0123] However, it is also understood that the compounds
encompassed by the present invention are those that are chemically
stable, i.e., heteroalicyclic substituents of the present invention
should not be attached in such a way that a heteroatom in said
heteroalicyclic substituent is alpha to a point of attachment
wherein said point of attachment is also a heteroatom.
[0124] An embodiment or aspect which depends from another
embodiment or aspect, will describe only the variables having
values or provisos that differ from the embodiment or aspect from
which it depends. If for example a dependent embodiment only
addresses R.sup.2, then the variables and provisos not related to
R.sup.2 should reflect that of the embodiment from which it
depends.
[0125] If a variable is quantified with a value of zero, then a
bond attaching said variable should no longer be represented.
[0126] As used herein, "alkylene" means a divalent alkane, i.e., an
alkane having two hydrogen atoms removed from said alkane (said
hydrogen removed from two different carbon atoms when said alkane
contains more than one carbon atom), e.g.,
--CH.sub.2CH.sub.2CH.sub.2--.
[0127] As used herein, "alkylidene" means an alkane having two
hydrogen atoms removed from one carbon atom in said alkane, e.g.,
3
[0128] It should be understood that the alternating double bond
designations in the six-membered ring of the 5,6-membered fused
structure represented in Formula (I) are relative and represent the
delocalized .pi. orbital electrons of said ring.
[0129] As used herein, "aryl" or "ar-" includes phenyl or
napthyl.
[0130] As used herein, "heterocyclic" or "heterocyclo" includes
both heteroaryl and heteroalicyclic.
[0131] As used herein, "halo" or "halogen" includes fluoro, chloro,
bromo and iodo and further means one or more of the same or
different halogens may be substituted on a respective moiety.
[0132] Unless specificied otherwise, acyclic hydrocarbons such as
alkyl, alkoxy, alkenyl and alkynyl may be branched or straight
chained.
[0133] It is to be understood that the present invention may
include any and all possible stereoisomers, geometric isomers,
diastereoisomers, enantiomers, anomers and optical isomers, unless
a particular description specifies otherwise.
[0134] The compounds of this invention may exist in the form of
pharmaceutically acceptable salts. Such salts may include addition
salts with inorganic acids such as, for example, hydrochloric acid
and sulfuric acid, and with organic acids such as, for example,
acetic acid, citric acid, methanesulfonic acid, toluenesulfonic
acid, tartaric acid and maleic acid. Further, in case the compounds
of this invention contain an acidic group, the acidic group may
exist in the form of alkali metal salts such as, for example, a
potassium salt and a sodium salt; alkaline earth metal salts such
as, for example, a magnesium salt and a calcium salt; and salts
with organic bases such as a triethylammonium salt and an arginine
salt. In the case of a sublingual formulation a saccharin salt or
maleate salt may be of particular benefit. The compounds of the
present invention may be hydrated or non-hydrated.
[0135] The compounds of this invention can be administered in such
oral dosage forms as tablets, capsules (each of which includes
sustained release or timed release formulations), pills, powders,
granules, elixirs, tinctures, suspensions, syrups and emulsions.
The compounds of this invention may also be administered
intravenously, intraperitoneally, subcutaneously, or
intramuscularly, all using dosage forms well known to those skilled
in the pharmaceutical arts. The compounds can be administered
alone, but generally will be administered with a pharmaceutical
carrier selected upon the basis of the chosen route of
administration and standard pharmaceutical practice. Compounds of
this invention can also be administered in intranasal form by
topical use of suitable intranasal vehicles, or by transdermal
routes, using transdermal skin patches. When compounds of this
invention are administered transdermally the dosage will be
continuous throughout the dosage regimen.
[0136] While dosing from 0.01 mg/kg to 30 mg/kg is envisaged for
compounds of the present invention, the dosage and dosage regimen
and scheduling of a compounds of the present invention must in each
case be carefully adjusted, utilizing sound professional judgment
and considering the age, weight and condition of the recipient, the
route of administration and the nature and extent of the disease
condition. In accordance with good clinical practice, it is
preferred to administer the instant compounds at a concentration
level which will produce effective beneficial effects without
causing any harmful or untoward side effects.
Synthesis
[0137] 4
[0138] Compounds of the present invention may be synthesized
according to the general schemes provided below. Variables provided
in the schemes are defined in accordance with the description of
compounds of Formula (I) in the first asepct of the invention
unless otherwise specified. It may also be possible to use
variations of said schemes to prepare the compounds of the present
inventions, said variations discernible to those skilled in the
art.
[0139] The compounds of the present invention may be prepared
according to Scheme 1. 5
[0140] Representative V-Metal: 6
[0141] The synthesis described in Scheme I begins with commercially
available or synthesized aldehydes. The three-carbon homologation
and the conjugated double-bond formation with two consecutive
Wittig reactions are well-known in the literature leading to
compounds of Formula V. Some Formula V compounds are also
commercially available and can be prepared by other literature
methods. The group V can be any carbon (C) or nitrogen (N) based
nucleophile that can add to the double bond in a process known as
1,4-Michael addition leading to compounds of Formula VI. Nitrogen
based nucleophiles usually undergo the desired 1,4-addition. For
carbon based nucleophiles, known modifications using copper salts
usually favor the desired 1,4-addition. Aryl boronic acid or
organosiloxane can be added to the desired beta-position through
rhodium catalysis and asymmetric synthesis through chiral ligands
is also known (JOC, 2000, 65, 5951-5955; Tetrahedron Asymmetry
1999, 10, 4047-4056; JACS 1998, 120, 5579-5580; Org. Lett. 2002, 4,
667-669). Hydrolysis of compounds of Formula VI leads to Formula
VII, free carboxylic acids, which react with amines to afford
Formula I compounds.
[0142] Oxadiazole-containing compounds of Formula I may be prepared
according to Scheme 2. 7
[0143] Treatment of N-hydroxyamidines with bases such as sodium
hydride followed by addition of esters of Formula VIII and heating
give [1,2,4]oxadiazoles of Formula I, after heating.
[0144] Tetrazole-containing compounds of Formula I may be prepared
according to Scheme 3. 8
[0145] Esters of Formula VIII can be hydrolyzed to the
corresponding carboxylic acids using either acids or bases,
controlling conditions to spare other functionality. Acids of
Formula IX can be converted to the primary amides of Formula X by
simple coupling with ammonia using various amide coupling agents
well known in the art. Nitriles of Formula XI are available from
the amides by dehydration using agents such as trifluoroacetic
anhydride. These are converted to the corresponding tetrazoles of
Formula I (where R.sup.4.dbd.H) by treatment with
azidotrimethyltin. Deprotonation of these compounds with bases such
as sodium hydride, followed by alkylation with various agents such
as alkyl halides and alkyl sulfonates gives further compounds of
Formula I that are substituted on the tetrazole ring.
[0146] Compounds of Formula VIII in which X.dbd.CH.sub.2 can be
prepared according to Scheme 4. 9
[0147] Scheme 4 starts with commercially available or synthesized
aldehydes. These are reacted with dimethyl succinate in the
presence of bases to give compounds of Formula XIII. The double
bond of the Formula XIII compound is reduced to give compounds of
Formula XIV. Reduction can be carried out to give either a racemate
or by use of a stereoselective catalyst to give either enantiomer
of Formula XIV. Such reductions can result from transfer
hydrogenation from hydrogen donors such as formic acid or
cyclohexadiene, or hydrogenation using gaseous hydrogen, both in
the presence of a suitable catalyst. Amide coupling with amines of
Formula XV leads to compounds of Formula VIII using well known
amide synthesis protocols.
[0148] Compounds of Formula XX and XXI in which X.dbd.O or NH can
be prepared according to Scheme 5. 10
[0149] Scheme 5 starts with commercially available or synthesized
aldehydes of Formula XII. These are reacted in the presence of a
base with phosphonates of Formula XVI where PG is a protecting
group such as acetyl, benzoyl, benzyloxycarbonyl,
tert-butoxycarbonyl, a trisubstituted silyl, or another appropriate
protecting group. Compound XVI need not be the trimethyl
phosphonoacetate. The methyl groups of XVI may be exchanged with
other alkyl groups such as ethyl, t-butyl, benzyl groups, or
combinations thereof. Such modifications are familiar to those with
ordinary skill in the art. In some cases, there exists
functionality on R.sup.3 that requires protection with an
appropriate protecting group such that subsequent chemistry can
proceed as described. The use of such protecting groups is also
well known to those of ordinary skill in the art. The double bond
of the Formula XVII compound is reduced to give compounds of
Formula XVIII. Reduction can be carried out to give either a
racemate or by use of a stereoselective catalyst to give either
enantiomer of Formula XVIII. Such reductions can result from
transfer hydrogenation from hydrogen donors such as formic acid or
cyclohexadiene, or hydrogenation using gaseous hydrogen, both in
the presence of a suitable catalyst. Deprotection of the protecting
group (PG) under standard deprotection protocols affords Formula
XXI compounds. In some cases, removal of the protecting group gives
rise to concomitant hydrolysis of the methyl ester to give
compounds of Formula XX. The carboxylic acids can be protected to
give Formula XXI compounds by treatment with diazomethane or
another suitable alkylating agent. Alternately, esters of Formula
XVIII can be hydrolyzed to the corresponding carboxylic acids of
Formula XIX, using either acids or bases, controlling reaction
conditions to spare other functional groups.
[0150] Compounds of Formula VIII can be prepared according to
Scheme 6. 11
[0151] The synthesis described by Scheme 6 begins with a compound
of Formula XXI, which is an amino acid (where X.dbd.NH) or a
hydroxy acid (where X.dbd.O) with a protected carboxylate terminus.
The protecting group is generally a methyl ester, but other
protecting groups such as ethyl, t-butyl, and benzyl esters may
also be used. The Formula XXI compound is coupled with an amine of
Formula XV in a mixed urea or urea isostere reaction, as above, to
generate a Formula VIII compound. This can involve activation of
either Compound XXI or XV with a reagent such as carbonyl
diimidazole or p-nitrophenylchloroformate, giving an intermediate
that is activated toward nucleophilic addition, and treating that
intermediate with Compound XXI or XV in the presence of a base, if
necessary.
[0152] Imidazole-containing compounds of Formula I can be prepared
according to Scheme 7. 12
[0153] The synthesis described by Scheme 7 begins with an ester of
Formula VIII. The ester may be reduced directly to an aldehyde of
Formula XXIII using diisobutylaluminum hydride or other appropriate
reducing agent. Alternately, compounds of Formula VIII can be
reduced to an alcohol of Formula XXII by using lithium borohydride
or another appropriate reducing agent. Alcohols of Formula XXII are
oxidized to aldehydes of Formula XXIII by treatment with an
appropriate oxidant. Such oxidations and reductions are well known
to those skilled in the art. Aldehydes of Formula XXIII are
condensed with dicarbonyl compounds of Formula XXIV in the presence
of ammonia to afford N-unsubstituted imidazoles (R.sup.7.dbd.H) of
Formula I. These Formula I compounds can be further derivatized by
alkylation with appropriate electrophiles such as alkyl halides or
alkyl sulfonates in the presence of a base or aryl halides in the
presence of a base and an appropriate catalyst to give Formula I
compounds where R.sup.7 is not H. In cases where a protecting group
is employed on the group R.sup.3, deprotection conditions
appropriate to the protecting group and compatible with the rest of
the molecule can be employed to remove it. Such protecting group
manipulations are well known to those skilled in the art.
[0154] Imidazole-containing compounds of Formula I can also be
prepared according to Scheme 8. 13
[0155] Scheme 8 begins with reduction of a methyl ester of Formula
XVIII to an alcohol of Formula XXV using an appropriate reducing
reagent such as lithium borohydride. The resulting alcohol can then
be oxidized to an aldehyde of Formula XXVI by treatment with an
appropriate oxidant. In some cases it is possible to reduce
compounds of Formula XVIII directly to compounds of Formula XXVI by
use of diisobutylaluminum hydride or another appropriate reducing
agent. Such oxidations and reductions are well known to those
skilled in the art. The Formula XXVI aldehyde can be condensed with
a Formula XXIV dicarbonyl compound to afford an N-unsubstituted
(R.sup.7.dbd.H) imidazole of Formula XXVII. In some cases, it is
desirable to alkylate the imidazole with an appropriate
electrophilic reagent such as alkyl halides or alkyl sulfonates in
the presence of a base, or aryl halides in the presence of a base
and an appropriate catalyst to afford substituted imidazoles of
Formula XXVII where R.sup.7 is not H. The protecting group (PG) can
then be removed to liberate the hydroxyl group (when X.dbd.O) or
the primary amine (when X.dbd.NH) by application of deprotection
conditions appropriate to the protecting group. Such deprotections
are well known in the art. Compounds of Formula XXVIII are coupled
with an amine of Formula XV in the presence of phosgene or a
phosgene equivalent to generate a urethane (when X.dbd.O) or mixed
urea (when X.dbd.NH) of Formula I. Compounds of Formula XXVIII can
also be used in a urea isostere reaction, as above, to generate a
Formula I compound. Where protecting groups have been utilized on
the group Q, they are removed by conditions appropriate to the
protecting group and compatible with the rest of the molecule.
[0156] Tetrazole-containing compounds of Formula I may also be
prepared according to Scheme 9. 14
[0157] Scheme 9 begins with the coupling of a carboxylic acid of
Formula XIX to a primary amine to give secondary amides of Formula
XXIX using various amide coupling agents well known in the art.
Conversion of Formula XXIX amides to tetrazoles of Formula XXX can
be accomplished by treatment with a dehydrating agent such as
phosphorous pentachloride or phosphorous oxychloride followed by
treatment with an azide source such as tributyltin azide. The
protecting group (PG) can then be removed to liberate the hydroxyl
group (when X.dbd.O) or the primary amine (when X.dbd.NH) by
application of deprotection conditions appropriate to the
protecting group. Such deprotections are well known in the art.
Resulting compounds of Formula XXXI can be coupled with an amine of
Formula XV in the presence of phosgene or a phosgene equivalent to
generate a urethane (when X.dbd.O) or mixed urea (when X.dbd.NH) of
Formula I. Compounds of Formula XXXI can also be used in a urea
isostere reaction, as above, to generate Formula I compounds. Where
protecting groups have been utilized on Q, they are removed by
conditions which are appropriate to the protecting group.
[0158] Compounds of Formula I may also be prepared according to
Scheme 10. 15
[0159] Scheme 10 begins with the coupling of a carboxylic acid of
Formula XIX to a compound of Formula XXXII to give secondary amides
of Formula XXXIII using various amide coupling agents well known in
the art. The pyridinyl-amide of Formula XXXIII can be made to
undergo cyclization to give heterocycles of Formula XXXIV by use of
a dehydrating agent such as phosphorous pentachloride or
phosphorous oxychloride either alone or in the presence of an amine
base such as pyridine or quinoline. The protecting group (PG) can
then be removed to liberate the hydroxyl group (when X.dbd.O) or
the primary amine (when X.dbd.NH) by application of deprotection
conditions appropriate to the protecting group. Such deprotections
are well known in the art. Compounds of Formula XXXV are coupled
with an amine of Formula XV in the presence of phosgene or a
phosgene equivalent to generate a urethane (when X.dbd.O) or mixed
urea (when X.dbd.NH) of Formula I. Compounds of Formula XXXV can
also be used in a urea isostere reaction, as above, to generate
Formula I compounds. Where protecting groups have been utilized on
Q, they are removed by conditions which are appropriate to the
protecting group and compatible with the rest of the molecule.
[0160] Compounds of Formula I may also be prepared according to
Scheme 11. 16
[0161] The general synthesis described in Scheme 11 begins with
commercially available or synthesized aldehydes of Formula XXXVI.
Conversion of Formula XXXVI aldehydes to .alpha.-aminophosphonates
XXXVII and the following Wittig reactions with other commercially
available or synthesized aldehydes of Formula XII followed by
acidic hydrolysis afford ketones of Formula XXXVIII (Tetrahedron
Lett. 1998, 39, 1717-1720). The ketones of Formula XXXVIII can be
conveniently reduced to the corresponding alcohols XXXIX.
Completion of the synthesis of Formula I compounds with X.dbd.O can
be achieved through formation of activated intermediates such as
p-nitrophenyl or N-succinimidyl carbonates followed by coupling
with amines of Formula XV. On the other hand, alcohols of Formula
XXXIX can also be converted to phthalimides XL using Mitsunobu
conditions that are well known in the art. Treatment of Formula XL
compounds with hydrazine affords amines XLI which can be further
converted to compounds of Formula I with X.dbd.NH through
activation with carbonyl diimidazole or similar activating agents.
Furthermore, the ketones of Formula XXXVIII can be converted to
esters of Formula XLII using Wittig conditions. Reduction of the
double bond affords compounds of Formula VI. Hydrolysis of Formula
VI esters leads to carboxylic acids of Formula VII which can be
coupled with amines of formula XV to afford Formula I compounds
with X.dbd.CH.sub.2 using amide coupling agents well known in the
art. Furthermore, Formula I compounds can be further expanded to
other Formula I compounds if the aldehydes of Formula XXXVI contain
suitable functional groups that can be modified using general
synthetic methods known in the art.
[0162] Imidazole-containing compounds of Formula I may also be
prepared as shown in Scheme 12. 17
[0163] The synthesis begins with succinyl monoesters XIV from
Scheme 4. The free carboxyl group can be protected with various
blocking groups (PG) such as tert-butyl, using methods well known
in the art, to give diesters XLIV. The methyl ester can be
selectively hydrolyzed using mild basic conditions and the
resulting carboxyl group reduced to the corresponding aldehydes
XLV. This can be accomplished either by direct reduction of the
ester using a selective hydride source such as diisobutylaluminum
hydride or by reduction of the carboxyl group first to the
corresponding alcohol, through an activated ester, and then
oxidation to the aldehyde using, for example, Dess-Martin
protocols. There are numerous alternative methods for these
transformations well known to those skilled in the art. Aldehydes
XLV can be converted to substituted or unsubstituted imidazoles of
Formula XLVI by heating with glyoxal or other suitable dicarbonyl
compounds of Formula XXIV such as pyruvic aldehyde in the presence
of ammonia in a polar, non-nucleophilic solvent such as dioxane.
The imidazole ring can be further functionalized by alkylation of
one of the nitrogen atoms with a suitable electrophile, such as an
alkyl halide, in the presence of a base in a non-nucleophilic
solvent to give N-substituted derivatives XLVII. Removal of the
ester protecting group (PG) and amide coupling gives
imidazole-containing compounds of Formula I.
[0164] Compounds of Formula XVII where X.dbd.NH, and where R.sup.3
is an aromatic ring, can also be prepared as shown in Scheme 13.
18
[0165] Scheme 13 starts with an N-protected aminoacrylate of
Formula XLVIII that can be coupled to a compound of Formula XLIX
comprising an aromatic ring to which is attached a leaving group
such as iodine or bromine in the presence of a transition metal
catalyst such as palladium (II) acetate in a non-reactive solvent
with or without heating.
[0166] Preparation of Intermediates and Examples
General
[0167] .sup.1H- and .sup.13C-NMR spectra were run on a Bruker 500
or 300 MHz instrument and chemical shifts were reported in ppm
(.delta.) with reference to tetramethylsilane (.delta.=0.0). All
evaporations were carried out under reduced pressure. Unless
otherwise stated, LC/MS analyses were carried out on a Shimadzu
instrument using a YMC C18 column (3.times.50 mm) employing a 2 min
linear gradient of 0% to 100% solvent B in A in a 3 min run. For
LC/MS and for Shimadzu Preparative HPLC system, Solvent A-was: 10%
methanol/90% water/0.1% trifluoroacetic acid, and solvent B was 90%
methanol/10% water/0.1% trifluoroacetic acid with a UV detector set
at 220 nm.
Tert-Butyl 2-fluorophenylcarbamate
[0168] 19
[0169] To a solution of di-tert-butyldicarbonate (45.2 g, 207 mmol,
1.0 equiv) in tetrahydrofuran (210 mL) at room temperature was
added 2-fluoroaniline (20.0 mL, 207 mmol). The reaction was heated
to reflux and held there for 6 h. It was cooled, concentrated,
dissolved in pentane, washed with 5% citric acid, then 1 M
potassium bisulfate (2.times.), then water, then 20% potassium
hydroxide, then brine, dried over magnesium sulfate, and
concentrated to give 48.0 g (quant) as an amber oil which was used
without purification. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta.
1.52 (s, 9H), 6.68 (bs, 1H), 6.85-7.20 (m, 3H), 8.07 (dd, J=8.1,
8.1, 1H). Mass spec.: 234.18 (MNa).sup.+.
2-(tert-Butoxycarbonylamino)-3-fluoro-benzoic Acid
[0170] 20
[0171] To a solution of tert-butyl 2-fluorophenylcarbamate (44.0 g,
208 mmol) in tetrahydrofuran (660 mL) at -78.degree. C. was added
tert-butyllithium in pentane (1.7 M, 306 mL, 2.5 equiv) drop wise.
After addition was complete, the reaction was stirred at
-78.degree. C. for 30 min. The solution was allowed to gradually
reach -20.degree. C. before being recooled to -78.degree. C. and
transferred via canula to a slurry of carbon dioxide (excess) and
tetrahydrofuran (500 mL). The solution was allowed to slowly warm
to room temperature. The reaction mixture was concentrated to
remove most of the tetrahydrofuran, and poured into a sep funnel
containing water and diethyl ether. The layers were separated, and
the aqueous extracted with diethyl ether twice more. The ethereals
were discarded. The aqueous was acidified with 5% citric acid,
extracted with diethyl ether (3.times.). The ethereal was dried
over magnesium sulfate, and concentrated to give a light yellow
solid which was recrystallized from hot toluene to give 37.1 g
(70%) as a faint yellow solid. .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. 1.50 (s, 9H), 6.25 (bs, 1H), 7.18 (ddd, J=7.9, 7.9, 4.9,
1H), 7.33 (dd, J=9.5, 9.2, 1H), 7.79 (d, J=7.9, 1H), 7.94 (s, 1H).
Mass spec.: 278.21 (MNa).sup.+.
Tert-Butyl
2-(1-benzylpiperidin-4-ylcarbamoyl)-6-fluorophenylcarbamate
[0172] 21
[0173] To a solution of
2-(tert-butoxycarbonylamino)-3-fluoro-benzoic acid (37.1 g, 145
mmol), 4-amino-1-benzylpiperidine (35.6 mL, 1.20 equiv.),
1-hydroxybenzotriazole (21.6 g, 1.1 equiv), and triethylamine (44.1
g, 3.0 equiv.) in ethyl acetate (450 mL) was added
1-(3-dimethylaminopropyl)- -3-ethylcarbodiimide hydrochloride (30.7
g, 1.1 equiv) in one portion. Initially, everything went into
solution, but a precipitate formed very rapidly. The reaction was
fitted with a reflux condenser and heated at reflux for 5 h. The
reaction was diluted with ethyl acetate, washed with water
(2.times.), then 1N sodium hydroxide (2.times.), then brine, dried
over magnesium sulfate, and concentrated to give 67.0 g (quant) as
a white solid which was used without purification. .sup.1H-NMR
(CDCl.sub.3, 500 MHz) .delta. 1.48 (s, 9H), 1.55 (m, 2H), 1.99 (bd,
J=11.0, 2H), 2.17 (dd, J=1.0, 11.0, 2H), 2.84 (bd, J=11.3, 2H),
3.51 (s, 2H), 3.94 (m, 1H), 6.13 (bd, J=7.6, 1H), 7.10-7.28 (m,
4H), 7.31 (m, 4H), 7.59 (s, 1H). Mass spec.: 428.41 (MH).sup.+.
2-Amino-N-(1-benzylpiperidin-4-yl)-3-fluorobenzamide
[0174] 22
[0175] To a solution of tert-butyl
2-(1-benzylpiperidin-4-ylcarbamoyl)-6-f- luorophenylcarbamate (67.0
g, 157 mmol) in dichloromethane (700 mL) at 0.degree. C. was added
trifluoroacetic acid (100 mL). The ice bath was removed and the
reaction stirred at room temperature overnight. The reaction was
concentrated and partitioned between ethyl acetate and saturated
sodium bicarbonate. The aqueous portion was extracted with ethyl
acetate (2.times.), which were washed with water (3.times.), then
brine, dried over magnesium sulfate, and concentrated to give 47.6
g (93%) as a white solid which was used without purification. Mass
spec.: 328.33 (MH).sup.+.
N-(2-Amino-3-fluorobenzyl)-1-benzylpiperidin-4-amine
[0176] 23
[0177] To a refluxing suspension of lithium aluminum hydride (16.1
g, 424 mmol, 3.50 equiv) in dioxane (800 mL) was added a solution
of 2-amino-N-(1-benzylpiperidin-4-yl)-3-fluorobenzamide (39.7 g,
121 mmol) in dioxane (250 mL) at such a rate that gas evolution was
limited to a safe flow. Upon completion of the addition, the
resulting suspension was heated at reflux for 4 h. The reaction was
cooled to 0.degree. C., and quenched by the cautious addition of
20% potassium hydroxide. Upon formation of a white, filterable
precipitate, the solid was filtered through a course glass sintered
funnel, and the eluent concentrated to give 36.3 g (96%) as a light
yellow oil which was used without purification. Mass spec.: 314.29
(MH).sup.+.
3-(1-Benzylpiperidin-4-yl)-8-fluoro-3,4-dihydroquinazolin-2(1H)-one
[0178] 24
[0179] To a solution of
N-(2-amino-3-fluorobenzyl)-1-benzylpiperidin-4-ami- ne (36.3 g, 116
mmol) in tetrahydrofuran (600 mL) at room temperature was added
carbonyl diimidazole (20.7 g, 1.10 equiv) in one portion. The
reaction was stirred at room temperature for 3 h, heated at reflux
for 30 min, and concentrated. The resulting solid was dissolved in
1:1 diethyl ether/ethyl acetate, washed with water (3.times.), then
brine, dried over magnesium sulfate, and concentrated to give the
crude product as a wet, yellow solid. The solid was triturated with
diethyl ether and filtered to give 30.0 g (76%) as a white powder.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 1.68 (m, 2H), 1.86 (dddd,
J=11.9, 11.9, 11.9, 3.4, 2H), 2.14 (dd, J=11.6, 10.1, 2H), 2.98 (d,
J=11.6, 2H), 3.51 (s, 2H), 4.34-4.44 (m, 3H), 6.71 (bs, 1H),
6.79-6.89 (m, 2H), 6.94 (dd, J=9.2, 9.2, 1H), 7.21-7.34 (m, 5H).
Mass spec.: 340.30 (MH).sup.+.
8-Fluoro-3,4-dihydro-3-(piperidin-4-yl)quinazolin-2(1H)-one
[0180] 25
[0181] A 250 mL flask was charged with
3-(1-benzylpiperidin-4-yl)-8-fluoro-
-3,4-dihydroquinazolin-2(1H)-one (1.40 g, 4.12 mmol) and methanol
(25.0 mL). The suspension was heated with a heat gun to aid in
dissolution. The flask was flushed with nitrogen, treated with
palladium on charcoal (141 mg, 0.032 equiv), flushed with nitrogen,
then hydrogen, and vigorously stirred under an atmosphere of
hydrogen overnight. The reaction was flushed with nitrogen,
filtered through celite, and concentrated to give 0.99 g (97%) as a
white solid which was used without purification. .sup.1H-NMR
(CDCl.sub.3, 500 MHz) .delta. 1.71 (m, 4H), 2.75 (m, 2H), 3.16 (m,
2H), 4.38 (s, 2H), 4.46 (m, 1H), 6.77 (bs, 1H), 6.81-6.89 (m, 2H),
6.95 (m, 1H). Mass spec.: 250.22 (MH).sup.+.
4-Bromo-2,6-dimethylphenyldiazo-t-butyl Sulfide
[0182] 26
[0183] 4-Bromo-2,6-dimethylaniline (20.00 g, 100 mmol) was ground
to a powder with a mortar and pestle and then suspended in 24%
hydrochloric acid (41 mL). The stirred mixture was cooled to
-20.degree. C. and treated with sodium nitrite (7.24 g, 1.05 equiv)
in water (16 mL), dropwise over 40 min while the temperature was
maintained below -5.degree. C. After a further 30 min at -5.degree.
C. to -20.degree. C., the mixture was buffered to ca. pH 5 with
solid sodium acetate. This mixture (kept at ca. -10.degree. C.) was
added in portions to a stirred solution of t-butyl thiol (11.3 mL,
1 equiv) in ethanol (100 mL) at 0.degree. C. over ca. 10 min.
Following addition, the mixture was stirred at 0.degree. C. for 30
min and then crushed ice (ca. 150 mL) was added. The mixture was
stored in the refrigerator overnight. The resulting light-brown
solid was collected by filtration, washed with water, and dried
under high vacuum for several hours. (26.90 g, 89%). The compound
appeared to be stable as a solid but underwent significant
decomposition when recrystallization from ethanol was attempted.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 1.58 (9H, s), 1.99 (6H,
s), 7.21 (2H, s). Mass spec.: 303.05 (MH).sup.+.
5-Bromo-7-methylindazole
[0184] 27
[0185] Into a flame-dried round bottom flask,
4-bromo-2,6-dimethylphenyldi- azo-t-butyl sulfide (12.50 g, 41.5
mmol) and potassium t-butoxide (46.56 g, 10 equiv) were combined. A
stir bar was added and the mixture placed under nitrogen. To this
was added dry dimethylsulfoxide (120 mL). The mixture was stirred
vigorously overnight at to room temperature. The reaction mixture
was then carefully poured into a mixture of crushed ice (400 mL)
and 10% hydrochloric acid (200 mL). The resulting suspension was
left to stand at 4.degree. C. overnight and the solid was collected
by filtration and washed with water. The crude solid was dissolved
in 5:1 methylene chloride/methanol and the solution dried over
magnesium sulfate and evaporated to give the product as an
off-white solid (7.60 g, 87%). .sup.1H-NMR (CDCl.sub.3/CD.sub.3OD,
500 MHz) .delta. 2.51 (3H, s), 7.22 (1H, s), 7.69 (1H, s), 7.94
(1H, s). Mass spec.: 211.03 (MH).sup.+.
7-methylindazole-5-carboxaldehyde
[0186] 28
[0187] 5-Bromo-7-methylindazole (6.10 g, 28.9 mmol) and sodium
hydride (60% in mineral oil, 1.27 g, 1.1 equiv) were weighed into a
flame-dried round-bottom flask containing a magnetic stir bar.
Under a nitrogen atmosphere at room temperature, dry
tetrahydrofuran (30 mL) was added. The mixture was stirred at room
temperature for 15 min, during which time it became homogeneous.
The stirred mixture was cooled to -70.degree. C. and a solution of
sec-butyllithium in cyclohexane (1.4M, 45 mL, 2.2 equiv) was added
over several minutes. After 1 h at -70.degree. C.,
dimethylformamide (10 mL) was added over several minutes. The
mixture was allowed to warm to room temperature and was stirred
overnight. It was then cooled to 0.degree. C. and carefully treated
with 1N hydrochloric acid (60 mL). After a few minutes, solid
sodium bicarbonate was added to basify the mixture to pH 9-10. The
layers were separated and the aqueous phase washed twice with ethyl
acetate. The combined organic phases were extracted with 0.8M
sodium hydrogen sulfate (3.times.125 mL). The combined aqueous
phases were washed with ethyl acetate (100 mL) and then the pH was
adjusted to ca. 10 with solid sodium hydroxide. The resulting
suspension was extracted with ethyl acetate (3.times.150 mL). The
combined organic phases were washed with brine, dried (magnesium
sulfate) and evaporated to give the product as a light-tan solid
(3.01 g, 65%). .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 2.63 (3H,
s), 7.73 (1H, s), 8.12 (1H, s), 8.25 (1H, s), 10.03 (1H, s). Mass
spec.: 161.06 (MH).sup.+.
5-(2-methoxy-vinyl)-7-methyl-1H-indazole
[0188] 29
[0189] Methoxymethyl triphenylphosphonium chloride (2.74 g, 8 mmol,
2.0 equiv.) and potassium tert-butoxide (1.35 g, 12 mmol, 3.0
equiv.) were weighed into a 250-mL oven-dried flask.
Tetrahydrofuran (15 mL) was slowly introduced via syringe under
nitrogen. After the resulting red solution was stirred at room
temperature for 10 min, 7-methylindazole aldehyde (641 mg, 1.0
equiv.) was added in one portion. LCMS indicated that the reaction
was complete within 1 h. The reaction was quenched with water and
the mixture was then diluted with ethyl acetate. The layers were
separated and the organic layer was washed with brine, dried over
sodium sulfate and concentrated in vacuo to give a tan oil. The
crude product was purified by flash column chromatography on silica
gel (1:1 hexane/ethyl acetate) to afford the desired product as an
off-white solid (710 mg, 94%). MS (ESI) [M+H].sup.+=189; .sup.1H
NMR indicated a mixture of isomers (trans/cis .about.3:1). Trans
isomer: .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.3 (br., 1H),
8.13 (s, 1H), 7.88 (s, 1H), 7.42 (s, 1H), 6.12 (d, J=7.0 Hz, 1H),
5.31 (d, J=7.0 Hz, 1H), 3.80 (s, 3H), 2.60 (s, 3H).
(7-methyl-1H-indazol-5-yl)-acetaldehyde
[0190] 30
[0191] To a solution of 5-(2-methoxy-vinyl)-7-methyl-1H-indazole
(365 mg, 1.94 mmol, 1.0 equiv.) in tetrahydrofuran (8 mL) was added
60% perchloric acid (0.63 mL, 3 equiv) in one portion under
nitrogen. After 2 h, more perchloric acid (0.63 mL) was added.
After 4 h, LCMS indicated that no starting material was present.
The reaction mixture was diluted with water and ethyl acetate. The
layers were separated and the organic layer was washed with water
(3.times.). The organic layer was separated, dried over sodium
sulfate and concentrated in vacuo to give an off-white solid. The
crude material was carried on without further purification. MS
(ESI) [M+H].sup.+=175.
4-(7-methyl-1H-indazol-5-yl)-but-2-enoic Acid Tert-Butyl Ester
[0192] 31
[0193] Tetrahydrofuran (8 mL) was added to a flask containing
(7-methyl-1H-indazol-5-yl)-acetaldehyde (1.94 mmol, 1.0 equiv) and
(tert-butoxycarbonyl-methylene)triphenylphosphorane (1.46 g, 3.88
mmol, 2.0 equiv) at room temperature under nitrogen. The resulting
yellow solution was stirred overnight (15 h). LCMS indicated
completion. The mixture was partitioned between water and ethyl
acetate. The organic layer was separated and washed with brine,
dried over sodium sulfate and concentrated in vacuo. The residue
was purified by flash column chromatography to afford the desired
product as a yellow oil (272 mg, 51.5% for two steps). MS (ESI)
[M+H].sup.+=273; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.3
(br., 1H), 8.06 (s, 1H), 7.36 (s, 1H), 7.04 (m, 1H), 6.96 (s, 1H),
5.74 (dd, J=15.6 and 1.6 Hz, 1H), 3.54 (d, J=6.8 Hz; 2H), 2.57 (s,
3H), 1.47 (s, 9H).
(.+-.)-4-(7-methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyric Acid
Tert-Butyl Ester
[0194] 32
[0195] To a solution of 2-bromopyridine (281.4 mg, 1.781 mmol, 6.4
equiv.) in anhydrous ether (1 mL) at -70.degree. C. in an
oven-dried flask was added n-butyllithium (2.5 M, 0.713 mL, 1.781
mmol, 6.4 equiv), dropwise under nitrogen. The resulting deep-red
solution was stirred for 5 min before being used in the next
step.
[0196] To a 50-mL oven-dried flask was added di-n-butylsulfide (261
mg, 1.781 mmol, 6.4 equiv) and cuprous iodide (170 mg, 0.891 mmol,
3.2 equiv) under nitrogen. Anhydrous ether (1 mL) was added and the
suspension was cooled to 0.degree. C. before the solution of
2-pyridinyl lithium was added via canuula. A yellowish brown
precipitate was formed. After stirring at 0.degree. C. for 15 min,
the cooling bath was removed and
4-(7-methyl-1H-indazol-5-yl)-but-2-enoic acid tert-butyl ester
(75.8 mg, 0.278 mmol, 1.0 equiv) in anhydrous ether (1 mL) was
added via syringe. The dark solution was stirred at room
temperature for 40 min. LCMS indicated the formation of the desired
product. The reaction mixture was then partitioned between an
aqueous ammonium hydroxide/ammonium chloride solution and ethyl
acetate (upon shaking, the solids gradually dissolved to a blue
aqueous solution). The layers were separated and the organic layer
was washed with water, brine, dried over sodium sulfate and
concentrated in vacuo to an oil. Careful flash column
chromatography (5% methanol in methylene chloride) afforded the
desired product (10.4 mg, 11%) which was carried on without farther
purification. MS (ESI) 352 (M H).sup.+, 296 (M-.sup.tBu).sup.+.
(.+-.)-4-(7-methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyric Acid
[0197] 33
[0198] To a flask containing
4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-b- utyric acid
tert-butyl ester (10 mg, 0.028 mmol) was added hydrogen chloride in
dioxane (4 M, 0.8 mL). The suspension was stirred at room
temperature overnight (LCMS indicated 2/3 conversion after 2 h).
The reaction mixture was concentrated in vacuo to dryness. Dioxane
(1 mL) was added and the mixture again concentrated to dryness. The
residue was carried on without further characterization. MS (ESI)
296 (MH).sup.+.
EXAMPLE 1
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyryl]-piperidi-
n-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0199] 34
[0200] To a solution of
4-(7-methyl-1H-indazol-5-yl)-3-pyridin-2-yl-butyri- c acid (white
solid, 0.028 mmol) in methylene chloride (2 mL) was added
3,4-dihydro-3-(4-piperidinyl-2(1H)-quinazolinone (7.2 mg, 0.031
mmol, 1.1 equiv). Triethylamine (30 .mu.L) was added followed by
3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT, 9.4
mg, 0.031 mmol 1.1 equiv). The resulting yellow solution was
stirred at room temperature for 1 h and LCMS. A further 1
equivalent of the amine and DEPBT were added. After stirring for
another 4 h, LCMS indicated complete conversion. The reaction
mixture was diluted with ethyl acetate and quenched with 0.5 N
sodium hydroxide. The layers were separated and the organic layer
was washed with brine, dried over sodium sulfate and concentrated
in vacuo. The residue was purified by flash column chromatography
(10% methanol in methylene chloride) to afford the desired product
(9.0 mg, 62% for two steps) as a glassy solid. MS (ESI)
[M+H].sup.+=509, .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 11.5
(br., 1H), 8.61-8.52 (m, 1H), 7.93 (d, J=4.8 Hz, 1H), 7.50-7.38 (m,
1H), 6.90 (m, 8H), 6.66 (d, J=7.6 Hz, 1H), 4.72-4.62 (m, 1H),
4.59-4.48 (m, 1H), 4.24 (s, 1H), 4.09 (s, 1H), 4.07-3.94 (m, 1H),
3.80-3.66 (m, 1H), 3.20-2.80 (m, 4H), 2.72-2.46 (m, 2H), 2.45 (d,
J=4.8 Hz, 3H), 1.85-1.48 (m, 4H).
2-(7-Methyl-1H-indazol-5-ylmethylene)-succinic Acid 1-Methyl
Ester
[0201] 35
[0202] To a mixture of 7-methyl indazole aldehyde (0.2619 g, 1.64
mmol) and DBE-4 dibasic ester (dimethyl succinate) (0.32 mL, 2.45
mmol) in t-butanol (20 mL) was added potassium t-butoxide (0.4036
g, 3.60 mmol). The reaction mixture was heated at 50.degree. C. for
2 h under nitrogen. After a further 16 h at room temperature, the
solvent was removed in vacuo and the residue was taken up in water
(100 mL) and extracted with ethyl acetate (3.times.50 mL). The
aqueous layer was acidified with 1N hydrochloric acid to pH
3.about.4 and extracted with ethyl acetate (3.times.50 mL). The
combined ethyl acetate solution was dried and concentrated in vacuo
to give the crude product as a yellow solid (99%, cis/trans isomer
approximately 40:60). The crude mixture was carried to next step
without further purification. Mass spec.: 275 (MH).sup.+.
(.+-.)-2-(7-Methyl-1H-indazol-5-ylmethyl)-succinic Acid 1-Methyl
Ester
[0203] 36
[0204] A suspension of
2-(7-methyl-1H-indazol-5-ylmethylene)-succinic acid 1-methyl ester
(0.4440 g, 1.62 mmol) and 10% palladized charcoal (0.04 g) in ethyl
acetate (15 mL) and methanol (5 mL) was hydrogenated in a Parr
apparatus overnight at 50 psi. The reaction mixture was filtered
through a pad of celite and the filtrate evaporated to give the
desired product as a yellow solid (100%). Mass spec.: 277
(MH).sup.+.
(.+-.)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[1',2'-dihydro-2'-oxospi-
ro-[4H-3',1-benzoxazine-4,4'-piperidinyl]-butyric Acid Methyl
Ester
[0205] 37
[0206] A solution of 2-(7-methyl-1H-indazol-5-ylmethyl)-succinic
acid 1-methyl ester (0.2253 g, 0.82 mmol),
1,2-dihydro-2-oxospiro-4H-3,1-dihyd- ro-benzoxazine-4'4-piperidine
(0.1938 g, 0.89 mmol) and triethylamine (0.099 g, 0.98 mmol) in
methylene chloride (15 mL) was treated with
3-(diethoxyphosphoryloxy)-1,2,3-benzotriain-4(3H)-one (DEPBT,
0.2685 g, 0.90 mmol). The mixture was stirred overnight and then
washed with water (3.times.5 mL). The organic layer was dried, and
concentrated in vacuo. The residue was purified by flash
chromatography on silica gel, eluting with 0-10% 2M ammonia in
methanol/methylene chloride, to afford the desired product (53%).
LC/MS: t.sub.R=1.40 min, 477.28 (MH).sup.+.
[0207] Similarly prepared:
(.+-.)-2-(7-Methyl-1H-indazol-5-ylmethyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H
quinazolin-3-yl)-piperidin-1-yl]-butyric Acid Methyl Ester
[0208] 38
[0209] .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.02 (1H, s), 7.98
(1H, m), 7.90 (1H, m), 7.35-6.89 (4H, m), 6.72 (1H, m), 4.71 (1H,
m), 4.57 (1H, m), 4.27 (1H, s), 4.22 (1H, m), 3.85 (1H, m), 3.65
(3H, m), 3.30 (1H, m), 3.11 (2H, m), 2.83 (2H, m), 2.81-2.54 (4H,
m), 2.35 (1H, m), 1.73-1.67 (4H, m). Mass spec.: 490.32
(MH).sup.+.
EXAMPLE 2
(.+-.)-3-{1-[3-(3-Benzyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1H-indazol-5-y-
l)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0210] 39
[0211] To a solution of N-hydroxy-2-phenyl-acetamidine (0.27 mmol,
3 equiv, this and the other amidine intermediates of the present
invention were prepared as described in J. Med. Chem. 1993,
1529-1538) in anhydrous tetrahydrofuran (4 mL) was added sodium
hydride (0.27 mmol, 3 equiv) under nitrogen. The mixture was heated
at 65.degree. C. for 30 min before addition of a solution of
(.+-.)-2-(7-methyl-1H-indazol-5-ylmethyl)-4-oxo-
-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyric
acid methyl ester (0.09 mmol, 1 equiv) in tetrahydrofuran (3 mL).
The reaction mixture was heated at 65.degree. C. overnight.
Tetrahydrofuran was removed in vacuo and the reaction mixture was
taken up in methylene chloride, washed with water (3.times.4 mL),
dried over sodium sulfate and concentrated. Flash chromatography on
silica gel using methanol/methylene chloride from 0 to 10% gave an
impure product. The final product was obtained by preparative HPLC
in 27% yield. LC/MS: t.sub.R=1.60 min, 590 (MH).sup.+. .sup.1H-NMR
(400 MHz, CD.sub.3OD) .delta. 7.92 (1H, s), 6.90-7.25 (10H, m),
6.74 (1H, d, J=8.00 Hz), 4.32-4.57 (2H, m), 4.24-4.29 (2H, m),
3.79-4.06 (5H, m), 2.79-3.31 (5H, m), 2.57 (1H, m), 2.44 (3H, s),
1.50-1.82 (4H, m).
EXAMPLE 3
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-piperidin-1-ylmethyl-[1,2,4-
]oxadiazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0212] 40
[0213] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.23 min, 597.48 (MH).sup.+.
EXAMPLE 4
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-phenyl-[1,2,4]oxadiazol-5-y-
l)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0214] 41
[0215] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.69 min, 576.37 (MH).sup.+. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 9.07 (3H, m), 670-7.47 (10H, m), 4.55-4.73 (2H,
m), 3.94-4.26 (4H, m), 3.11-3.30 (4H, m), 2.54-2.82 (2H, m), 2.53
(3H, s), 1.65-1.77 (4H, m).
EXAMPLE 5
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-methyl-[1,2,4]oxadiazol-5-y-
l)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0216] 42
[0217] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.40 min, 514.41 (MH).sup.+. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.05 (1H, d, J=5.20 Hz), 7.45 (1H, d, J=7.6
Hz), 7.32 (1H, d, J=6.0 Hz), 7.14 (1H, m), 6.90-7.05 (3H, m), 6.72
(1H, m) 4.45-4.72 (2H, m), 3.85-4.28 (3H, m), 2.60-3.21 (7H, m),
2.55 (3H, s), 2.36 (3H, m), 1.61-1.82 (5H, m).
EXAMPLE 6
(.+-.)-3-{1-[4-(7-Methyl-1H-indazol-5-yl)-3-(3-pyridin-4-ylmethyl-[1,2,4]o-
xadiazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0218] 43
[0219] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.24 min, 577.33 (MH).sup.+. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.47 (2H, m), 7.95 (1H, d, J=4.0 Hz), 6.86-7.25
(6H, m), 6.85 (1H, s), 6.66-6.68 (2H, d, J=8.0 Hz), 4.44-4.78 (2H,
m), 3.82-4.28 (6H, m), 2.58-3.14 (6H, m), 2.43 (3H, s), 1.55-1.79
(4H, m).
EXAMPLE 7
(.+-.)-3-{1-[3-(3-Dimethylaminomethyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1-
H-indazol-5-yl)-butyryl]-piperidin-4-yl}-3,4-dihydro-1H-quinazolin-2-one
[0220] 44
[0221] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.19 min, 557.55 (MH).sup.+.
EXAMPLE 8
(.+-.)-3-{1-[3-(3-Benzyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1H-indazol-5-y-
l)-butyryl]-4,4'-piperidinyl}-1',2'-dihydro-2'-oxospiro-[4H-3',1-benzoxazi-
ne
[0222] 45
[0223] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.57 min, 577.29 (MH).sup.+.
EXAMPLE 9
(.+-.)-3-{1-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-4-(7-methyl-1H-indazol-5-y-
l)-butyryl]-4,4'-piperidinyl}-1',2'-dihydro-2'-oxospiro-[4H-3',1-benzoxazi-
ne
[0224] 46
[0225] Prepared as described above for Example 2. LC/MS:
t.sub.R=1.35 min, 501.31 (MH).sup.+. .sup.1H-NMR (400 MHz,
CD.sub.3OD) .delta. 8.01 (1H, m), 6.84-7.38 (7H, m), 4.45 (1H, m),
3.89 (2H, m), 3.40-3.64 (2H, m), 2.71-3.18 (4H, m), 2.51 (3H, m),
2.26 (3H, s), 1.85-2.14 (4H, m).
2-Benzyloxycarbonylamino-3-(7-methyl-1H-indazol-5-yl)-acrylic Acid
Methyl Ester
[0226] 47
[0227] A stirred solution of
N-benzyloxycarbonyl-.alpha.-phosphonoglycine trimethyl ester (5.51
g, 1.2 equiv) in tetrahydrofuran (30 mL) at room temperature was
treated with tetramethylguanidine (1.91 mL, 1.1 equiv). After 10
min, 7-methylindazole-5-carboxaldehyde (2.22 g, 13.86 mmol) in
tetrahydrofuran (20 mL) was added. Disappearance of starting
material was monitored by TLC and LC/MS. After 5 days at room
temperature, the solvent was evaporated and the residue dissolved
in ethyl acetate. The solution was washed with 2% phosphoric acid
and brine, dried over magnesium sulfate and evaporated. The residue
was purified by flash chromatography on silica gel, eluting with 1)
1:1 and 2) 2:1 ethyl acetate/hexane, to give the product as a
colorless foam (4.93 g, 97%). .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. 2.43 (3H, s), 3.80 (3H, s), 5.12 (2H, s), 6.66 (1H, s),
7.28 (5H, brs), 7.33 (1H, s), 7.47 (1H, s), 7.74 (1H, s), 7.96 (1H,
s). Mass spec.: 366.16 (MH).sup.+.
(.+-.)-2-Amino-3-(7-methyl-1H-indazol-5-yl)-propionic Acid Methyl
Ester
[0228] 48
[0229] A solution of
2-benzyloxycarbonylamino-3-(7-methyl-1H-indazol-5-yl)- -acrylic
acid methyl ester (4.93 g, 13.49 mmol) in methanol (125 mL) was
degassed by bubbling nitrogen through it for 30 min and then 10%
palladium on charcoal (0.6 g) was carefully added. The mixture was
hydrogenated at 40 psi in a Parr shaker apparatus overnight. The
catalyst was removed by filtration through a pad of celite and the
filtrate was concentrated in vacuo to give the product as a
colorless foam (3.62 g, quant.). .sup.1H-NMR (CD.sub.3OD, 500 MHz)
.delta. 2.45 (3H, s), 2.99 (1H, Abq), 3.22 (1H, Abq), 3.74 (3H, s),
3.89 (1H, m), 6.91 (1H, s), 7.31 (1H, s), 7.73 (1H, s). Mass spec.:
234.11 (MH).sup.+.
(.+-.)-3-(7-Methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-
-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid methyl
ester
[0230] 49
[0231] A stirred solution of
(.+-.)-2-amino-3-(7-methyl-1H-indazol-5-yl)-p- ropionic acid methyl
ester (162.9 mg, 0.698 mmol) in methylene chloride (3 mL) at room
temperature was treated with carbonyl diimidazole (113.2 mg, 1
equiv). After 1.5 h at room temperature,
3-piperidin-4-yl-3,4-dihydro-1- H-quinazolin-2-one (161.5 mg, 1
equiv.) was added. The mixture was stirred at room temperature
overnight. A white precipitate had formed that was shown to be the
desired product. The solvent was evaporated and the residue
triturated with methylene chloride. The product was collected by
filtration, washed with methylene chloride and dried in vacuo to
give a white solid (241.5 mg, 71%). Some product remained in the
mother liquors. .sup.1H-NMR (dimethylformamide-d.sub.7, 500 MHz)
.delta. 1.75 (4H, m), 2.78 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, m),
3.86 (3H, s), 4.44 (2H, s), 4.57 (1H, m), 4.72 (1H, m), 7.11 (3H,
m), 7.31 (1H, s), 7.34 (2H, m), 7.72 (1H, s), 9.34 (1H, s). Mass
spec.: 491.13 (MH).sup.+.
EXAMPLE 10
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid
[1-(3-benzyl-[1,2,4]oxadiazol-5-yl)-2-(7-methyl-1H-indazol-5-yl)-eth-
yl]-amide
[0232] 50
[0233] Sodium hydride (8 mg, 0.366 mmol) was added to a solution of
N-hydroxy-2-phenyl-acetamidine (50 mg, 0.366 mmol) in
tetrahydrofuran (15 mL). The solution was stirred at 60.degree. C.
for 15 min. A solution of
(.+-.)-3-(7-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-quinazoli-
n-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid methyl ester
(60 mg, 0.122 mmol) in tetrahydrofuran (5 mL) was added. The
reaction mixture was stirred at 60.degree. C. for 18 h. The
reaction was then cooled to room temperature and the solvent
removed under reduced pressure. The residue was dissolved with
methylene chloride and partitioned with water and extracted with
methylene chloride (3.times.50 mL). The organic layer was dried
over magnesium sulfate, filtered and concentrated under reduce
pressure. Purification was carried out by preparative HPLC. LC/MS:
t.sub.R=1.79 min, 591 (MH).sup.+.
EXAMPLE 11
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-methyl-1H-indazol-5-yl)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-eth-
yl]-amide
[0234] 51
[0235] Prepared as described above for Example 10. .sup.1H-NMR
(DMSO-d.sub.6); 9.21 (s, 1H), 7.99 (s, 1H), 7.41 (s, 1H),
7.11-7.03, (m, 3H), 6.91-6.86 (m, 2H), 6.76-6.74 (m, 2H), 4.29-4.25
(m, 2H), 4.11 (s, 1H), 4.06-4.03 (m,3H), 3.59 (s, 3H), 3.05-3.00
(m, 2H), 2.67 (m, 2H), 1.46-1.43 (m, 4H). LC/MS: t.sub.R=1.83 min,
515 (MH).sup.+.
EXAMPLE 12
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-methyl-1H-indazol-5-yl)-1-(3-pyridin-4-ylmethyl-[1,2,4]oxadiaz-
ol-5-yl)-ethyl]-amide
[0236] 52
[0237] Prepared as described above for Example 10. LC/MS:
t.sub.R=1.30 min, 592 (MH).sup.+.
EXAMPLE 13
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid
[1-(3-dimethylaminomethyl-[1,2,4]oxadiazol-5-yl)-2-(7-methyl-1H-inda-
zol-5-yl)-ethyl]-amide
[0238] 53
[0239] Prepared as described above for Example 10. LC/MS:
t.sub.R=1.16 min, 557 (MH).sup.+.
4-Bromo-2,6-diethylphenyldiazo-t-butyl Sulfide
[0240] 54
[0241] 4-Bromo-2,6-diethylaniline (6.3 g, 27.6 mmol) was suspended
in 24% hydrochloric acid (15 mL). The stirred mixture was cooled to
-20.degree. C. and treated with sodium nitrite (2.0 g, 1.05 equiv)
in water (5 mL), dropwise over 30 min while the temperature was
maintained below -5.degree. C. After a further 30 min at -5.degree.
C. to -20.degree. C., the mixture was buffered to ca. pH 5 with
solid sodium acetate. This mixture (kept at ca. -10.degree. C.) was
added in portions to a stirred solution of t-butyl thiol (3.15 mL,
1.0 equiv) in ethanol (25 mL) at 0.degree. C. over ca. 30 min.
Following addition, the mixture was stirred at 0.degree. C. for 30
min and then crushed ice (ca. 50 mL) was added. The resulting
light-brown solid was collected by filtration, washed with water,
and dried under high vacuum for several hours to afford 6.0 g (66%)
of the desired product. .sup.1H-NMR (CDCl.sub.3) .delta. 1.15 (t,
J=7.6, 6H), 1.50 (s, 9H), 2.27 (m, 4H), 7.21 (s, 2H). Mass spec.:
331.08 (MH).sup.+.
5-Bromo-7-ethyl-3-methylindazole
[0242] 55
[0243] A flame-dried round bottom flask was charged with
4-bromo-2,6-diethylphenyldiazo-t-butyl sulfide (4.0 g, 12.1 mmol)
and potassium t-butoxide (13.2 g, 121 mmol). A stir bar was added
and the mixture placed under nitrogen. To this was added dry
dimethylsulfoxide (35 mL). The mixture was stirred vigorously
overnight at room temperature. The reaction mixture was then
carefully poured into a mixture of crushed ice (130 mL) and 10%
hydrochloric acid (60 mL). The resulting suspension was collected
by filtration and washed severally with water. The solid was
collected and dried in vacuo to give 2.85 g (98%) as a beige solid.
.sup.1H-NMR (CD.sub.3OD) .delta. 1.32 (t, J=7.6, 3H), 2.50 (s, 3H),
2.88 (m, 2H), 7.25 (s, 1H), 7.68 (s, 1H). Mass spec.: 239.26
(MH).sup.+.
7-Ethyl-3-methylindazole-5-carboxaldehyde
[0244] 56
[0245] 5-Bromo-7-ethyl-3-methylindazole (2.85 g, 11.9 mmol) and
sodium hydride (0.31 g, 1.1 equiv) were weighed into a flame-dried
round-bottom flask containing a magnetic stir bar. Under a nitrogen
atmosphere at room temperature, dry tetrahydrofuran (15 mL) was
added. The mixture was stirred at room temperature for 15 min,
during which time it became homogeneous. The stirred mixture was
cooled to -78.degree. C. and a solution of tert-butyllithium in
pentane (1.4 M, 18.7 mL, 2.0 equiv) was added over several minutes.
After 1 h at -78.degree. C., dimethylformamide (2.8 mL) was slowly
added and the mixture allowed to warm to room temperature
overnight. The solution was cooled to 0.degree. C. and carefully
treated with 1N hydrochloric acid (30 mL). After a few minutes,
solid sodium bicarbonate was added until a pH of 9-10 was attained.
The two layers were separated and the aqueous phase washed twice
with ethyl acetate. The combined organic layers were washed with
water (2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated. Column chromatography gave 1.5 g (67%) of pure
material. LC/MS: t.sub.R=1.15 min, 189.12 (MH).sup.+.
2-Benzyloxycarbonylamino-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-acrylic
Acid Methyl Ester
[0246] 57
[0247] A stirred solution of
N-benzyloxycarbonyl-.alpha.-phosphonoglycine trimethyl ester (3.17
g, 9.57 mmol, 1.2 equiv) in tetrahydrofuran (15 mL) at room
temperature was treated with tetramethylguanidine (1.1 mL, 1.1
equiv). After 10 minutes, 7-ethyl-3-methylindazole-5-carboxaldehyde
(1.5 g, 7.98 mmol) was added. After stirring at room temperature
for 3 days, the solvent was evaporated and the residue purified by
flash chromatography on silica gel to give 2.5 g (80%) of product.
LC/MS: t.sub.R=1.61 min, 394.16 (MH).sup.+.
(.+-.)-2-Amino-3-(7-ethyl-3 methyl-1H-indazol-5-yl)-propionic Acid
Methyl Ester
[0248] 58
[0249]
2-Benzyloxycarbonylamino-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-acryl-
ic acid methyl ester (1.0 g, 2.54 mmol) in methanol (15 mL) was
flushed with nitrogen, and treated with palladium on charcoal (10%,
100 mg). The flask was flushed with hydrogen and allowed to stir
under an atmosphere of hydrogen overnight. The reaction was flushed
with nitrogen, filtered through celite, and concentrated. Column
chromatography gave 0.6 g (91%) of the desired material.
.sup.1H-NMR (CD.sub.3OD) .delta. 1.32 (m, 3H), 2.5 (s, 3H), 2.88
(dd, J=7.3, 7.6, 1H), 2.89 (dd, J=7.6, 7.6, 1H), 3.02 (dd, J=6.4,
7.0, 1H), 3.11 (dd, J=7.6, 5.8, 1H), 3.35 (s, 1H), 3.65 (m, 3H),
7.0 (s, 1H), 7.33 (s, 1H). Mass spec.: 262.24 (MH).sup.+.
(.+-.)-3-(7-Ethyl-3-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-qu-
inazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionic Acid Methyl
Ester
[0250] 59
[0251] A stirred solution of (.+-.)-2-amino-3-(7-ethyl-3
methyl-1H-indazol-5-yl)-propionic acid methyl ester (0.55 g, 2.1
mmol) in tetrahydrofuran (6 mL) at 0.degree. C. was treated with
carbonyl diimidazole (0.37 g, 1.1 equiv). The reaction was stirred
for 5 min at 0.degree. C., warmed to room temperature, stirred 10
min, and treated with
3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (0.53 g, 1.1
equiv). The mixture was stirred at room temperature overnight. The
solvent was evaporated and the residue purified by column
chromatography to give 0.94 g (86%) as a white powder. .sup.1H-NMR
(DMSO-d.sub.6) .delta. 1.26 (t, J=7.5, 3H), 1.49 (m, 1H), 2.44 (s,
3H), 2.83 (dd, J=7.3, 7.6, 1H), 2.84 (dd, J=115.0, 7.6, 1H),
2.88-3.10 (m, 1.5H), 3.18 (d, J=5.5, 0.5H), 3.61 (s, 3H), 4.04-4.16
(m, 3H), 4.28 (m, 2H), 6.76 (d, J=7.9, 1H), 6.86 (m, 2H), 7.04-7.25
(m, 3H), 7.36 (s, 1H), 7.40 (s, 1H), 9.18 (s, 1H), 12.59 (s, 1H).
Mass spec.: 519.37 (MH).sup.+.
(.+-.)-3-(7-Ethyl-3-methyl-1H-indazol-5-yl)-2-{[4-(2-oxo-1,4-dihydro-2H-qu-
inazolin-3-yl)-piperidine-1-carbonyl]-amino}-propionic Acid
[0252] 60
[0253] A suspension of
(.+-.)-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-2-{[4-(-
2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}-propio-
nic acid methyl ester (0.94 g, 1.81 mmol) in 1:1
tetrahydrofuran/methanol (30 mL) at room temperature was treated
with a solution of lithium hydroxide monohydrate in water (10 mL).
The solution was stirred at room temperature for 1 hand the
solvents evaporated. The resultant residue was diluted with water
(10 mL) and the pH adjusted to ca. 1 with 1N hydrochloric acid. The
resultant white suspension was stored at 4.degree. C. overnight and
the product was collected by filtration, washed by a small amount
of water and dried in vacuo for several hours to give 0.82 g (90%)
of the desired product. LC/MS: t.sub.R=1.57 min, 505.29
(MH).sup.+.
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid
[1-carbomoyl-2-(7-ethyl-3-methyl-1H-indazol-5-yl)-ethyl]-amide
[0254] 61
[0255] A stirred solution of
(.+-.)-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-2-
-{[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carbonyl]-amino}--
propionic acid (0.35 g, 0.7 mmol) in dimethylformamide (10 mL) was
cooled to 0.degree. C. and sequentially treated with methylene
chloride (5 mL), 7N ammonia in methanol (0.2 mL, 2 equiv),
N,N-diisopropylethylamine (0.3 mL, 2.5 equiv), and PyBop (0.38 mg,
0.73 mmol). The solution was stirred for 1.5 h and concentrated.
The product was purified by column chromatography to give 0.28 g
(80%) of the desired product. .sup.1H-NMR (CD.sub.3OD) .delta. 1.35
(m, 4H), 1.46-1.65 (m, 3H), 2.53 (s, 3H), 2.70-3.05 (m, 5H),
3.95-4.15 (m, 4H), 4.33 (bs, 1H), 4.55 (bs, 1H), 6.75 (m, 2H), 6.94
(bs, 1H), 7.00-7.10 (m, 3H). Mass spec.: 504.35 (MH).sup.+.
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
acid [1-cyano-2-(7-ethyl-3-methyl-1H-indazol-5-yl)-ethyl]-amide
[0256] 62
[0257] A stirred solution of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-pipe- ridine-1-carboxylic
acid [1-carbomoyl-2-(7-ethyl-3-methyl-1H-indazol-5-yl)-
-ethyl]-amide (0.25 g, 0.5 mmol) in pyridine (8 mL) at 0.degree. C.
was treated with trifluoroacetic anhydride (0.35 mL, 5.0 equiv).
The mixture was stirred for 30 min, and quenched by the addition of
excess methanol. The solvents were evaporated and the crude mixture
dissolved in ethyl acetate and washed with 5% citric acid
(2.times.), water (2.times.) and brine (2.times.), dried over
sodium sulfate, and concentrated. The residue was purified by
column chromatography to afford 0.24 g (99%) of the desired
nitrile. .sup.1H-NMR (CD.sub.3OD) .delta. 1.35 (t, J=7.6, 3H),
1.53-1.69 (m, 4H), 2.54 (s, 3H), 2.84 (m, 2H), 2.92 (dd, J=7.6,
7.6, 1H), 3.19-3.28 (m, 2H), 4.10 (m, 2H), 4.18 (s, 1H), 4.19 (s,
1H), 4.38 (m, 1H), 4.93 (dd, J=7.9, 7.9, 1H) 6.77 (d, J=7.9, 1H),
6.93 (dd, J=7.3, 7.6, 1H), 7.0 (d, J=7.3, 1H), 7.15 (m, 2H), 7.46
(s, 1H). Mass spec.: 486.22 (MH).sup.+.
EXAMPLE 14
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-ethyl]-am-
ide
[0258] 63
[0259] A stirred solution of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-pipe- ridine-1-carboxylic
acid [1-cyano-2-(7-ethyl-3-methyl-1H-indazol-5-yl)-eth- yl]-amide
(0.25 g, 0.5 mmol) in tetrahydrofuran (6 mL) was treated with
azidotrimethyltin (0.16 g, 0.77 mmol). The resulting suspension was
heated at reflux overnight. The solvents were evaporated, dissolved
in ethyl acetate and washed with water (2.times.), brine
(2.times.), dried over sodium sulfate, and concentrated. Column
chromatography afforded the desired tetrazole. .sup.1H-NMR
(CD.sub.3OD) .delta. 1.3 (t, J=7.6, 3H), 1.45-1.70 (m, 4H), 1.87
(m, 1H), 2.0 (s, 3H), 2.75-2.90 (m, 4H), 3.42 (m, 1H), 3.72 (d,
J=6.6, 1H), 4.12 (m, 4H), 4.88 (m, 1H), 5.48 (dd, J=7.0, 7.9, 1H),
6.77 (d, J=7.9, 1H), 6.94 (m, 1H) 6.98 (s, 1H), 7.09 (d, J=7.3,
1H), 7.14 (dd, J=7.9, 7.6, 1H), 7.30 (s, 1H). Mass spec.: 529.26
(MH).sup.+.
EXAMPLE 15
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(phenethyl-1H-tetrazol-5-yl)-
-ethyl]-amide and
EXAMPLE 16
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(2-phenethyl-2H-tetrazol-5-y-
l)-ethyl]-amide
[0260] 64
[0261] A mixture of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-- carboxylic
acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-
-ethyl]-amide (30 mg, 0.05 mmol, 1.0 equiv), sodium carbonate (18.0
mg, 3.0 equiv), and 2-bromoethyl-benzene (11 mg, 1.1 equiv) were
combined in dimethylsulfoxide and the mixture stirred at room
temperature overnight. The mixture was then diluted with water and
extracted with ethyl acetate (3.times.). The combined organic
extracts were washed with water (3.times.), brine (3.times.), dried
over sodium sulfate, and concentrated. Purification by preparative
HPLC afforded the title regioisomers. .sup.1H-NMR (CD.sub.3OD)
.delta. 1.24-1.35 (m, 6H), 1.43-1.72 (m, 5H), 2.5 (s, 3H), 3.40 (m,
1H), 4.14 (m, 3H), 4.38 (m, 1H), 4.84 (m, 1H), 4.85 (dd, J=7.0,
7.0, 1H), 5.45 (m, 1H), 6.75 (d, J=7.6, 1H), 6.93 (dd, J=7.3, 8.5,
1H), 7.04 (m, 3H), 7.10 (s, 1H), 7.15 (m, 4H). Mass spec.: 633.89
(MH).sup.+ and 4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl-
)-piperidine-1-carboxylic acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(2--
Phenethyl-2H-tetrazol-5-yl)-ethyl]-amide. .sup.1H-NMR (CD.sub.3OD)
.delta. 1.15 (m, 7H), 1.29 (m, 3H), 2.5 (m, 3H), 2.82 (m, 1H), 2.85
(dd, J=7.3, 8.2, 1H), 3.4-3.6 (m, 2H) 14.3, 3H), 3.75-4.0 (m, 3H),
4.85 (m, 1H), 6.90-7.12 (m, 3H), 7.40 (s, 1H), 7.57 (dd, J=7.9,
6.4, 1H), 8.02 (s, 1H), 8.03 (s, 1H). Mass spec.: 633.89
(MH).sup.+.
EXAMPLE 17
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1-methyl-1H-tetrazol-5-yl)--
ethyl]-amide
[0262] 65
[0263] A mixture of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-- carboxylic
acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-
-ethyl]-amide (50 mg, 0.1 mmol, 1.0 equiv), sodium carbonate (40.0
mg, 3.0 equiv), and iodomethane (24 .mu.L, 3.0 equiv) were combined
in dimethylsulfoxide and the mixture stirred at room temperature
overnight. The mixture was then diluted with water and extracted
with ethyl acetate (3.times.). The combined organic extracts were
washed with water (3.times.), brine (3.times.), dried over sodium
sulfate, and concentrated. Purification by preparative HPLC
afforded the title compound. .sup.1H-NMR (CD.sub.3OD) .delta. 1.30
(m, 4H), 1.57 (m, 3H), 2.50 (s, 3H), 2.75-2.95 (m, 5H), 3.40 (m,
2H), 3.68 (m, 3H), 4.05-4.40 (m, 6H), 5.35 (m, 1H), 6.75 (m, 1H),
6.95 (dd, J=7.3, 7.6, 1H), 6.98 (s, 1H), 7.12 (m, 2H), 7.35 (s,
1H). Mass spec.: 543.42 (MH).sup.+.
EXAMPLE 18
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[1-(1-benzyl-1H-tetrazol-5-yl)-2-(7-ethyl-3-methyl-1H-indazol-5-yl)--
ethyl]-amide
[0264] 66
[0265] A mixture of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-- carboxylic
acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-
-ethyl]-amide (30 mg, 0.05 mmol, 1.0 equiv), sodium carbonate (18.0
mg, 3.0 equiv), and benzyl bromide (8 .mu.L, 1.1 equiv) were
combined in dimethylsulfoxide and the mixture stirred at room
temperature overnight. The mixture was then diluted with water and
extracted with ethyl acetate (3.times.). The combined organic
extracts were washed with water (3.times.), brine (3.times.), dried
over sodium sulfate, and concentrated. Purification by preparative
HPLC afforded a mixture of the two alkylated regioisomers which
were not separated. LC/MS: t.sub.R=1.68 min, 619.44 (MH).sup.+.
EXAMPLE 19
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-pyridin-4-yl
methyl-1H-tetrazol-5-yl)-ethyl]-amide
[0266] 67
[0267] A mixture of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-- carboxylic
acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-
-ethyl]-amide (30 mg, 0.05 mmol, 1.0 equiv), sodium carbonate (18.0
mg, 3.0 equiv), and benzyl bromide (17 mg, 1.1 equiv) were combined
in dimethylsulfoxide and the mixture stirred at room temperature
overnight. The mixture was then diluted with water and extracted
with ethyl acetate (3.times.). The combined organic extracts were
washed with water (3.times.), brine (3.times.), dried over sodium
sulfate, and concentrated. Purification by preparative HPLC
afforded a mixture of the two alkylated regioisomers which were not
separated. LC/MS: t.sub.R=1.68 min, 619.44 (MH).sup.+.
EXAMPLE 20
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic
Acid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(2-oxo-2Phenethyl-2H-tetrazo-
l-5-yl)-ethyl]-amide and
EXAMPLE 21
(.+-.)-4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylicaci-
d
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-[1-(2-oxo-2-phenyl-ethyl)-1H-tet-
razol-5-yl)-ethyl]-amide
[0268] 68
[0269] A mixture of
4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-- carboxylic
acid [2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-(1H-tetrazol-5-yl)-
-ethyl]-amide (30 mg, 0.05 mmol, 1.0 equiv), sodium carbonate (18.0
mg, 3.0 equiv), and 2-bromoethyl-benzene (8 .mu.L, 1.1 equiv) were
combined in dimethylsulfoxide and the mixture stirred at room
temperature overnight. The mixture was then diluted with water and
extracted with ethyl acetate (3.times.). The combined organic
extracts were washed with water (3.times.), brine (3.times.), dried
over sodium sulfate, and concentrated. Purification by preparative
HPLC afforded the title regioisomers. .sup.1H-NMR (CD.sub.3OD)
.delta. 0.88 (m, 3H), 1.10-1.40 (m, 8H), 1.46-1.78 (m, 6H), 1.94
(s, 1H), 2.5 (m, 2H), 2.78-2.93 (m, 2H), 3.33-3.68 (m, 3H),
4.06-4.43 (m, 3H), 5.50 (m, 1H), 6.87 (m, 1H), 6.91 (m, 1H), 7.10
(m, 2H), 7.65-7.80 (m, 3H), 8.07 (d, J=8.6, 1H). Mass spec.: 647.83
(MH)+ and 4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidi-
ne-1-carboxylicacid
[2-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-[1-(2-oxo-2-ph-
enyl-ethyl)-1H-tetrazol-5-yl)-ethyl]-amide. .sup.1H-NMR
(CD.sub.3OD) .delta. 1.25-1.40 (m, 6H), 1.58 (d, J=15.87, 1H), 2.48
(m, 2H), 2.50-2.60 (m, 2H), 2.77-2.93 (m, 2H), 3.30-3.60 (m, 6H),
3.80 (dd, J=11.9, 13.1, 1H), 3.92 (d, J=14.0, 14.0, 1H), 3.96 (d,
J=14.0, 1H), 4.07-4.22 (m, 2.5H), 5.40-5.55 (m, 1H), 6.10-6.30 (m,
2H), 6.75 (dd, J=7.3, 7.3, 1H), 6.92 (m, 1H), 7.03-7.16 (m, 3H)
7.41 (s, 1H), 7.57 (m, 2H), 7.70 (m,1H). Mass spec.: 647.85
(MH).sup.+.
Ethyl
4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)but-
-2-enoate
[0270] 69
[0271] To the clear solution of ethyl
4-(7-methyl-1H-indazol-5-yl)but-2-en- oate (760 mg, 3.11 mmol, 1.0
equiv.) in tetrahydrofuran (10 mL) was added dicyclohexylmethyl
amine (2.6 mL, 6.2 mL, 2.0 equiv) followed by
2-(trimethylsilyl)ethoxymethyl chloride (0.66 mL, 3.73 mmol, 1.2
equiv). The reaction mixture was stirred at room temperature for 2
h. The mixture was partitioned between 0.5 N sodium hydroxide and
ethyl acetate. The organic layer was separated and washed with
brine, dried over sodium sulfate and concentrated in vacuo. The
residual colorless oil was purified by flash column chromatography
(20% ethyl acetate in hexanes) to afford the desired product as a
colorless oil (1.08 g, 93%). MS (ESI) [M+H].sup.+=375.
(.+-.)-Ethyl
3-(4-ethylpyridin-2-yl)-4-(7-methyl-2-((2-(trimethylsilyl)eth-
oxy)methyl)-2H-indazol-5-yl)butanoate
[0272] 70
[0273] To a solution of 2-bromo-4-ethylpyridine (310 mg, 1.665
mmol, 4.4 equiv) in anhydrous ether (1.2 mL) at -70.degree. C. in
an oven-dried flask was added n-butyllithium (2.5 M, 0.67 mL, 1.66
mmol, 4.4 equiv) dropwise under nitrogen via syringe. The resulting
deep-red solution was stirred for 5 min before use in the next
step.
[0274] To a 50-mL oven-dried flask was added di-n-butylsulfide (244
mg, 1.665 mmol, 4.4 equiv) and cuprous iodide (159 mg, 0.832 mmol,
2.2 equiv) under nitrogen. Anhydrous ether (1.2 mL) was added and
the suspension was cooled to 0.degree. C. before the solution of
2-pyridinyl lithium was added via canuula. A yellowish brown
precipitate was formed. After stirring at 0.degree. C. for 20 min,
the cooling bath was removed and ethyl
4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)bu-
t-2-enoate (141.7 mg, 0.378 mmol, 1.0 equiv.) in anhydrous ether
(1.2 mL) was added via syringe. The solution was stirred at room
temperature for 1 h. The reaction mixture was then partitioned
between an aqueous ammonium hydroxide/ammonium chloride solution
and ethyl acetate (upon shaking, the solids gradually dissolved to
a give blue aqueous solution). The layers were separated and the
organic layer was washed with water, brine, dried over sodium
sulfate and concentrated in vacuo. Flash column chromatography (5%
methanol in methylene chloride) afforded the desired product (80
mg, 44%) which was carried on without farther purification. MS
(ESI) 482 (MH).sup.+.
(.+-.)-3-(4-Ethylpyridin-2-yl)-4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)butanoic Acid
[0275] 71
[0276] To a flask containing (.+-.)-ethyl
3-(4-ethylpyridin-2-yl)-4-(7-met-
hyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoate
(80 mg, 0.166 mmol, 1.0 equiv) in tetrahydrofuran (4 mL) was added
lithium hydroxide (2.0 M, 0.34 mL, 4.0 equiv). The suspension was
heated at 60.degree. C. under nitrogen overnight. The reaction
mixture was concentrated in vacuo. Hydrochloric acid (1 N, 0.6 mL)
was added and the solution was extracted with ethyl acetate. The
aqueous solution was adjusted to pH 7 with sodium hydroxide (1 N)
and re-extracted with ethyl acetate. The combined ethyl acetate
layers were washed with brine, dried over sodium sulfate and
concentrated in vacuo to give a light yellow oil. MS (ESI) 454
(MH).sup.+.
(.+-.)-3-(1-(3-(4-Ethylpyridin-2-yl)-4-(7-methyl-2-((2-(trimethylsilyl)eth-
oxy)methyl)-2H-indazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-
-2(1H)-one
[0277] 72
[0278] To a solution of
(.+-.)-3-(4-ethylpyridin-2-yl)-4-(7-methyl-2-((2-(-
trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoic acid (0.166
mmol, 1.0 equiv) in methylene chloride (3 mL) was added
3,4-dihydro-3-(4-piperi- dinyl-2(1H)-quinazolinone (46 mg, 0.199
mmol, 1.2 equiv). Triethylamine (70 .mu.L) was then added followed
by 3-(diethoxyphosphoryloxy)-1,2,3-ben- zotriain-4(3H)-one (DEPBT,
60 mg, 0.199 mmol 1.2 equiv) under nitrogen. The resulted cloudy
yellow solution was stirred at room temperature overnight. The
reaction mixture was diluted with ethyl acetate and quenched with
0.5 N sodium hydroxide solution. The layers were separated and the
organic layer was washed with brine, dried over sodium sulfate and
concentrated in vacuo. The residue was purified by flash column
chromatography (10% methanol in methylene chloride) to afford the
desired product (72 mg, 65% for two steps): (ESI) 667
(MH).sup.+.
EXAMPLE 22
(.+-.)-3-(1-(3-(4-Ethylpyridin-2-yl)-4-(7-methyl-1H-indazol-5-yl)butanoyl)-
piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0279] 73
[0280] To the solution of
(.+-.)-3-(1-(3-(4-ethylpyridin-2-yl)-4-(7-methyl-
-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoyl)piperidin-4-
-yl)-3,4-dihydroquinazolin-2(1H)-one (69 mg, 0.103 mmol) in
tetrahydrofuran (2 mL) was added 1M tetrabutylammonium fluoride in
tetrahydrofuran (0.21 mL, 0.207 mmol, 2 equiv). The mixture was
stirred at 60.degree. C. under nitrogen for 4 h. Tetrahydrofuran
was removed in vacuo and the residue was partitioned between water
and ethyl acetate. The layers were separated and the organic layer
was washed with brine, dried over sodium sulfate and concentrated
in vacuo. The residue was purified by flash column chromatography
(10% methanol in methylene chloride) to afford the desired product
(50.3 mg, 91%) as a white powder: MS (ESI) [M+H].sup.+=537.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.48-8.42 (m, 1H),
7.95-7.91 (m, 2H), 7.22-7.10 (m, 2H), 7.06-6.60 (m, 6H), 4.70-4.64
(m, 1H), 4.60-4.42 (m, 1H), 4.24-3.90 (m, 3H), 3.78-3.60 (m, 1H),
3.26-2.92 (m, 3H), 2.92-2.38 (m, 8H), 1.78-1.50 (m, 3H), 1.50-1.12
(m, 2H), 1.12-0.94 (m, 3H).
[0281] The following examples were prepared using methodologies
analogous to those used to prepare Example 22:
EXAMPLE 23
(.+-.)-8-Fluoro-3-(1-(4-(7-methyl-1H-indazol-5-yl)-3-(pyridin-2-yl)butanoy-
l)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0282] 74
[0283] MS (ESI) [M+H].sup.+=527, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 8.68-8.50 (m, 1H), 7.92 (d, J=4.8 Hz, 1H), 7.56-7.36 (m,
2H), 7.24-6.70 (m, 7H), 4.76-4.60 (m, 1H), 4.60-4.42 (m, 1H), 4.26
(s, 1H), 4.13 (s, 1H), 4.01 (t, 1H), 3.80-3.62 (m, 1H), 3.20-2.76
(m, 4H), 2.72-2.32 (m, 5H), 1.78-1.46 (m, 3H), 1.46-1.12 (m,
2H).
EXAMPLE 24
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(pyridin-2-yl)butanoyl)piperid-
in-4-yl)quinolin-2(1H)-one
[0284] 75
[0285] MS (ESI) [M+H].sup.+=506, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 8.60-8.54 (m, 1H), 7.92 (s, 1H), 7.50-6.86 (m, 10H), 4.72
(d, J=12.8 Hz, 1H), 4.03 (d, J=13.0 Hz, 1H), 3.78-3.70 (m, 1H),
3.20-2.90 (m, 5H), 2.80-2.50 (m, 2H), 2.42 (s, 3H), 2.42-2.10 (br,
1H), 2.06-1.80 (m, 2H), 1.58-0.96 (m, 3H). HPLC t.sub.R=1.23
min.
EXAMPLE 25
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(3-methylpyridin-2-yl)butanoyl-
)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0286] 76
[0287] MS (ESI) [M+H].sup.+=523, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 8.52-8.40 (m, 1H), 7.93 (s, 1H), 7.26-6.60 (m, 9H),
4.72-4.36 (m, 2H), 4.24 (s, 1H), 4.20-3.90 (m, 2H), 3.20-2.78 (m,
2H), 2.46 (s, 3H), 2.30-1.96 (m, 2H), 1.90-1.24 (m, 8H), 1.24 (s,
3H).
EXAMPLE 26
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(5-methylpyridin-2-yl)butanoyl-
)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0288] 77
[0289] MS (ESI) [M+H].sup.+=523, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 8.39 (d, J=11.2 Hz, 1H), 8.02 (d, J=16.8 Hz, 1H), 7.93 (d,
J=4.8 Hz, 1H), 7.32-7.05 (m, 3H), 7.05-6.78 (m, 4H), 6.78-6.65 (m,
1H), 4.72-4.60 (m, 1H), 4.60-4.42 (m, 1H), 4.22 (s, 1H), 4.10 (s,
1H), 4.08-3.90 (m, 1H), 3.78-3.60 (m, 1H), 3.20-2.78 (m, 4H),
2.70-2.56 (m, 1H), 2.44 (d, J=6.8 Hz, 3H), 2.25 (s, 3H), 1.80-1.52
(m, 4H), 1.52-1.10 (m, 2H).
EXAMPLE 27
(.+-.)-3-(1-(3-(5-(Hydroxymethyl)pyridin-2-yl)-4-(7-methyl-1H-indazol-5-yl-
)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0290] 78
[0291] MS (ESI) [M+H].sup.+=539, .sup.1H-NMR (500 MHz, CD.sub.3OD)
.delta. 8.53 (d, J=26.0 Hz, 1H), 7.89 (d, J=7.5 Hz, 1H), 7.66-7.58
(m, 1H), 7.23 (d, J=8.5 Hz, 1H), 7.20-7.07 (m, 4H), 6.98 (d, J=8.5
Hz, 1H), 6.96-6.90 (m, 1H), 6.78 (dd, J=8.0 and 2.0 Hz, 1H), 4.61
(s, 2H), 4.60-4.48 (m, 2H), 4.45-4.32 (m, 1H), 4.32 (s, 1H), 4.20
(s, 1H), 4.06 (t, J=15.0 Hz, 1H), 3.72-3.64 (m, 1H), 3.34-3.31 (m,
1H), 3.28-2.94 (m, 5H), 2.82-2.50 (m, 2H), 1.90-1.20 (m, 6H).
EXAMPLE 28
(.+-.)-6-(1-(7-Methyl-1H-indazol-5-yl)-4-oxo-4-(4-(2-oxo-1,2-dihydroquinaz-
olin-3(4H)-yl)piperidin-1-yl)butan-2-yl)nicotinaldehyde
[0292] 79
[0293] Solid
(.+-.)-3-(1-(3-(5-(hydroxymethyl)pyridin-2-yl)-4-(7-methyl-1H-
-indazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
(20.9 mg, 0.025 mmol, 1.0 equiv) and Dess-Martin reagent (21.8 mg,
2.0 equiv) were dissolved in anhydrous methylene chloride (2 mL).
The cloudy solution was stirred at room temperature for 1 h. The
reaction was quenched with 0.5 N sodium hydroxide. The layers were
separated and the organic layer was washed with brine, dried over
sodium sulfate and concentrated to give an off-white solid.
Purification by flash column chromatography (10% MeOH in methylene
chloride) afforded the desired product (9.5 mg, 69%) as a colorless
oily solid. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 10.02 (d,
J=8.0 Hz, 1H), 9.06 (d, J=16.4 Hz, 1H), 7.94-7.82 (m, 2H),
7.18-7.08 (m, 4H), 7.08-6.84 (m, 3H), 6.65 (d, J=7.6 Hz, 1H),
4.68-4.44 (m, 2H), 4.24, 4.16 (2s, 1H), 4.05-3.95 (m, 1H),
3.88-3.76 (br. 1H), 3.30-2.92 (m, 4H), 2.72-2.47 (m, 2H), 2.47 (s,
3H), 1.84-1.35 (m, 6H).
EXAMPLE 29
(.+-.)-3-(1-(4-(7-Methyl-1H-indazol-5-yl)-3-(5-(piperidin-1-ylmethyl)pyrid-
in-2-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0294] 80
[0295] A solution of
(.+-.)-6-(1-(7-methyl-1H-indazol-5-yl)-4-oxo-4-(4-(2--
oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-1-yl)butan-2-yl)nicotinaldehy-
de (previous example, 8 mg, 0.015 mmol, 1.0 equiv.) in
dichloroethane (1 mL) was treated with by 2 drops of piperidine.
Excess Na(OAc).sub.3BH was added and the reaction mixture was
stirred at room temperature overnight. The mixture was directly
purified by flash column chromatography (10% of 2M ammonia in
methanol in methylene chloride) afforded the desired product (10.1
mg, 72% for two steps). MS (ESI) [M+H].sup.+=606, .sup.1H-NMR (400
MHz, CDCl.sub.3) .delta. 8.47 (d, J=16.0 Hz, 1H), 7.89 (d, J=8.0
Hz, 1H), 7.42-7.33 (m, 1H), 7.16-7.10 (m, 2H), 7.04-6.97 (m, 2H),
6.94-6.85 (m, 3H), 6.64 (d, J=8.0 Hz, 1H), 4.67 (d, J=14.0 Hz, 1H),
4.60-4.45 (m, 1H), 4.24, 4.14 (2s, 1H), 4.10-3.90 (m, 1H),
3.70-3.64 (m, 1H), 3.41-3.37 (m, 2H), 3.18-2.80 (m, 5H), 2.72-2.10
(m, 12H), 1.75-1.28 (m, 8H). HPLC t.sub.R=1.22 min.
4-Nitrophenyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxy-
late
[0296] 81
[0297] To a solution of
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one hydrochloride
salt (1.5347 g, 5.73 mmol) in methylene chloride (100 mL) and
triethylamine (2.39 mL, 3.0 equiv) was added
nitrophenylchloroformate (1.3863 g, 1.2 equiv) at room temperature
under nitrogen. The reaction was stirred at room temperature
overnight. The solvent was removed in vacuo to give a yellow solid.
This solid was taken up in methylene chloride (60 mL) and washed
with 1 N sodium hydroxide (30 mL). The methylene chloride layer was
dried over sodium sulfate, filtered and concentrated to give a
solid. The solid was further tritrated with methylene chloride (20
mL) to give the desired product (1.41 g, 62%). HPLC t.sub.R=1.85
min, MS(ESI)[M+H.sup.+=397.07.
[0298] Similarly prepared:
4-Nitrophenyl 4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxylate
[0299] 82
[0300] Yield: 60%. .sup.1H-NMR (500 MHz, DMSO-d.sub.6) .delta. 9.28
(s, 1H), 8.30 (d, J=9.2 Hz, 2H), 7.47 (d, J=9.2 Hz, 2H), 7.08-7.04
(m, 1H), 6.98 (d, J=7.3 Hz, 1H), 6.91-6.88 (m, 1H), 4.46-4.40 (m,
1H), 4.41 (s, 2H), 4.32-4.26 (m, 1H), 4.18-4.13 (m, 1H), 3.19-3.14
(m, 1H), 3.05-2.99 (m, 1H), 1.95-1.80 (m, 2H), 1.68-1.66 (m, 2H).
Mass spec.: 415 (MH).sup.+.
Isoquinoline-3-carbaldehyde
[0301] 83
[0302] A solution of methyl 3-isoquinolinecarboxylate (2.0 g, 10.7
mmol) in toluene was cooled to -78.degree. C. To the solution was
added diisobutylaluminum hydride (1M in toluene, 21.4 mL, 21.4
mmol) slowly over 15 minutes via syringe. While still at
-78.degree. C., the reaction was quenched with a solution of ether
(80 mL), acetic acid (20 mL) and water (8 mL) and then the mixture
was allowed to slowly warm to room temperature overnight. The
organics were decanted and the solvent was evaporated. Flash column
chromatography (gradient 1:4 ethyl acetate/hexanes to 1:3 ethyl
acetate/hexanes) provided 1.1 grams of the title compound (65%
yield). .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 10.24 (s, 1H),
9.35 (s, 1H), 8.36 (s, 1H), 8.07-7.98 (m, 2H), 7.82-7.32 (m, 2H).
Mass spec.: 158 (MH).sup.+.
Diphenyl (6-bromopyridin-2-yl)(phenylamino)methylphosphonate
[0303] 84
[0304] To 2-bromopyridyl-6-carboxaldehyde (1.92 g, 10 mmol)
dissolved in isopropanol (22 mL) at room temperature, was added
aniline (1.1 mL, 12 mmol) followed by (PhO).sub.2P(O)H (3.4 mL, 16
mmol). The mixture was stirred at room temperature for 1 h. The
mixture was left to stand at room temperature for 2 h and was
cooled in a refrigerator for 20 min before the solids were filtered
and washed three times with isopropanol. Drying under high vacuum
afforded the desired product as a white solid (4.38 g, 88%). MS
(ESI) [M+H].sup.+=495.
[0305] The following intermediates were similarly prepared:
Diphenyl (4-nitropyridin-2-yl)(phenylamino)methylphosphonate
[0306] 85
[0307] MS (ESI) [M+H].sup.+=484. HPLC t.sub.R=1.83 min.
Diphenyl (phenylamino)(quinolin-2-yl)methylphosphonate
[0308] 86
[0309] Yield: 83.2%. MS (ESI) [M+H].sup.+=467. HPLC t.sub.R=1.93
min.
Diphenyl
(6-tert-butoxypyridin-2-yl)(phenylamino)methylphosphonate
[0310] 87
[0311] Yield: 82.3%. MS (ESI) [M+Na].sup.+=511. HPLC t.sub.R=2.03
min.
Diphenyl (4-((tert-butyldimethylsilyloxy)methyl)pyridin-2-yl)
(phenylamino) methyl-phosphonate
[0312] 88
[0313] Yield: 78.2%. MS (ESI) [M+H].sup.+=561. HPLC t.sub.R=2.36
min.
Methyl
2-((diphenoxyphosphoryl)(phenylamino)methyl)isonicotinate
[0314] 89
[0315] Yield: 74.6%. MS (ESI) [M+Na].sup.+=496. HPLC t.sub.R=2.03
min.
Diphenyl isoquinolin-3-yl(phenylamino)methylphosphonate
[0316] 90
[0317] Yield: 84%. .sup.1H-NMR (DMSO-d.sub.6, 300 MHz) .delta. 9.33
(s, 1H), 8.17-8.12 (m, 2H), 7.94 (d, J=8.1 Hz, 1H), 7.70 (t, J=7.0
Hz, 1H), 7.68 (t, J=7.4 Hz, 1H), 7.37-7.25 (m, 4H), 7.21-7.04 (m,
6H), 6.99-6.02 (m, 4H), 6.71 (dd, J=10.2, 4.8 Hz, 1H), 6.59 (t,
J=7.0 Hz, 1H), 5.80 (d, J=10.2 Hz, 0.5H), 5.72 (d, J=10.2 Hz,
0.5H). Mass spec.: 467 (MH).sup.+.
Diphenyl
(4,6-dimethylpyrimidin-2-yl)(phenylamino)methylphosphonate
[0318] 91
[0319] Yield: 92%. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
7.24-6.74 (14H, m), 5.53 (1H, d, J=24.), 2.37 (6H, s). HPLC
t.sub.R=2.05 min, MS(ESI)[M+H.sup.+]=446.11.
Diphenyl furan-2-yl(phenylamino)methylphosphonate
[0320] 92
[0321] Yield: 98%. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
7.37-6.31 (18H, m), 5.30 (1H, d, J=24.4 Hz). HPLC t.sub.R=2.10 min,
MS(ESI)[M+Na.sup.+]=428.04.
Diphenyl benzofuran-2-yl(phenylamino)methylphosphonate
[0322] 93
[0323] Yield: 98%. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
7.37-6.31 (20H, m), 5.41 (1H, d, J=24.8 Hz). HPLC t.sub.R=2.23 min,
MS(ESI) [M+H.sup.+]=456.01.
7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole-5-carbaldehyde
[0324] 94
[0325] To a solution of 7-methyl-1H-indazole-5-carbaldehyde (5.0 g,
31.25 mmol) and N-methyl-dicyclohexylamine (13.5 mL, 62.35 mmol) in
dry tetrahydrofuran (120 mL) at 0.degree. C., was added
2-(trimethylsilyl)ethoxymethyl chloride (6.65 mL, 39.5 mmol). The
ice-bath was removed and stirring continued for 5 h. The reaction
mixture was diluted with ethyl acetate, washed with water
(2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated in vacuo. Column chromatography afforded 8.5 g (93%).
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 12.3 (br., 1H), 8.13 (s,
1H), 7.88 (s, 1H), 7.42 (s, 1H), 6.12 (d, J=7.0 Hz, 1H), 5.31 (d,
J=7.0 Hz, 1H), 3.80 (s, 3H), 2.60 (s, 3H).
1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2-
H-indazol-5-yl)ethanone
[0326] 95
[0327] To an oven-dried flask under nitrogen was charged with
cesium carbonate (1.98 g, 6.09 mmol, 1.3 equiv, dried at
150.degree. C. under high vacuum for 16 h) followed by diphenyl
(6-bromopyridin-2-yl)(phenylam- ino)methylphosphonate (2.32 g, 4.68
mmol) and 7-methyl-2-((2-(trimethylsil-
yl)ethoxy)methyl)-2H-indazole-5-carbaldehyde (1.36 g, 4.68 mmol).
Anhydrous tetrahydrofuran (9.6 mL) was introduced followed by
anhydrous isopropanol (2.4 mL) via syringe under nitrogen. The
yellow suspension was stirred at room temperature under nitrogen
overnight (16.5 h). To the resulting suspension was added 1N
hydrochloric acid (16 mL) and the resulting red solution was
stirred at room temperature for 2 h until LCMS showed complete
hydrolysis to the desired product. The reaction mixture was
neutralized with 1N sodium hydroxide (12 mL) and then extracted
with ethyl acetate (3.times.). The combined organic layers was
washed with brine, dried over sodium sulfate and concentrated in
vacuo. The residue was purified by flash column chromatography to
afford the desired product as a yellow oil (2.013 g, 93.6%). MS
(ESI) [M+H].sup.+=461. HPLC t.sub.R=2.09 min.
[0328] The following intermediates were similarly prepared:
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(quino-
lin-2-yl)ethanone
[0329] 96
[0330] Yield: 75.4% (2 steps). MS (ESI) [M+H].sup.+=432. HPLC
t.sub.R=2.11 min.
1-(6-tert-Butoxypyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)met-
hyl)-2H-indazol-5-yl)ethanone
[0331] 97
[0332] Yield: 100%. MS (ESI) [M+H].sup.+=454. HPLC t.sub.R=2.16
min.
Methyl
2-(2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)acetyl)isonicotinate
[0333] 98
[0334] MS (ESI) [M+H].sup.+=440. HPLC t.sub.R=2.20 min. Mixed with
the isopropyl ester (from solvent exchange): MS (ESI)
[M+H].sup.+=468. HPLC t.sub.R=2.31 min.
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyrid-
in-2-yl)ethanone
[0335] 99
[0336] Yield: 80%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 8.71
(d, J=4.8 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H), 7.98 (s, 1H), 7.83-7.77
(m, 1H), 7.47-7.43 (m, 1H), 7.42 (s, 1H), 7.00 (s, 1H), 5.68 (s,
2H), 4.55 (s, 2H), 3.60-3.55 (m, 2H), 2.57 (s, 3H), 0.93-0.87 (m,
2H), -0.06 (s, 9H). Mass spec.: 382 (MH).sup.+.
1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-i-
ndazol-5-yl)ethanone
[0337] 100
[0338] Yield: 53%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 9.31
(s, 1H), 8.48 (s, 1H), 8.05-8.02 (m, 1H), 7.98 (s, 1H), 7.97-7.94
(m, 1H), 7.77-7.68 (m, 2H), 7.46 (s, 1H), 7.06 (s, 1H), 5.68 (s,
2H), 4.66 (s, 2H), 3.60-3.54 (m, 2H), 2.58 (s, 3H), 0.92-0.85 (m,
2H), -0.07 (s, 9H). Mass spec.: 432 (MH).sup.+.
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)ethanol
[0339] 101
[0340] To a solution of
(.+-.)-1-(6-bromopyridin-2-yl)-2-(7-methyl-2-((2-(-
trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethanone (977 mg,
2.12 mmol) in methanol (10 mL) at room temperature under nitrogen
was added sodium borohydride (97 mg, 2.55 mmol, 1.2 equiv) in one
portion. The solution was stirred at room temperature for 1 h.
Methanol was then removed under vacuum and the residue was
partitioned between water and ethyl acetate. The organic layer was
separated, washed with brine, dried and concentrated to give a
light yellow oil (1 g, 100%). MS (ESI) [M+H].sup.+=463. HPLC
t.sub.R=1.93 min.
[0341] The following intermediates were similarly prepared:
(.+-.)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-
-(4-nitropyridin-2-yl)ethanol
[0342] 102
[0343] Yield: 11.3% (2 steps). MS (ESI) [M+H].sup.+=429. HPLC
t.sub.R=1.81 min.
(.+-.)-1-(6-tert-Butoxypyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)eth-
oxy)methyl)-2H-indazol-5-yl)ethanol
[0344] 103
[0345] Yield: 51.8%. MS (ESI) [M+Na].sup.+=478. HPLC t.sub.R=1.97
min.
(.+-.)-Methyl
2-(1-hydroxy-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl-
)-2H-indazol-5-yl)ethyl)isonicotinate
[0346] 104
[0347] Yield: 30% (along with 28% of the isopropyl ester). MS (ESI)
[M+Na].sup.+=464. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.47
(d, J=5.2 Hz, 1H), 7.84 (s, 1H), 7.81 (s, 1H), 7.58-7.52 (m, 1H),
7.16 (s, 1H), 6.81 (s, 1H), 5.53 (s, 2H), 5.02-4.95 (m, 1H), 4.30
(br., 1H), 3.77 (s, 3H), 3.50 (t, J=8.2 Hz, 2H), 3.12 (dd, J=13.8
and 3.8 Hz, 1H), 2.83 (dd, J=13.6 and 8.8 Hz, 1H), 2.42 (s, 3H),
0.81 (t, J=8.2 Hz, 2H), -0.14 (s, 9H). HPLC t.sub.R=1.98 min.
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyrid-
in-2-yl)ethanol
[0348] 105
[0349] Yield: 68%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 8.53
(d, J=4.8 Hz, 1H), 7.96 (s, 1H), 7.60 (td, J=7.7, 1.8 Hz, 1H), 7.25
(bs, 1H), 7.17 (t, J=7.7 Hz, 2H), 5.68 (s, 2H), 5.01-4.97 (m, 1H),
3.62-3.56 (m, 2H), 3.16-3.09 (m, 1H), 3.02-2.95 (m, 1H), 2.56 (s,
3H), 0.93-0.88 (m, 2H), -0.06 (s, 9H). Mass spec.: 384
(MH).sup.+.
1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-i-
ndazol-5-yl)ethanol
[0350] 106
[0351] Yield: 68%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 9.22
(s, 1H), 7.96 (s, 1H), 7.95 (d, J=7.0 Hz, 1H), 7.73 (d, J=8.0 Hz,
1H), 7.65 (t, J=7.0 Hz, 1H), 7.58-7.53 (m, 2H), 7.30 (s, 1H), 6.95
(s, 1H), 5.68 (s, 2H), 5.16-5.11 (m, 1H), 3.62-3.56 (m, 2H), 3.30
(dd, J=13.5, 4.8 Hz, 1H), 3.04 (dd, J=13.9, 8.4 Hz, 1H), 2.55 (s,
3H), 0.94-0.88 (m, 2H), -0.06 (s, 9H). Mass spec.: 434
(MH).sup.+.
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyrid-
in-3-yl)ethanol
[0352] 107
[0353] Yield: 14% (3 steps). HPLC t.sub.R=1.72 min,
MS(ESI)[M+H.sup.+]=384.19.
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)ethanol
[0354] 108
[0355] Yield: 36% (3 steps). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.98 (1H, s), 7.36 (1H, s), 6.93 (1H, s), 6.92 (1H, s),
5.69 (2H, s), 5.05 (1H, m), 3.59 (2H, t, J=8.0 Hz), 3.36 (1H, m),
2.94 (1H, m), 2.56 (3H, s), 2.48 (6H, s), 0.92 (2H, t, J=8.0 Hz),
-0.04 (9H, s). HPLC t.sub.R=1.94 min,
MS(ESI)[M+H.sup.+]=413.21.
1-(Furan-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-
-5-yl)ethanol
[0356] 109
[0357] Yield: 27% (3 steps). .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 8.21 (1H, s), 7.40 (1H, s), 7.32 (1H, s), 6.89 (1H, s),
6.23 (1H, m), 5.68 (2H, s), 4.96 (1H, m), 3.64 (2H, t, J=8.4 Hz),
3.23 (1H, m), 3.18 (1H, m), 2.56 (3H, s), 0.92 (2H, t, J=8.4 Hz),
-0.06 (9H, s). HPLC t.sub.R=2.06 min,
MS(ESI)[M+H.sup.+]=373.12.
1-(Benzofuran-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-in-
dazol-5-yl)ethanol
[0358] 110
[0359] Yield: 35% (3 steps). HPLC t.sub.R=2.15 min,
MS(ESI)[M+H.sup.+=423.06.
(.+-.)-2-(1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy-
)methyl)-2H-indazol-5-yl)ethyl)isoindoline-1,3-dione
[0360] 111
[0361] A solution of phthalimide (294 mg, 2 mmol) and
triphenylphosphine (525 mg, 2 mmol) in anhydrous methylene chloride
(10 mL) was added via syringe to
(.+-.)-1-(6-bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsil-
yl)ethoxy)methyl)-2H-indazol-5-yl)ethanol (460 mg, 1 mmol). To the
resulting suspension was then added diisopropylazidodicarboxylate
(0.3 mL, 1.5 mmol) under nitrogen at room temperature via syringe.
The resulting mixture was stirred at room temperature overnight (17
h). The mixture was diluted with hexane and purified by flash
column chromatography to give a light yellow oil (700 mg, 100%). MS
(ESI) [M+H].sup.+=592. HPLC t.sub.R=2.05 min.
[0362] The following intermediates were similarly prepared:
(.+-.)-2-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(pyridin-2-yl)ethyl)isoindoline-1,3-dione
[0363] 112
[0364] Yield: 79%. MS (ESI) [M+H]+=513. HPLC t.sub.R=1.87 min.
(.+-.)-2-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(4-nitropyridin-2-yl)ethyl)isoindoline-1,3-dione
[0365] 113
[0366] Yield: 83%. MS (ESI) [M+H].sup.+=558. HPLC t.sub.R=1.99
min.
(.+-.)-2-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(quinolin-2-yl)ethyl)isoindoline-1,3-dione
[0367] 114
[0368] Yield: 89.4%. MS (ESI) [M+H].sup.+=563. HPLC t.sub.R=2.03
min.
2-(1-(isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2-
H-indazol-5-yl)ethyl)isoindoline-1,3-dione
[0369] 115
[0370] Yield: 44%. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 9.24
(s, 1H), 7.95 (d, J=8.2 Hz, 1H), 7.91 (s, 1H), 7.84-7.81 (m, 2H),
7.76-7.73 (m, 2H), 7.68 (t, J=7.6 Hz, 1H), 7.64-7.62 (m, 2H), 7.58
(t, J=7.6 Hz, 1H), 7.39 (s, 1H), 7.08 (s, 1H), 6.09-6.06 (m, 1H),
5.64 (s, 2H), 4.04-3.99 (m, 1H), 3.90-3.86 (m, 1H), 3.61-3.57 (m,
2H), 2.53 (s, 3H), 0.92-0.88 (m, 2H), -0.07 (s, 9H). Mass spec.:
563 (MH).sup.+.
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)ethanamine
[0371] 116
[0372] A solution of
(O)-2-(1-(6-bromopyridin-2-yl)-2-(7-methyl-2-((2-(tri-
methylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl)isoindoline-1,3-dione
(1 mmol) in methanol (10 mL) was treated with hydrazine (0.16 mL, 5
mmol) at room temperature for 30 min and at 70.degree. C. for 5 h.
The mixture was concentrated in vacuo and the residue was
partitioned between 1N sodium hydroxide and ethyl acetate. The
organic layer was washed with water, brine, dried and concentrated.
The pale yellow oil (100%) was pure enough to carry on. MS (ESI)
[M+H].sup.+=461. HPLC t.sub.R=1.62 min.
[0373] The following intermediates were similarly prepared:
(.+-.)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-
-(pyridin-2-yl)ethanamine
[0374] 117
[0375] Yield: 100%. MS (ESI) [M+H].sup.+=383. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.58 (d, J=4.4 Hz, 1H), 7.97 (s, 1H), 7.62-7.54
(m, 1H), 7.24 (s, 2H), 7.16-7.10 (m, 1H), 6.89 (s, 1H), 5.69 (s,
2H), 4.30-4.24 (m, 1H), 3.64-3.56 (m, 2H), 3.15 (dd, J=13.4 and 5.0
Hz, 1H), 2.85 (dd, J=13.2 and 8.8 Hz, 1H), 2.57 (s, 3H), 2.15-1.85
(br., 2H), 0.95-0.86 (m, 2H), -0.051 (s, 9H). HPLC t.sub.R=1.54
min.
(.+-.)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-
-(4-nitropyridin-2-yl)ethanamine
[0376] 118
[0377] Yield: 100%. MS (ESI) [M+H].sup.+=428. HPLC t.sub.R=1.51
min.
(.+-.)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-
-(quinolin-2-yl)ethanamine
[0378] 119
[0379] Yield: 96.4%. MS (ESI) [M+H].sup.+=433. HPLC t.sub.R=1.67
min.
1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-i-
ndazol-5-yl)ethanamine
[0380] 120
[0381] Yield: 88%. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 9.26
(s, 1H), 7.98 (s, 1H), 7.97 (d, J=7.3 Hz, 1H), 7.75 (d, J=8.2 Hz,
1H), 7.66 (t, J=8.2 Hz, 1H), 7.62 (s, 1H), 7.57 (t, J=7.0 Hz, 1H),
7.31 (s, 1H), 6.95 (s, 1H), 5.70 (s, 2H), 4.52-4.49 (m, 1H),
3.64-3.60 (m, 2H), 3.35-3.32 (m, 1H), 3.02-2.98 (m, 1H), 2.57 (s,
3H), 0.95-0.92 (m, 2H), -0.03 (s, 9H). Mass spec.: 433
(MH).sup.+.
(.+-.)-N-(1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy-
)methyl)-2H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide
[0382] 121
[0383] A solution of
(.+-.)-1-(6-bromopyridin-2-yl)-2-(7-methyl-2-((2-(tri-
methylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethanamine (389 mg,
0.843 mmol) and carbonyl diimidazole (144 mg, 0.885 mmol, 1.05
equiv) in anhydrous methylene chloride (6 mL) was stirred at room
temperature for 1 h. Solid
3,4-dihydro-3-(4-piperidinyl-2(1H)-quinazolinone (HCl salt, 248 mg,
0.927 mmol, 1.1 equiv) was then added in one portion followed by
diisopropylethylamine (0.22 mL, 1.26 mmol, 1.5 equiv). The
resulting reaction mixture was stirred at room temperature
overnight. The mixture was purified by flash column chromatography
(10% methanol in methylene chloride) to afford the desired product
(548 mg, 90.4%) as a light yellow oil: (ESI) 718 (MH).sup.+.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.10 (br. 1H), 7.91 (s,
1H), 7.28-7.26 (m, 1H), 7.17-6.75 (m, 7H), 6.71 (d, J=7.6 Hz, 1H),
5.73 (d, J=8.0 Hz, 1H), 5.62 (s, 2H), 5.20-5.10 (m, 1H), 5.00-4.84
(m, 2H), 4.58-4.45 (m, 1H), 4.06 (d, J=14.0 Hz, 2H), 3.57 (t, J=8.2
Hz, 2H), 3.25-3.18 (dd, 1H), 3.02-2.92 (dd, 1H), 2.90-2.78 (m, 2H),
2.52 (s, 3H), 1.78-1.46 (m, 4H), 0.88 (t, J=8.2 Hz, 2H), -0.083 (s,
9H). HPLC t.sub.R=1.96 min.
[0384] The following intermediates were similarly prepared:
(.+-.)-N-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(pyridin-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-
e-1-carboxamide
[0385] 122
[0386] Yield: 62%. (ESI) 640 (MH).sup.+. HPLC t.sub.R=1.61 min.
(.+-.)-N-(2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(4-nitropyridin-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pi-
peridine-1-carboxamide
[0387] 123
[0388] Yield: 79.5%. (ESI) 684 (MH).sup.+. HPLC t.sub.R=1.89
min.
(.+-.)-N-(2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(quinolin-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidi-
ne-1-carboxamide
[0389] 124
[0390] Yield: 16%. (ESI) 690 (MH).sup.+. HPLC t.sub.R=1.71 min.
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)-N-(2-(7-methyl-2-
-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(quinolin-2-yl)ethy-
l)piperidine-1-carboxamide
[0391] 125
[0392] Yield: 28.4%. (ESI) 708 (MH).sup.+. HPLC t.sub.R=1.74
min.
N-(1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2-
H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide
[0393] 126
[0394] Yield: 61%. Mass spec.: 690 (MH).sup.+.
4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(1-(isoquinolin-3-yl)--
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl)pip-
eridine-1-carboxamide
[0395] 127
[0396] Yield: 85%. Mass spec.: 708 (MH).sup.+.
1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2-
H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pipe-
ridine-1-carboxylate
[0397] 128
[0398] To an oven-dried flask was added
(.+-.)-1-(6-bromopyridin-2-yl)-2-(-
7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethanol
(102.6 mg, 0.222 mmol) and p-nitrophenyl chloroformate (89.4 mg,
0.444 mmol, 2.0 equiv) followed by methylene chloride (2 mL) under
nitrogen and diisopropylethylamine (0.1 mL, 0.555 mmol, 2.5 equiv).
The mixture was stirred at room temperature for 2 days. Solid
8-fluro-3,4-dihydro-3-(4-pi- peridinyl-2(1H)-quinazolinone (105 mg,
0.44 mmol, 2.0 equiv) was added followed by diisopropylethylamine
(0.2 mL). The resulting mixture was stirred at room temperature
overnight. It was then diluted with ethyl acetate and washed with
0.5 N sodium hydroxide, water, brine, dried and concentrated. The
residue was purified by flash column chromatography (70% ethyl
acetate in hexane) to afford the desired product (91 mg, 55.6%).
(ESI) 737 (MH).sup.+. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
7.92 (s, 1H), 7.50-6.70 (m, 9H), 6.02-5.80 (m, 1H), 5.80-5.45 (m,
2H), 4.60-3.78 (m, 4H), 3.70-3.48 (m, 2H), 3.48-3.02 (m, 2H),
3.00-2.62 (m, 2H), 2.57 (s, 3H), 1.90-0.70 (m, 7H), -0.08 (s, 9H).
HPLC t.sub.R=2.04 min.
[0399] The following intermediates were similarly prepared:
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperi-
dine-1-carboxylate
[0400] 129
[0401] Yield: 45.9%. (ESI) 719 (MH).sup.+. HPLC t.sub.R=2.07
min.
(.+-.)-1-(6-tert-Butoxypyridin-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)eth-
oxy)methyl)-2H-indazol-5-yl)ethyl 4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxylate
[0402] 130
[0403] Yield: 67%. (ESI) 735 (M+Na).sup.+. HPLC t.sub.R=2.69
min.
N-(1-(isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2-
H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carbo-
xamide
[0404] 131
[0405] Yield: quantitative. .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. 9.52 (s, 1H), 9.26 (s, 1H), 7.97 (d, J=7.0 Hz, 1H), 7.87
(s, 1H), 7.67-7.63 (m, 2H), 7.60-7.56 (m, 1H), 7.53 (d, J=7.0 Hz,
1H), 7.46-7.42 (m, 2H), 7.86-7.81 (m, 1H), 7.19 (t, J=7.0 Hz, 1H),
7.15 (d, J=8.2 Hz, 1H), 7.10-7.07 (m, 1H), 6.85 (bs, 1H), 5.63 (s,
2H), 5.41-5.37 (m, 1H), 4.22-4.13 (m, 2H), 3.60-3.56 (m, 2H),
3.45-3.37 (m, 1H), 3.25-3.17 (m, 1H), 3.13-3.08 (m, 1H), 2.50 (s,
3H), 3.00-2.91 (m, 2H), 1.98-1.92 (m, 2H), 1,58-1.43 (m, 3H),
0.99-0.93 (m, 1H), 0.91-0.88 (m, 2H), -0.06 (s, 9H). Mass spec.:
687 (MH).sup.+.
(.+-.)-2-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl-
)-1-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbonyloxy)ethy-
l)isonicotinic acid
[0406] 132
[0407] To a suspension of (.+-.)-methyl
2-(1-hydroxy-2-(7-methyl-2-((2-(tr-
imethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl)isonicotinate
(233 mg, 0.527 mmol 1.0 equiv) and 4-nitrophenyl
4-(2-oxo-1,2-dihydroquinazolin-3(- 4H)-yl)piperidine-1-carboxylate
(251 mg, 0.632 mmol, 1.2 equiv) in tetrahydrofuran (6 mL) was added
sodium hydride (91 mg, 7 equiv) in one portion. The resulting
mixture was stirred at room temperature under nitrogen overnight.
The mixture was partitioned between water and ethyl acetate. The
layers were separated and the aqueous layer was acidified to pH 5
with acetic acid. The aqueous portion was extracted twice with
ethyl acetate. The combined organic layers were washed with brine,
dried and concentrated. The residue was purified by flash column
chromatography (20% methanol in methylene chloride) to afford the
desired acid (227 mg, 62.8%) as a tan solid. (ESI) 685 (MH).sup.+.
HPLC t.sub.R=2.19 mm.
EXAMPLE 30
(.+-.)-N-(1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2--
oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0408] 133
[0409] To the solution of
(.+-.)-N-(1-(6-bromopyridin-2-yl)-2-(7-methyl-2--
((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dih-
ydroquinazolin-3(4H)-yl)piperidine-1-carboxamide (197.4 mg, 0.274
mmol) in tetrahydrofuran (8 mL) was added 1M tetrabutylammonium
fluoride in tetrahydrofuran (0.55 mL, 0.549 mmol, 2 equiv). The
mixture was stirred under nitrogen at 60.degree. C. for 4 h.
Another 0.5 mL of TBAF was added and the mixture was stirred
overnight. Tetrahydrofuran was removed in vacuo and the residue was
partitioned between water and ethyl acetate. The layers were
separated and the organic layer was washed with brine, dried over
sodium sulfate and concentrated in vacuo. The solid residue was
purified by flash column chromatography (10% methanol in methylene
chloride) to afford the desired product (98 mg, 61%) as a white
solid. MS (ESI) [M+H].sup.+=588, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 7.93 (s, 1H), 7.32-6.78 (m, 9H), 6.69 (d, J=7.6 Hz, 1H),
5.79 (d, J=7.2 Hz, 1H), 5.17 (q, J=6.8 Hz, 1H), 4.60-4.48 (m, 1H),
4.25-4.00 (m, 4H), 3.27 (dd, J=13.2 and 6.4 Hz, 1H), 3.06 (dd,
J=13.6 and 8.0 Hz, 1H), 2.85 (t, J=11.4 Hz, 2H), 2.45 (s, 3H),
1.80-1.50 (m, 5H). HPLC t.sub.R=1.62 mm.
[0410] The following examples were similarly prepared:
EXAMPLE 31
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl)-4-(2-oxo-1,2-
-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0411] 134
[0412] Yield: 95%. MS (ESI) [M+H].sup.+=510. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.52 (m, 1H), 7.90 (s, 1H), 7.58-7.40 (m, 2H),
7.20-6.77 (m, 7H), 6.67 (d, J=8.0 Hz, 1H), 6.18 (d, J=7.2 Hz, 1H),
5.20 (q, J=7.6 Hz, 1H), 4.58-4.48 (m, 1H), 4.21 (s, 2H), 4.21-4.05
(m, 1H), 3.33 (dd, J=13.2 and 5.6 Hz, 1H), 3.08 (dd, J=13.4 and 8.2
Hz, 1H), 3.00-2.77 (m, 2H), 2.45 (s, 3H), 1.80-1.50 (m, 6H). HPLC
t.sub.R=1.07 min.
EXAMPLE 32
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(4-nitropyridin-2-yl)ethyl)-4-(2--
oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0413] 135
[0414] Yield: 6.2%. MS (ESI) [M+H].sup.+=555. HPLC t.sub.R=1.46
min.
EXAMPLE 33
(.+-.)-N-(1-(4-Fluoropyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0415] 136
[0416] Yield: 8.7% (This was formed as a co-product along with
(.+-.)-N-(2-(7-methyl-1H-indazol-5-yl)-1-(4-nitropyridin-2-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide). MS
(ESI) [M+H].sup.+=528. HPLC t.sub.R=1.23 mM.
EXAMPLE 34
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(quinolin-2-yl)ethyl)-4-(2-oxo-1,-
2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0417] 137
[0418] Yield: 80%. MS (ESI) [M+H]+=560. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.20-7.42 (m, 5H), 7.20-6.78 (m, 8H), 6.65 (d,
J=8.0 Hz, 1H), 5.48-5.30 (m, 1H), 4.65-4.48 (m, 1H), 4.23-4.12 (m,
4H), 3.58-3.40 (m, 1H), 3.28-3.08 (m, 1H), 3.02-2.82 (m, 2H), 2.42
(s, 3H), 1.90-1.48 (m, 6H). HPLC t.sub.R=1.22 min.
EXAMPLE 35
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-(7-methyl-1H-
-indazol-5-yl)-1-(quinolin-2-yl)ethyl)piperidine-1-carboxamide
[0419] 138
[0420] Yield: 56%. MS(ESI)[M+H].sup.+=578. .sup.1H-NMR(400 MHz,
CDCl.sub.3) .delta. 8.20-7.42 (m, 5H), 7.20-6.40 (m, 8H), 5.50-5.35
(m, 1H), 4.67-4.50 (m, 1H), 4.31-4.12 (m, 4H), 3.54-3.40 (m, 1H),
3.24-3.08 (m, 1H), 3.02-2.84 (m, 2H), 2.41 (s, 3H), 1.90-1.45 (m,
6H). HPLC t.sub.R=1.23 min.
EXAMPLE 36
N-(1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-di-
hydroquinolin-3-yl)piperidine-1-carboxamide
[0421] 139
[0422] Yield: 75%. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 10.80
(bs, 1H), 9.23 (s, 1H), 7.93 (d, J=7.9 Hz, 1H), 7.86 (s, 0.7H),
7.78 (s, 0.3H), 7.65-7.59 (m, 2H), 7.56-7.53 (m, 1H), 7.51 (d,
J=7.3 Hz, 1H), 7.46-7.40 (m, 2H), 7.33 (s, 0.3H), 7.30 (s, 0.7H),
7.25-7.23 (m, 1H), 7.18-7.12 (m, 2H), 6.93-6.92 (m, 1H), 5.96-5.90
(m, 1H), 5.40-5.35 (m, 1H), 4.16-4.12 (m, 2H), 3.43-3.37 (m, 1H),
3.25-3.20 (m, 1H), 3.14-3.09 (m, 1H), 2.99-2.91 (m, 2H), 2.62 (s,
1H), 2.41 (s, 2H), 1.52-1.43 (m, 3H). Mass spec.: 557
(MH).sup.+.
EXAMPLE 37
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(6-phenylpyridin-2-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0423] 140
[0424] To a microwave tube charged with
(.+-.)-N-(1-(6-bromopyridin-2-yl)--
2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide (24.6 mg, 0.0418 mmol, 1.0 equiv)
was added phenyl boronic acid (7.1 mg, 0.0585 mmol, 1.4 equiv),
Pd(PPh.sub.3).sub.4 (4.8 mg, 0.1 equiv), toluene (1 mL), ethanol
(0.2 mL), and potassium carbonate solution (2M, 0.085 mL). The vial
was sealed and heated by microwave at 140.degree. C. for 30 min.
The mixture was extracted with ethyl acetate. The organic layer was
washed with brine, dried and concentrated. Flash column
chromatography (10% methanol/methylene chloride) afforded the
desired product (20 mg, 81.6%) as an off-white solid: MS (ESI)
[M+H].sup.+=586. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
8.00-7.86 (m, 3H), 7.65-6.82 (m, 12H), 6.74 (d, J=7.2 Hz, 1H), 6.66
(d, J=8.0 Hz, 1H), 6.32 (br., 1H), 5.35-5.20 (m, 1H), 4.62-4.48 (m,
1H), 4.30-4.08 (m, 4H), 3.40 (dd, J=13.2 and 4.2 Hz, 1H), 3.13 (dd,
J=13.2 and 8.4 Hz, 1H), 3.02-2.83 (m, 2H), 2.42 (s, 3H), 1.80-1.55
(m, 4H). HPLC t.sub.R=1.51 min.
EXAMPLE 38
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(6-methylpyridin-2-yl)ethyl)-4-(2-
-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0425] 141
[0426] A microwave tube was charged with
(.+-.)-N-(1-(6-bromopyridin-2-yl)-
-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-y-
l)piperidine-1-carboxamide (11 mg, 0.0187 mmol, 1.0 equiv),
Pd(PPh.sub.3).sub.4 (2 mg, 0.1 equiv) and anhydrous tetrahydrofuran
(0.5 mL) under nitrogen. ZnMeCl (2.0 M in tetrahydrofuran, 0.12 mL,
0.24 mmol) was added via syringe resulting in gas evolution. The
vial was sealed and heated by microwave at 110.degree. C. for 4 h.
Tetrahydrofuran was removed in vacuo and the residue was
partitioned between ethyl acetate and concentrated ammonium
hydroxide solution. The organic layer was separated and washed with
brine, dried and concentrated. Flash column chromatography (10%
methanol/methylene chloride) afforded the desired product (9.2 mg,
94%) as a white powder. MS (ESI) [M+H].sup.+=524. .sup.1H-NMR (400
MHz, CDCl.sub.3) .delta. 7.91 (s, 1H), 7.33 (br., 1H), 7.22-6.80
(m, 7H), 6.65 (d, J=8.0 Hz, 1H), 6.59 (br., 1H), 6.20 (br., 1H),
5.20-5.08 (m, 1H), 4.62-4.48 (m, 1H), 4.22 (s, 2H), 4.20-4.03 (m,
2H), 3.40-3.28 (m, 1H), 3.10-2.97 (m, 1H), 2.97-2.78 (m, 2H), 2.54
(s, 3H), 2.45 (s, 3H), 1.95-1.50 (m, 5H). HPLC t.sub.R=1.11 mm.
EXAMPLE 39
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0427] 142
[0428] Yield: 74.2%. MS (ESI) [M+H]+=607. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 7.98 (s, 1H), 7.60-6.60 (m, 8H), 5.92 (br.,
1H), 4.65-3.80 (m, 5H), 3.55-3.07 (m, 2H), 3.02-2.60 (m, 2H), 2.49
(s, 3H), 1.90-1.00 (m, 6H). HPLC t.sub.R=1.77 min.
EXAMPLE 40
(.+-.)-1-(6-Bromopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0429] 143
[0430] Yield: 26.7%. MS (ESI) [M+H].sup.+=589. HPLC t.sub.R=1.76
min.
EXAMPLE 41
(.+-.)-1-(6-tert-Butoxypyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0431] 144
[0432] Yield: 43%. MS (ESI) [M+Na].sup.+=605. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 7.95 (s, 2H), 7.45-6.59 (m, 7H), 6.50 (d, J=8.4
Hz, 1H), 5.90-5.80 (m, 1H), 4.60-3.90 (m, 4H), 3.42-3.18 (m, 2H),
3.05-2.60 (m, 3H), 2.48 (s, 3H), 1.82-1.68 (m, 2H), 1.59 (s, 9H),
1.45-1.28 (m, 4H). HPLC t.sub.R=2.42 min.
EXAMPLE 42
(.+-.)-2-(7-Methyl-1H-indazol-5-yl)-1-(6-oxo-1,6-dihydropyridin-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0433] 145
[0434] Solid
(.+-.)-1-(6-tert-butoxypyridin-2-yl)-2-(7-methyl-1H-indazol-5-
-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
(previous example) (20.6 mg) was treated with 1 mL formic acid
(90%). After 2 h, the mixture was diluted with water and extracted
three times with ethyl acetate. The combined organic layers were
washed with water, saturated sodium bicarbonate solution, dried and
concentrated. Further drying under high vacuum afforded the product
(11.8 mg, 63.4%) as an off-white powder. MS (ESI) [M+H].sup.+=527.
HPLC t.sub.R=1.68 min.
EXAMPLE 43
(.+-.)-1-(6-Isobutylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0435] 146
[0436] A microwave tube was charged with
(.+-.)-1-(6-bromopyridin-2-yl)-2-- (7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(-
4H)-yl)piperidine-1-carboxylate (13.9 mg, 0.0229 mmol, 1.0 equiv)
and Pd(PPh.sub.3).sub.4 (ca. 2 mg). Isobutylzinc bromide (0.5 M in
tetrahydrofuran, 0.46 mL, 0.23 mmol, 10 equiv) was then added via
syringe under nitrogen. The vial was sealed and heated by microwave
at 110.degree. C. for 4 h. Tetrahydrofuran was removed in vacuo and
the residue was partitioned between ethyl acetate and 0.5 N sodium
hydroxide solution. The organic layer was separated and washed with
brine, dried and concentrated. Flash column chromatography 10%
methanol/methylene chloride) afforded the desired product (9.8 mg,
73.3%) as a glassy solid. MS (ESI) [M+H].sup.+=585. .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. 7.94 (s, 1H), 7.60-7.28 (m, 2H),
7.15-6.68 (m, 7H), 6.01 (br., 1H), 4.60-4.40 (m, 1H), 4.40-4.15 (m,
2H), 4.15-3.90 (m, 1H), 3.85-3.15 (m, 2H), 3.03-2.60 (m, 4H), 2.70
(s, 3H), 2.20-2.02 (m, 1H), 1.82-1.40 (m, 4H), 1.40-1.12 (m, 2H),
1.00-0.90 (m, 6H). HPLC t.sub.R=1.44 min.
[0437] The following example was similarly prepared:
EXAMPLE 44
(.+-.)-1-(6-(3,5-Difluorobenzyl)pyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)-
ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
ylate
[0438] 147
[0439] Yield: 43%. MS (ESI) [M+H].sup.+=655. .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 8.05-7.85 (m, 1H), 7.60-7.40 (m, 1H), 7.15-6.52
(m, 9H), 5.98 (t, J=6.4 Hz, 1H), 4.65-3.88 (m, 8H), 3.52-3.18 (m,
2H), 3.05-2.60 (m, 4H), 2.46 (s, 3H), 1.82-1.38 (m, 4H). HPLC
t.sub.R=2.32 min.
EXAMPLE 45
(.+-.)-1-(6-Cyanopyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0440] 148
[0441] A microwave tube was charged with
(.+-.)-1-(6-bromopyridin-2-yl)-2-- (7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(-
4H)-yl)piperidine-1-carboxylate (18 mg, 0.0296 mmol, 1.0 equiv) and
Pd(PPh.sub.3).sub.4 (ca. 4 mg) and Zn(CN).sub.2 (14 mg, 0.12 mmol,
4 equiv). DMF (0.5 mL) was added via syringe. The vial was sealed
and heated by microwave at 200.degree. C. for 20 min.
Tetrahydrofuran was removed in vacuo and the residue was
partitioned between ethyl acetate and ammonium hydroxide solution.
The organic layer was separated and washed with water, brine, dried
and concentrated. Flash column chromatography (10%
methanol/methylene chloride) afforded the desired product (15.9 mg,
97%) as a white solid. MS (ESI) [M+H].sup.+=554. .sup.1H-NMR (400
MHz, CDCl.sub.3) .delta. 8.01 (s, 1H), 7.72 (br., 1H), 7.62-7.54
(m, 1H), 7.37 (br., 1H), 7.18-6.70 (m, 6H), 6.08-5.83 (m, 1H),
4.65-3.80 (m, 6H), 3.55-3.10 (m, 2H), 3.10-2.64 (m, 2H), 2.53 (s,
3H), 1.90-1.40 (m, 4H). HPLC t.sub.R=1.90 min.
EXAMPLE 46
(.+-.)-1-(4-(Hydroxymethyl)pyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0442] 149
[0443] Yield: 64% (2 steps). MS (ESI) [M+H].sup.+=541. .sup.1H-NMR
(400 MHz, CD.sub.3OD) .delta. 8.50 (d, 1H), 8.04-7.85 (m, 1H),
7.55-7.20 (m, 4H), 7.20-6.80 (m, 4H), 6.73 (d, J=8.0 Hz, 1H),
5.98-5.78 (m, 1H), 4.65 (s, 2H), 4.52-3.70 (m, 4H), 3.40-3.03 (m,
4H), 3.03-2.62 (m, 2H), 2.52 (s, 3H), 2.05-1.10 (m, 5H). HPLC
t.sub.R=1.43 min.
EXAMPLE 47
(.+-.)-1-(4-Formylpyridin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0444] 150
[0445] To solid
(.+-.)-1-(4-(hydroxymethyl)pyridin-2-yl)-2-(7-methyl-1H-in-
dazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carb- oxylate
(28 mg, 0.0518 mmol, 1.0 equiv) was added Dess-Martin reagent (44
mg, 0.104 mmol, 2.0 equiv) and anhydrous methylene chloride (4 mL).
The cloudy solution was stirred at room temperature for 2 h. The
reaction was quenched with 0.5 N sodium hydroxide. The layers were
separated and the organic layer was washed with brine, dried and
concentrated to give an off-white solid. Purification by flash
column chromatography (10% methanol/methylene chloride) afforded
the desired product (23 mg, 82.4%) as an off-white powder. MS (ESI)
[M+Na].sup.+=559. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 10.02
(s, 1H), 8.88 (d, J=3.2 Hz, 1H), 7.97 (s, 1H), 7.70-7.40 (m, 3H),
7.26-6.75 (m, 5H), 6.67 (br., 1H), 6.13-5.90 (m, 1H), 4.65-3.75 (m,
4H), 3.50-3.10 (m, 3H), 3.10-2.68 (m, 2H), 2.50 (s, 3H), 1.95-1.38
(m, 5H). HPLC t.sub.R=1.59 min.
EXAMPLE 48
(.+-.)-2-(2-(7-Methyl-H-indazol-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazolin-3(-
4H)-yl)piperidine-1-carbonyloxy)ethyl)isonicotinic Acid
[0446] 151
[0447] A solution of
(.+-.)-2-(2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)me-
thyl)-2H-indazol-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidi-
ne-1-carbonyloxy)ethyl)isonicotinic acid (ca. 14.5 mg) in methylene
chloride (0.8 mL) was treated with 0.4 mL trifluoroacetic acid
overnight under nitrogen. After LCMS indicated complete conversion,
the crude product was purified by prep-HPLC to afford the desired
acid as a light yellow oil (4.5 mg, 38.5%). MS (ESI)
[M+H].sup.+=555. HPLC t.sub.R=1.75 min.
EXAMPLE 49
(.+-.)-2-(7-Methyl-1H-indazol-5-yl)-1-(4-(piperidine-1-carbonyl)pyridin-2--
yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0448] 152
[0449] To a solution of
(.+-.)-2-(2-(7-methyl-2-((2-(trimethylsilyl)ethoxy-
)methyl)-2H-indazol-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piper-
idine-1-carbonyloxy)ethyl)isonicotinic acid (39.2 mg, 0.057 mmol,
1.0 equiv.) in methylene chloride (0.7 mL) was added a drop of
dimethylformamide (catalytic) followed by dropwise addition of
oxalyl chloride (2 M in methylene chloride, 0.15 mL, 0.3 mmol, 5
equiv) at room temperature under nitrogen. After 2 h, excess
piperidine was added dropwise and the mixture was further stirred
for 1 h. The mixture was concentrated to a gel and was suspended in
methylene chloride (2 mL). Trifluoroacetic acid (1 mL) was added
and the resulting clear tan solution was stirred at room
temperature for 6 h. The solvents were removed in vacuo and the
residue was partitioned between 1 N sodium hydroxide and ethyl
acetate. The layers were separated. The organic layer was washed
with brine, dried and concentrated. Purification by flash column
chromatography (6% methanol/methylene chloride) afforded the
desired product (30.4 mg, 85.4%) as an off-white powder. MS (ESI)
[M+H].sup.+=622. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.69 (d,
J=4.4 Hz, 1H), 7.95 (br., 1H), 7.70 (br., 1H), 7.50-6.80 (m, 6H),
6.68 (br., 1H), 6.05-5.94 (m, 1H), 4.65-3.80 (m, 4H), 3.64 (br.,
2H), 3.50-3.18 (m, 2H), 3.18-2.60 (m, 4H), 2.48 (s, 3H), 1.85-1.44
(m, 9H), 1.44-1.10 (m, 4H). HPLC t.sub.R=1.79 min.
1-(Furan-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-
-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxyla-
te
[0450] 153
[0451] To a solution of
1-(furan-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)e-
thoxy)methyl)-2H-indazol-5-yl)ethanol (0.11 mmol) and 4-nitrophenyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
(0.13 mmol) in tetrahydrofuran (3 mL) was added sodium hydride
(95%, 0.33 mmol) at room temperature under nitrogen. The reaction
was stirred overnight. Methylene chloride (15 mL) was added and the
mixture washed with water (4.times.5 mL). The organic layer was
dried, filtered and concentrated to give the crude product, which
was used without further purification.
[0452] The following intermediates were similarly prepared:
2-(7-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1-(pyrid-
in-4-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxy-
late
[0453] 154
[0454] Not isolated.
2-(7-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1-(pyrid-
in-3-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxy-
late
[0455] 155
[0456] Not isolated.
2-(7-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1-(pyrid-
in-3-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine--
1-carboxylate
[0457] 156
[0458] Not isolated.
1-(7-(Furan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)pro-
pan-2-yl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-car-
boxylate
[0459] 157
[0460] Not isolated.
2-(7-Methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)-1-(quino-
lin-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
ylate
[0461] 158
[0462] Not isolated.
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1-((2-(trimethylsilyl)ethoxy)me-
thyl)-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)--
yl)piperidine-1-carboxylate
[0463] 159
[0464] Not isolated.
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1-((2-(trimethylsilyl)ethoxy)me-
thyl)-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1- -carboxylate
[0465] 160
[0466] Not isolated.
1-(Benzofuran-2-yl)-2-(7-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-in-
dazol-5 yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carb-
oxylate
[0467] 161
[0468] Not isolated.
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyrid-
in-2-yl)ethyl 4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxylate
[0469] 162
[0470] Yield: 82%. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 8.65
(s, 1H), 7.96 (s, 1H), 7.67-7.60 (m, 1H), 7.25-7.19 (m, 2H),
6.98-6.96 (m, 2H), 6.94-6.91 (m, 2H), 6.66 (s, 1H), 6.04-5.95 (m,
1H), 5.71-5.57 (m, 2H), 4.54-4.45 (m, 1H), 4.35-4.16 (m, 3H),
3.97-3.90 (m, 0.6H), 3.65-3.52 (m, 2H), 3.40-3.25 (m, 2H),
2.94-2.74 (m, 2H), 2.58 (s, 3H), 1.63-1.55 (m, 3H), 1.40-1.35 (m,
0.4H), 0.94-0.91 (m, 3H), -0.04 (s, 9H). Mass spec.: 659
(MH).sup.+.
2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyrid-
in-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxy-
late
[0471] 163
[0472] Yield: 54%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 8.63
(s, 1H), 7.94 (s, 1H), 7.68-7.57 (m, 1H), 7.20-6.86 (m, 5H), 6.60
(d, J=8.1 Hz, 1H), 6.51 (s, 1H), 6.02-5.91 (m, 1H), 5.70-5.55 (m,
2H), 4.52-3.83 (m, 5H), 3.64-3.50 (m, 2H), 3.39-3.20 (m, 2H),
2.94-2.68 (m, 2H), 2.56 (s, 3H), 1.77-1.58 (m, 2H), 1.28-1.17 (m,
2H), 0.93-0.82 (m, 3H), -0.07 (s, 9H). Mass spec.: 641
(MH).sup.+.
1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-i-
ndazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperid-
ine-1-carboxylate
[0473] 164
[0474] Yield: 74%. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 9.34
(bs, 1H), 8.05-7.99 (m, 1H), 7.95 (s, 1H), 7.82-7.64 (m, 4H),
7.06-6.86 (m, 4H), 6.64 (s, 1H), 6.21-6.14 (m, 1H), 5.70-5.59 (m,
2H), 4.50-4.04 (m, 5H), 3.63-3.54 (m, 2H), 3.48-3.39 (m, 2H),
2.94-2.74 (m, 2H), 2.58 (s, 3H), 1.72-1.56 (m, 4H), 0.93-0.87 (m,
2H), -0.05 (s, 9H). Mass spec.: 709 (MH).sup.+.
1-(Isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-i-
ndazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-car-
boxylate
[0475] 165
[0476] Yield: 48%. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 9.31
(s, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.92 (s, 1H), 7.77-7.59 (m, 4H),
7.15-6.88 (m, 4H), 6.62-6.57 (m, 2H), 6.16-6.10 (m, 1H), 5.68-5.53
(m, 2H), 4.46-3.87 (m, 5H), 3.61-3.33 (m, 4H), 2.95-2.67 (m, 2H),
2.56 (s, 3H), 1.74-1.62 (m, 2H), 1.38-1.20 (m, 2H), 0.93-0.84 (m,
2H), -0.08 (s, 9H). Mass spec.: 691 (MH).sup.+.
EXAMPLE 50
N-(1-(isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-di-
hydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0477] 166
[0478] This was prepared as described above for Example 36 from
N-(1-(isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)--
2H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine--
1-carboxamide in quantitative yield. .sup.1H-NMR (DMSO-d.sub.6, 500
MHz) .delta. 13.00 (bs, 1H), 9.36 (s, 1H), 9.18 (s, 1H), 8.14 (d,
J=8.2 Hz, 1H), 7.98 (s, 1H), 7.95 (d, J=8.2 Hz, 1H), 7.79-7.74 (m,
2H), 7.68-7.65 (m, 1H), 7.44 (s, 1H), 7.12 (t, J=7.6 Hz, 1H), 7.11
(s, 1H), 7.02 (t, J=7.6 Hz, 2H), 6.87 (t, J=7.6 Hz, 1H), 6.76 (d,
J=7.9 Hz, 1H), 5.19-5.14 (m, 1H), 4.80-4.25 (m, 1H), 4.13-4.11 (m,
2H), 3.19-3.11 (m, 4H), 3.05-3.01 (m, 1H), 2.76-2.62 (m, 1H), 2.50
(s, 3H), 1.60-1.54 (m, 4H). Mass spec.: 560 (MH).sup.+.
EXAMPLE 51
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(1-(isoquinolin-3-yl)--
2-(7-methyl-1H-indazol-5-yl)ethyl)piperidine-1-carboxamide
[0479] 167
[0480] This was prepared as described above for Example 36 from
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(1-(isoquinolin-3-yl)-
-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl)pi-
peridine-1-carboxamide in quantitative yield. .sup.1H-NMR
(CDCl.sub.3, 500 MHz) .delta. 10.34 (s, 1H), 9.24 (s, 1H), 7.95 (d,
J=7.9 Hz, 1H), 7.87 (s, 0.8H), 7.80 (s, 0.2H), 7.85-7.63 (m, 2H),
7.57-7.54 (m, 1H), 7.26-7.24 (m, 1H), 7.13-7.11 (m, 1H), 6.96-6.93
(m, 2H), 6.88-6.77 (m, 3H), 5.98-5.94 (m, 1H), 5.35-5.31 (m, 1H),
4.56-4.51 (m, 1H), 4.22 (s, 2H), 4.14-4.11 (m, 2H), 3.42-3.36 (m,
1H), 3.22-3.17 (m, 1H), 2.92-2.82 (m, 3H), 2.63 (s, 0.6H), 2.42 (s,
2.4H), 1.64-1.60 (m, 3H). Mass spec.: 578 (MH).sup.+.
EXAMPLE 52
1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0481] 168
[0482] This was prepared as described above for Example 36 from
1-(isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H--
indazol-5-yl)ethyl 4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxylate in 59% yield. .sup.1H-NMR
(CDCl.sub.3, 500 MHz) .delta. 9.29 (s, 1H), 7.97 (d, J=8.2 Hz, 1H),
7.94-7.85 (m, 1H), 7.76 (d, J=8.2 Hz, 1H), 7.67-7.64 (m, 1H),
7.60-7.57 (m, 2H), 7.46-7.35 (m, 1H), 7.15-7.03 (m, 2H), 6.93-6.87
(m, 1H), 6.85-6.82 (m, 1H), 6.15-6.10 (m, 1H), 4.51-3.98 (m, 5H),
3.49-3.33 (m, 2H), 2.90-2.69 (m, 3H), 2.48 (s, 3H), 1.66-1.52 (m,
3H). Mass spec.: 579 (MH).sup.+.
EXAMPLE 53
1-(Isoquinolin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0483] 169
[0484] This was prepared as described above for Example 36 from
1-(isoquinolin-3-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H--
indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-ca- rboxylate
in 82% yield. .sup.1H-NMR (CDCl.sub.3, 300 MHz) 89.31 (s, 1H),
7.99-7.87 (m, 2H), 7.77-7.57 (m, 4H), 7.40-7.35 (m, 0.5H),
7.15-6.88 (m, 5H), 6.62 (d, J=8.1 Hz, 1H), 6.12-6.08 (m, 1H),
6.90-6.85 (m, 0.5H), 4.46-3.93 (m, 5H), 3.49-3.33 (m, 2H),
3.02-2.72 (m, 3H), 2.67 (s, 0.5H), 2.46 (s, 2.5H), 1.80-1.64 (m,
2H), 1.26-1.17 (m, 1H). Mass spec.: 561 (MH).sup.+.
EXAMPLE 54
2-(7-methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl
4-(2-oxo-1,2-dihydroqui-
nazolin-3(4H)-yl)piperidine-1-carboxylate
[0485] 170
[0486] This was prepared as described above for Example 36 from
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyri-
din-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox- ylate
in 40% yield. .sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 8.66 (s,
1H), 7.95 (s, 0.7H), 7.88 (s, 0.3H), 7.68-7.63 (m, 1H), 7.40-6.90
(m, 6H), 6.71 (s, 0.3H), 6.67 (s, 0.7H), 6.62 (d, J=7.7 Hz, 1H),
5.99-5.84 (m, 2H), 4.52-3.87 (m, 5H), 3.44-3.12 (m, 2H), 3.03-2.71
(m, 2H), 2.68 (s, 1H), 2.47 (s, 2H), 1.78-1.66 (m, 2H), 1.25-1.20
(m, 1H). Mass spec.: 511 (MH).sup.+.
EXAMPLE 55
2-(7-methyl-1H-indazol-5-yl)-1-(pyridin-2-yl)ethyl
4-(8-fluoro-2-oxo-1,2-d-
ihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0487] 171
[0488] This was prepared as described above for Example 36 from
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(pyri-
din-2-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-
-1-carboxylate in 64% yield. .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. 8.67 (s, 1H), 7.97 (s, 0.6H), 7.90 (s, 0.4H), 7.68-7.64 (m,
1H), 7.46-7.29 (m, 1H), 7.24-7.21 (m, 1H), 7.08-6.78 (m, 5H),
5.97-5.91 (m, 2H), 4.54-3.96 (m, 5H), 3.47-3.26 (m, 2H), 2.95-2.73
(m, 2H), 2.71 (s, 1H), 2.50 (s, 2H), 1.79-1.49 (m, 2H), 1.42-1.36
(m, 1H). Mass spec.: 529 (MH).sup.+.
EXAMPLE 56
1-(Furan-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquina-
zolin-3(4H)-yl)piperidine-1-carboxylate
[0489] 172
[0490] Prepared as described above for Example 30 in 77% yield.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.99 (1H, s), 7.66 (1H,
s), 7.41 (1H, s), 7.34 (1H, broad), 7.11 (1H, m), 7.09 (1H, m),
6.89 (1H, m), 6.69 (1H, s), 6.29 (1H, m), 6.25 (1H, m), 5.97 (1H,
m), 4.47 (1H, broad), 4.24 (2H, m), 4.05 (1H, broad), 3.33 (2H, m),
2.98 (1H, m), 2.80 (2H, broad), 2.51 (3H, s), 1.78 (1H, m), 1.62
(2H, broad), 1.32 (2H, m). HPLC t.sub.R=1.96 min,
MS(ESI)[M+Na].sup.+=522.07.
EXAMPLE 57
2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-4-yl)ethyl
4-(2-oxo-1,2-dihydroqui-
nazolin-3(4H)-yl)piperidine-1-carboxylate
[0491] 173
[0492] Prepared as described above for Example 30 in 6% yield (3
steps). HPLC t.sub.R=1.48 min, MS(ESI)[M+H].sup.+=511.21.
EXAMPLE 58
2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-3-yl)ethyl
4-(2-oxo-1,2-dihydroqui-
nazolin-3(4H)-yl)piperidine-1-carboxylate
[0493] 174
[0494] Prepared as described above for Example 30 in 29% yield.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.53 (2H, m), 7.95 (1H,
s), 7.56 (1H, s), 7.27 (2H, m), 7.16 (1H, m), 7.13-6.91 (4H, m),
6.66 (1H, d, J=8.0 Hz), 5.94 (1H, t, J=6.8 Hz), 4.50 (1H, br),
4.34-4.06 (4H, br), 3.31 (1H, br), 3.16 (1H, br), 2.90-2.68 (3H,
br), 2.48 (3H, s), 1.80-0.49 (3H, br). HPLC t.sub.R=1.48 min,
MS(ESI)[M+H].sup.+=511.26.
EXAMPLE 59
2-(7-Methyl-1H-indazol-5-yl)-1-(pyridin-3-yl)ethyl
4-(8-fluoro-2-oxo-1,2-d-
ihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0495] 175
[0496] Prepared as described above for Example 30 in 64% yield.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.52 (2H, m), 7.95 (1H,
s), 7.56 (1H, s), 7.27 (2H, m), 6.90-6.71 (5H, m), 5.95 (1H, t,
J=6.8 Hz), 4.50 (1H, br), 4.34-4.06 (4H, br), 3.31 (1H, br), 3.16
(1H, br), 2.90-2.68 (3H, br), 2.48 (3H, s), 1.80-1.49 (3H, br).
HPLC t.sub.R=1.50 min, MS(ESI)[M+H].sup.+=529.24.
EXAMPLE 60
1-(Furan-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dih-
ydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0497] 176
[0498] Prepared as described above for Example 30 in 22% yield.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.02 (1H, s), 7.41 (1H,
s), 7.36 (1H, s), 7.03-6.82 (6H, m), 6.29 (2H, m), 5.97 (1H, m),
4.48 (1H, broad), 4.30-4.04 (5H, m), 3.33 (2H, m), 2.51 (3H, s),
1.78 (1H, m), 1.62 (3H, broad). HPLC t.sub.R=1.96 min,
MS(ESI)[M+Na].sup.+=540.12.
EXAMPLE 61
2-(7-Methyl-1H-indazol-5-yl)-1-(quinolin-2-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0499] 177
[0500] Prepared as described above for Example 30 in 8% yield. HPLC
t.sub.R=1.77 min, MS(ESI)[M+H].sup.+=561.14.
EXAMPLE 62
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0501] 178
[0502] Prepared as described above for Example 30 in 45% yield.
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.98 (1H, s), 7.49-7.10
(7H, m), 6.88 (1H,s), 5.84 (1H, m), 4.48-4.09 (2H, m), 3.45-2.70
(5H, m), 2.46 (9H, s), 2.00-1.35 (4H, m). HPLC t.sub.R=1.90 min,
MS(ESI)[M+H].sup.+=537.18.
EXAMPLE 63
1-(4,6-Dimethylpyrimidin-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0503] 179
[0504] Prepared as described above for Example 30 in 2% yield. HPLC
t.sub.R=1.84 min, MS(ESI)[M+H].sup.+=558.
EXAMPLE 64
1-(Benzofuran-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0505] 180
[0506] Prepared as described above for Example 30 in 41% yield.
HPLC t.sub.R=2.14 min, MS(ESI)[M+H].sup.+=550.09.
Methyl-2-(tert-butoxycarbonyl)-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}me-
thyl]-2H-indazol-5-yl)acrylate
[0507] 181
[0508] To a stirred solution of
7-methyl-2-((2-(trimethylsilyl)ethoxy)meth-
yl)-2-H-indazole-5-carbaldehyde (8.5 g, 29.3 mmol) and
methyl-2-(tert-butoxycarbonyl)-2-(dimethoxyphosphoryl)acetate (10
g, 32.2 mmol, 1.1 equiv) in tetrahydrofuran (30 mL) at 0.degree. C.
was added tetramethylguanidine (5.9 mL, 49.8 mmol, 1.7 equiv).
After 10 min, the ice bath was removed and the reaction stirred at
room temperature overnight. The solvent was evaporated and the
residue purified by flash chromatography on silica gel to afford
11.2 g (83%). .sup.1H-NMR (CD.sub.3OD, 300 MHz) .delta. -0.05 (s,
9H), 0.84-0.96 (m, 2H), 1.14 (bs, 9H), 2.56 (s, 3H), 3.58-3.70 (m,
2H), 3.82 (s, 3H), 5.73 (s, 2H), 7.41 (s, 1H), 7.45 (s, 1H), 7.84
(s, 1H), 8.41 (s, 1H). Mass spec.: 462.5 (MH).sup.+.
(.+-.)-Methyl-2-(tert-butoxycarbonyl)-3-(7-methyl-2-[{2-[trimethylsilyl]et-
hoxy}methyl]-2H-indazol-5-yl)propanoate
[0509] 182
[0510] A solution of
methyl-2-(tert-butoxycarbonyl)-3-(7-methyl-2-[{2-[tri-
methylsilyl]ethoxy}methyl]-2H-indazol-5-yl)acrylate (3.7 g, 8.0
mmol) in methanol (20 mL) was flushed with nitrogen (2.times.), and
treated with palladium (10% on charcoal, 0.37 g). The flask was
flushed with hydrogen and was shaken in a parr apparatus overnight
at 60 psi. The reaction was flushed with nitrogen, filtered through
celite, and concentrated. Column chromatography gave 2.3 g (63%).
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. -0.03 (s, 9H), 0.92-0.97
(m, 2H), 1.41 (s, 9H), 2.59 (s, 3H), 3.00-3.17 (m, 2H), 3.59-3.67
(m, 2H), 3.71 (s, 1H), 4.54-4.64 (m, 1H), 4.92-5.01 (m, 1H), 5.71
(s, 2H), 6.82 (s, 1H), 7.12-7.19 (m, 2H), 8.01 (s, 1H). Mass spec.:
464.29 (MH).sup.+.
(.+-.)-tert-Butyl-1-hydroxy-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methy-
l]-2H-indazol-5-yl)propan-2-ylcarbamate
[0511] 183
[0512]
Methyl-2-(tert-butoxycarbonyl)-3-(7-methyl-2-[{2-[trimethylsilyl]et-
hoxy}methyl]-2H-indazol-5-yl)propanoate (2.35 g, 5.06 mmol) was
dissolved in tetrahydrofuran (15 mL) and cooled to 0.degree. C. To
this solution was added lithium borohydride (0.45 g, 4.0 equiv).
After 30 min, the ice bath was removed and the mixture stirred at
room temperature for 3 h. The reaction mixture was diluted with
ethyl acetate and carefully quenched with 10% citric acid. The
organic layer was separated and washed with water (2.times.), brine
(2.times.), dried over sodium sulfate, and concentrated to afford
2.12 g (quant.) of the title compound which was used for the next
reaction without purification. .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. -0.03 (s, 9H), 0.90-0.96 (m, 2H), 1.40 (s, 9H), 2.60 (s,
3H), 2.80-2.89 (m, 2H), 3.54-3.98 (m, 5H), 4.76 (d, J=7.6, 1H),
5.71 (s, 2H), 6.94 (s, 1H), 7.30 (s, 1H), 8.00 (s, 1H). Mass spec.:
436.4 (MH).sup.+.
(.+-.)-tert-Butyl-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-inda-
zol-5-yl)-1-oxopropan-2-ylcarbamate
[0513] 184
[0514]
tert-Buty-1-hydroxy-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl-
]-2H-indazol-5-yl)propan-2-ylcarbamate (0.3 g, 0.69 mmol) was
dissolved in anhydrous dimethyl sulfoxide (2.5 mL). Triethylamine
(0.29 mL, 2.07 mmol) was then added and the reaction mixture cooled
to ca. 5.degree. C. using an ice bath. A solution of sulfur
trioxide pyridine complex (0.33 g, 2.07 mmol) in dimethyl sulfoxide
(2 mL) was added in one portion. After 1 min, the ice bath was
removed and the reaction mixture stirred at room temperature for 20
min. The reaction mixture was poured into an ice slurry and
extracted with ethyl acetate (3.times.). The combined organic
extracts were washed with 10% citric acid (2.times.), water
(2.times.), 5% sodium bicarbonate (2.times.), brine (2.times.),
dried over sodium sulfate, and concentrated. Column chromatography
afforded 0.2 g (74%). Mass spec. (in methanol): 466.25
(M+MeOH+H).sup.+.
(.+-.)-tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate
[0515] 185
[0516]
tert-Butyl-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-inda-
zol-5-yl)-1-oxopropan-2-ylcarbamate (0.57 g, 1.3 mmol) and glyoxal
trimer (0.14 g, 2.0 mmol) were combined in a 1,4 dioxane/water
mixture (6:1, 8 mL). To this mixture was added 28% ammonia in water
(0.35 mL, 5.2 mmol) and the reaction mixture allowed to stir at
80.degree. C. After 16 h, additional glyoxal (50 mg) and 28%
ammonia in water (0.12 mL) was added and the reaction stirred at
80.degree. C. for 5 h. After cooling to room temperature the
solvents were removed and the crude mixture dissolved in methylene
chloride which was washed with water (2.times.), brine (2.times.),
dried over magnesium sulfate, and concentrated. Column
chromatography afforded 0.33 g (54%). .sup.1H-NMR (CDCl.sub.3, 500
MHz) .delta. -0.04 (s, 9H), 0.88-0.96 (m, 2H), 1.33 (s, 9H), 2.51
(s, 3H), 3.18-3.31 (m, 2H), 3.58-3.65 (m, 2H), 5.02-5.10 (m, 1H),
5.68 (s, 1H), 6.78 (s, 1H), 6.88 (s, 2H), 7.17 (s, 1H), 7.25 (s,
1H), 7.94 (s, 1H). Mass spec.: 472.16 (MH).sup.+.
EXAMPLE 65
(.+-.)-N-(1-(1H-Imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-
-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0517] 186
[0518]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (100 mg, 0.212 mmol)
was dissolved in a trifluoroacetic acid/methylene chloride mixture
(1:1, 2 mL) and stirred under nitrogen for 3 h. The solvent was
removed in vacuo and the resulting crude mixture passed through a
strong cationic exchange column. After washing the column with
several volumes of methanol, the desired amine was obtained by
washing the column with 2M ammonia in methanol. After
concentration, the amine was dissolved in dimethylformamide (1.5
mL) at 0.degree. C. and treated with carbonyl diimidazole (34.0 mg,
1.1 equiv). The reaction was stirred for 5 min at 0.degree. C.,
warmed to room temperature, stirred for 10 min, and treated with
3-piperidin-4-yl-3,4-dihydro-1H-quinazolin-2-one (48.0 mg, 1.1
equiv). The mixture was stirred at room temperature overnight. The
solvent was evaporated and the residue purified by column
chromatography to afford 48 mg (50%). .sup.1H-NMR (CD.sub.3OD, 500
MHz) .delta. 1.50-1.70 (m, 4H), 2.55 (s, 3H), 2.70-2.95 (m, 3H),
3.40 (m, 1H), 4.00-4.50 (m, 6H), 5.23 (dd, J=6.4, 9.2, 1H), 6.79
(d, J=7.6, 1H), 6.93-7.05 (m, 5H), 7.04-7.20 (m, 2H), 7.40 (s, 1H),
7.40 (s, 1H). Mass spec.: 499.4 (MH).sup.+.
EXAMPLE 66
(.+-.)-N-(1-(1-Methyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-
-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0519] 187
[0520] A solution of
N-(1-(1H-Imidazol-2-yl)-2-(7-methyl-H-indazol-5-yl)et-
hyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
(13 mg, 0.026 mmol) and iodomethane (4.0 .mu.L, 2 equiv) in
dimethyl sulfoxide (0.6 mL) was treated with potassium carbonate
(11 mg, 3.0 equiv) and the reaction mixture was stirred under
nitrogen for 16 h. The mixture was poured into ice water and
extracted with ethyl acetate (2.times.). The organic layer was
washed with brine (2.times.), dried over sodium sulfate,
concentrated and purified by column chromatography to afford 2.0 mg
(15%). .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.56-1.73 (m, 4H),
2.52 (s, 3H), 2.79-2.93 (m, 2H), 3.29 (s, 3H), 4.09-4.22 (m, 2H),
4.23 (s, 2H), 4.35-4.45 (m, 1H), 5.23 (dd, J=8.2, 7.4, 1H), 6.80
(d, J=7.9, 1H), 6.86 (s, 1H), 6.92 (s, 1H), 6.97 (s, 1H), 7.09-7.20
(m, 2H), 7.80 (s, 1H). Mass spec.: 513.1 (MH).sup.+.
EXAMPLE 67
(.+-.)-N-(1-(1-Benzyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-
-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0521] 188
[0522]
N-(1-(1H-Imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-
-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide (100 mg,
0.2 mmol) and benzyl bromide (25.0 .mu.L, 1.1 equiv) were combined
in dimethyl sulfoxide (0.6 mL). After stirring at room temperature
for 16 h, the reaction mixture was poured into ice water and
extracted with ethyl acetate (2.times.). The organic layer was
washed with brine (2.times.), dried over sodium sulfate,
concentrated, and purified by column chromatography to afford 14.0
mg (12%). .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.58-1.70 (m,
4H), 2.48 (s, 3H), 2.75-2.84 (m, 2H), 3.36-3.43 (m, 2H), 4.02-4.14
(m, 3H), 4.23 (s, 2H), 4.86 (m, 1H), 5.23 (s, 2H), 5.29-5.38 (m,
1H), 6.85-7.01 (m, 3H), 7.10-7.84 (m, 10H), 7.96 (s, 1H). Mass
spec.: 589.16 (MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(3-fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((-
2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0523] 189
[0524] A mixture of
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[tri-
methylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (20 mg,
0.042 mmol), 3-fluoro benzyl bromide (5.5 .mu.L, 0.045 mmol, 1.1
equiv), and potassium carbonate (11.7 mg, 0.09 mmol) in
dimethylformamide (0.6 mL) was stirred at room temperature for 16
h. The solvents were removed in vacuo and the residue purified by
column chromatography to afford 15.2 mg (63%). Mass spec.: 580.04
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl--
2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0525] 190
[0526] A mixture of
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[tri-
methylsilyl]ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (40 mg,
0.085 mmol), 3,5-difluoro benzyl bromide (11.5 .mu.L, 0.089 mmol,
1.05 equiv) and potassium carbonate (23.5 mg, 0.17 mmol) in
dimethylformamide (1.0 mL) was stirred at room temperature for 16
h. The solvents were removed and the residue purified by column
chromatography to afford 40.0 mg (79%). Mass spec.: 598.4
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(4-tert-Butylbenzyl)-1H-imidazol-2-yl)-2-(7-methyl--
2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0527] 191
[0528]
(tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]-
ethoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (40 mg, 0.085 mmol),
4-(tert-Butyl)-benzyl bromide (16.3 .mu.L, 0.089 mmol, 1.05 equiv),
and potassium carbonate (23.5 mg, 0.17 mmol) were combined in
dimethylformamide (1.0 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 36.0 mg (79%). Mass spec.: 618.6
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(3-cyanobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((2-
-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0529] 192
[0530]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (80 mg, 0.17 mmol),
3-cyano benzyl bromide (35.0 mg, 0.18 mmol, 1.05 equiv), and
potassium carbonate (47.0 mg, 0.34 mmol) were combined in
dimethylformamide (1.5 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 85.0 mg (85%). Mass spec.: 587.72
(MH).sup.+.
(.+-.)-tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-phenethyl-1H-imidazol-2-yl)ethylcarbamate
[0531] 193
[0532]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (25 mg, 0.53 mmol),
(2-bromoethyl)benzene (7.5 .mu.L, 0.056 mmol, 1.05 equiv), and
potassium carbonate (14.7 mg, 0.106 mmol) were combined in
dimethylformamide (1.0 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 9.0 mg (29%). Mass spec.: 576.5
(MH).sup.+.
(.+-.)-tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(pyridin-4-ylmethyl)-1H-imidazol-2-yl)ethylcarbamate
[0533] 194
[0534]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (25 mg, 0.53 mmol),
(4-bromomethyl) pyridine (14.1 mg 0.055 mmol, 1.05 equiv), and
potassium carbonate (22.0 mg, 0.16 mmol) were combined in
dimethylformamide (1.0 mL). After stirring at room temperature for
3 d, the solvents were removed and the residue purified by column
chromatography to afford 23.0 mg (77%). Mass spec.: 563.3
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(2-fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((-
2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0535] 195
[0536]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (38.2 mg, 0.081 mmol),
2-fluorobenzyl bromide (11.3 .mu.L, 0.09 mmol, 1.05 equiv), and
potassium carbonate (28.0 mg, 0.2 mmol) were combined in
dimethylformamide (1.0 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 26.0 mg (56%). Mass spec.: 580.38
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(4-fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((-
2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0537] 196
[0538]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (34.4 mg, 0.073 mmol),
4-fluorobenzyl bromide (10.5 .mu.L, 0.084 mmol, 1.05 equiv), and
potassium carbonate (25.0 mg, 0.18 mmol) were combined in
dimethylformamide (1.0 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 28.8 mg (68%). Mass spec.: 580.42
(MH).sup.+.
EXAMPLE 68
(.+-.)-N-(1-(1-(3-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-
-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamid-
e
[0539] 197
[0540] tert-Butyl
1-(1-(3-fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-2-((-
2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
(14.4 mg, 0.025 mmol) was dissolved in a minimum amount of ethyl
acetate, followed by addition of hydrochloric acid (4 N in dioxane,
1.0 mL). The mixture was stirred under nitrogen for 3 days. After
removing the solvents, the crude mixture was treated with diethyl
ether to give a precipitate which was collected by filtration. The
resulting solid was dissolved in dimethylformamide (1.0 mL). The
mixture was cooled to 0.degree. C. and treated with carbonyl
diimidazole (4.7 mg, 1.1 equiv) and triethylamine (7.5 .mu.L, 0.054
mmol). The reaction was stirred for 5 min at 0.degree. C., warmed
to room temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (6.7 mg, 1.1
equiv). The mixture was stirred at room temperature overnight. The
solvent was removed and the residue purified by column
chromatography to afford 7.2 mg (47%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.49-1.68 (m, 4H), 2.44 (s, 3H),
2.71-2.84 (m, 2H), 3.20-3.27 (m, 4H), 4.01-4.15 (m, 2H), 4.19 (s,
2H), 4.35 (m, 1H), 5.12 (d, J=16.2, 1H), 5.21-5.30 (m, 2H),
6.57-6.69 (m, 2H), 6.80 (d, J=7.9, 1H), 6.82 (s, 1H), 6.88-7.20 (m,
8H), 7.91 (s, 1H). Mass spec.: 607.71 (MH).sup.+.
[0541] The following examples were similarly prepared:
EXAMPLE 69
(.+-.)-N-(1-(1-(3,5-Difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indaz-
ol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
amide
[0542] 198
[0543] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.50-1.67 (m, 4H),
2.46 (s, 3H), 2.71-2.82 (m, 2H), 3.06 (dd, J=7.0, 7.0, 1H),
3.21-3.31 (m, 2H), 3.37 (s, 2H), 4.06 (d, J=13.7, 1H), 4.13 (dd,
J=13.1, 10.7, 1H), 4.20 (s, 2H), 4.32-4.40 (m, 1H), 5.08-5.32 (m,
3H), 5.50 (s, 1H), 6.44 (s, 1H), 6.45 (s, 1H), 6.68 (m, 1H), 6.80
(d, J=7.9, 1H), 6.83 (s, 1H), 6.94-6.99 (m, 1H), 7.06 (s, 1H), 7.11
(s, 2H), 7.14-7.19 (m, 1H), 7.25 (s, 1H), 7.89 (s, 1H). Mass spec.:
625.63 (MH).sup.+.
EXAMPLE 70
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-phenethyl-1H-imidazol-2-yl)eth-
yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0544] 199
[0545] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.40-1.67 (m, 4H),
1.50-1.70 (m, 3H), 2.52 (s, 3H), 2.60-2.70 (m, 1H), 2.76-2.91 (m,
2H), 3.08-3.16 (m, 1H), 3.24 (dd, J=7.6, 7.3, 2H), 4.00-4.20 (m,
3H), 4.35 (m, 1H), 5.20 (m, 3H), 6.69-6.88 (m, 1H), 6.92-7.54 (m,
10H), 7.60-7.83 (m, 1H), 7.98 (s, 1H). Mass spec.: 603.30
(MH).sup.+.
EXAMPLE 71
(.+-.)-N-(1-(1-(2-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-
-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamid-
e
[0546] 200
[0547] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.62-1.70 (m, 4H),
2.50 (s, 3H), 2.76-2.88 (m, 2H), 3.37 (s, 1H), 4.00 (s, 1H),
4.04-4.13 (m, 2H), 4.40-4.80 (m, 1H), 4.27 (s, 2H), 5.36-5.44 (m,
3H), 6.79 (s, 1H), 6.81 (s, 1H), 6.91 (s, 1H), 6.95-7.00 (m, 2H),
7.08-7.20 (m, 4H), 7.33 (s, 1H), 7.58 (d, J=1.9, 1H), 7.87 (d,
J=2.1, 1H), 7.98 (s, 1H). Mass spec.: 607.71 (MH).sup.+.
EXAMPLE 72
(.+-.)-N-(1-(1-(4-Fluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-
-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamid-
e
[0548] 201
[0549] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.60-1.72 (m, 4H),
2.50 (s, 3H), 2.78-2.90 (m, 2H), 3.51-3.58 (m, 1H), 4.00 (s, 1H),
4.06-4.16 (m, 2H), 4.28 (s, 2H), 4.32-4.41 (m, 1H), 5.28 (dd,
J=15.6, 14.2, 2H), 5.41 (m, 1H), 6.80 (d, J=7.9, 1H), 6.91 (s, 1H),
6.90-7.00 (m, 6H), 7.14 (d, J=7.3, 1H), 7.15-7.20 (m, 1H), 7.31 (d,
J=2.1, 1H), 7.32 (s, 1H), 7.58 (d, J=1.8, 1H), 7.99 (s, 1H). Mass
spec.: 607.57 (MH).sup.+.
EXAMPLE 73
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(pyridin-4-ylmethyl)-1H-imidaz-
ol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
amide
[0550] 202
[0551] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.57-1.70 (m, 4H),
2.49 (s, 3H), 2.70-2.82 (m, 2H), 3.37 (s, 2H), 3.53-3.60 (m, 1H),
4.05 (bs, 2H), 4.26 (s, 2H), 4.32-4.41 (m, 1H), 5.35-5.41 (m, 1H),
5.56-5.70 (m, 2H), 6.81 (d, J=7.9, 1H), 6.94 (s, 1H), 6.97 (dd,
J=7.9, 7.9, 1H), 7.12-7.20 (m, 2H), 7.33 (s, 1H), 7.38 (m, 1H),
7.56 (d, J=2.1, 1H), 7.75 (d, J=1.8, 1H), 7.96 (s, 1H), 8.52 (s,
1H), 8.53 (s, 1H). Mass spec.: 590.06 (MH).sup.+.
EXAMPLE 74
(.+-.)-N-(1-(1-(3-Cyanobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5--
yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0552] 203
[0553] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.51-1.66 (m, 4H),
2.46 (s, 3H), 2.69-2.80 (m, 2H), 3.20-3.30 (m, 2H), 4.00-4.15 (m,
1H), 5.14-5.35 (m, 3H), 5.51 (s, 2H), 6.80 (d, J=7.6, 1H), 6.83 (s,
1H), 6.97 (dd, J=7.9, 7.3, 1H), 7.06 (m, 1H), 7.08 (s, 1H), 7.13
(s, 2H), 7.16-7.20 (m, 3H), 7.24 (s, 1H), 7.30 (s, 1H), 7.49 (d,
J=7.5, 1H), 7.91 (s, 1H). Mass spec.: 614.05 (MH).sup.+.
EXAMPLE 75
(.+-.)-N-(1-(1-(4-tert-Butylbenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indaz-
ol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
amide
[0554] 204
[0555] MS: t.sub.R=2.46 min, 645.89 (MH).sup.+.
EXAMPLE 76
(.+-.)-3-((2-(2-(7-Methyl-1H-indazol-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazol-
in-3(4H)-yl)piperidine-1-carboxamido)ethyl)-1H-imidazol-1-yl)methyl)benzoi-
c Acid
[0556] 205
[0557] and
EXAMPLE 77
(.+-.)-N-(1-(1-(3-Carbamoylbenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazo-
l-5-yl)ethyl)-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxami-
de
[0558] 206
[0559]
N-(1-(1-(3-Cyanobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5--
yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamid- e (33 mg, 0.053 mmol) was
dissolved in methanol (0.8 mL). To this solution was added 1N
sodium hydroxide (0.27 mL, 0.27 mmol) and the mixture stirred at
room temperature overnight. The mixture was diluted with water and
extracted with a mixture of chloroform/isopropanol (3.times.). The
combined organic extracts were dried over sodium sulfate and
concentrated. Purification by preparative HPLC afforded 6.1 mg
(18%) of the acid and 2.5 mg (8%) of the carboxamide.
3-((2-(2-(7-Methyl-1H-indazo-
l-5-yl)-1-(4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxami-
do)ethyl)-1H-imidazol-1-yl)methyl)benzoic acid: .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.49-1.73 (m, 3H), 2.50 (s, 3H),
2.67-2.89 (m, 2H), 3.37 (s, 1H), 3.46-3.59 (m, 1H), 3.98-4.13 (m,
2H), 4.23 (s, 2H), 5.31-5.53 (m, 4H), 6.80 (d, J=8.2, 1H),
6.88-7.01 (m, 1H), 7.09 (dd, J=7.3, 7.0, 1H) 7.12-7.22 (m, 2H),
7.29-7.36 (m, 3H), 7.39-7.64 (m, 3H), 7.97 (m, 2H). Mass spec.:
633.40 (MH).sup.+. N-(1-(1-(3-Carbamoylbenzyl)-H-imidazo-
l-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide: .sup.1H-NMR (CD.sub.3OD, 500 MHz)
.delta. 1.30-1.60 (m, 4H), 2.46 (s, 3H), 2.68-2.80 (m, 2H),
3.15-3.27 (m, 3H), 3.97-4.12 (m, 2H), 4.17 (s, 2H), 5.13-5.31 (m,
3H), 6.97 (d, J=7.9, 1H), 6.83 (s, 1H), 6.93-6.99 (m, 2H),
7.01-7.24 (m, 7H), 7.26 (s, 1H), 7.70 (s, 1H), 7.76 (d, J=7.9, 1H),
7.93 (s, 1H). Mass spec.: 632.91 (MH).sup.+.
2-(Methoxymethyl)-7-methyl-2H-indazole-5-carbaldehyde
[0560] 207
[0561] To a solution of 7-methylindazole-5-carboxaldehyde (8.80 g,
54.9 mmol) and N-methyl-dicyclohexylamine (23.6 mL, 110 mmol) in
tetrahydrofuran (200 mL) at 0.degree. C. was added chloromethyl
methyl ether (7.50 mL, 1.8 equiv). The reaction was allowed to
gradually warm to room temperature overnight. The reaction was
concentrated, dissolved in diethyl ether, washed with water, then 1
M hydrochloric acid, then water, then brine, dried over magnesium
sulfate, and concentrated to give an oil. The oil was dissolved in
ethyl acetate and treated with hexanes until lasting turbidity. The
suspension was heated until a clear solution was obtained and the
flask placed in the freezer. The resulting crystalline solid was
crushed with a spatula to break it up, reheated to dissolve some of
the solids, and placed in the freezer. The solids were filtered,
washed with very cold ether (-78.degree. C.), and air-dried to give
5.43 g. The mother liquor was concentrated, redissolved in ca. 20
mL ether, cooled to -78.degree. C., and treated with a seed crystal
of the product. After 1 h, the resulting solids were filtered,
washed with cold ether (-78.degree. C.), and air-dried to give an
additional 1.05 g (total yield=58%). .sup.1H-NMR (CDCl.sub.3, 500
MHz) .delta. 2.66 (s, 3H), 3.44 (s, 3H), 5.73 (s, 2H), 7.59 (s,
1H), 8.09 (s, 1H), 8.32 (s, 1H), 9.97 (s, 1H). Mass spec.: 205.19
(MH).sup.+.
Methyl
2-acetoxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)acrylate
[0562] 208
[0563] To a solution of methyl
2-acetoxy-2-(diethylphosphoryl)acetate (4.89 g, 18.2 mmol) in
tetrahydrofuran (25 mL) was added lithium chloride (0.74 g, 17.5
mmol). The reaction was stirred until dissolution was complete. The
reaction was cooled to -78.degree. C., and treated with
tetramethylguanidine (2.20 mL, 17.5 mmol) to give a white
suspension which was stirred for 10 min. To this was added
2-(methoxymethyl)-7-methy- l-2H-indazole-5-carbaldehyde (3.10 g,
15.2 mmol) in one portion. After 10 min, the ice bath was
concentrated and the reaction stirred overnight. The reaction was
poured onto water/diethyl ether, and the layers separated. The
ethereal was washed with water, then brine, dried over magnesium
sulfate, and concentrated. Column chromatography gave recovered
2-(methoxymethyl)-7-methyl-2H-indazole-5-carbaldehyde (0.57 g, 18%)
and the title compound (2.86 g, 59%) as a colorless oil. NMR shows
a 3:2 ratio of Z and E isomers which were not separated. Major (Z
isomer): .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 2.25 (s, 3H),
2.62 (s, 3H), 3.40 (s, 3H), 3.71 (s, 3H), 5.69 (s, 2H), 6.88 (s,
1H), 7.09 (s, 1H), 7.72 (s, 1H), 8.10 (s, 1H). Mass spec.: 319.18
(MH).sup.+. Minor (E isomer): .sup.1H-NMR (CDCl.sub.3, 500 MHz)
.delta. 2.35 (s, 3H), 2.62 (s, 3H), 3.40 (s, 3H), 3.85 (s, 3H),
5.69 (s, 2H), 7.32 (s, 1H), 7.38 (s, 1H), 7.78 (s, 1H), 8.14 (s,
1H). Mass spec.: 319.18 (MH).sup.+.
(R)-Methyl
2-acetoxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)propano-
ate
[0564] 209
[0565] A solution of methyl
2-acetoxy-3-(2-(methoxymethyl)-7-methyl-2H-ind- azol-5-yl)acrylate
(2.80 g, 8.8 mmol) in dichloromethane (20 mL) was degassed by
passing a stream of nitrogen through the solution. To this solution
was quickly added (-)-1,2-bis((2R,5R)-2,5-diethylphospholano)ben-
zene(cyclooctadiene) rhodium (I) trifluoromethylsulfonate (100 mg,
0.016 equiv) as a solid. The reaction was placed under a hydrogen
atmosphere (55 psi) and shaken overnight. The reaction was
concentrated and purified by column chromatography (50% ethyl
acetate/hexanes) to give 2.74 g (97%) as a colorless oil.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 2.08 (s, 3H), 2.61 (s,
3H), 3.11 (dd, J=14.3, 8.9, 1H), 3.20 (dd, J=14.3, 4.6, 1H), 3.39
(s, 3H), 3.72 (s, 3H), 5.26 (dd, J=8.9, 4.6, 1H), 5.68 (s, 2H),
6.93 (s, 1H), 7.33 (s, 1H), 8.02 (s, 1H).
(R)-2-Hydroxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)propanoic
Acid
[0566] 210
[0567] To a solution of (R)-methyl
2-acetoxy-3-(2-(methoxymethyl)-7-methyl-
-2H-indazol-5-yl)propanoate (2.70 g, 8.4 mmol) in tetrahydrofuran
(20 mL) and methanol (20 mL) at 0.degree. C. was added a solution
of lithium hydroxide monohydrate (1.41 g, 4.0 equiv) in water (20
mL). The reaction was stirred at 0.degree. C. for 1 h. The reaction
was concentrated, dissolved in water (5 mL), cooled to 0.degree.
C., and treated with 1 M hydrochloric acid until mildly acidic. The
solution was was extracted extensively with ethyl acetate and then
dichloromethane. The organics were combined, dried over magnesium
sulfate, and concentrated to give 1.40 g (63%) as an oil which
solidified to a crystalline solid upon standing. .sup.1H-NMR
(CDCl.sub.3, 500 MHz) .delta. 2.40 (s, 3H), 2.78 (dd, J=14.0, 7.9,
1H), 3.00 (dd, J=14.0, 4.0, 1H), 3.18 (s, 3H), 4.24 (dd, J=7.9,
4.3, 1H), 5.47 (s, 2H), 6.85 (s, 1H), 7.22 (s, 1H), 7.90 (s, 1H).
Mass spec.: 265.08 (MH).sup.+.
(R)-Methyl
2-hydroxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)propano-
ate
[0568] 211
[0569] To a heterogeneous mixture of 5 M sodium hydroxide (20 mL)
and diethyl ether (60 mL) at 0.degree. C. was added
N-methyl-N'-nitro-N-nitro- soguanidine (1.17 g, 7.95 mmol) in small
portions with swirling (no stirbar). After addition was complete,
the mixture was allowed to stand at 0.degree. C. for 15 min with
occasional swirling. The ethereal was transferred in portions to a
suspension of (R)-2-hydroxy-3-(2-(methoxymet-
hyl)-7-methyl-2H-indazol-5-yl)propanoic acid (1.40 g, 5.30 mmol) in
dichloromethane (20 mL) until the solid had all dissolved and a
yellow color persisted. The reaction was allowed to rest at room
temperature for ca. 5 min. before bubbling nitrogen through the
solution to remove unreacted diazomethane. The reaction was
concentrated and purified by column chromatography (50%.fwdarw.75%
ethyl acetate/hexanes) to give 1.47 g (100%) as a colorless oil.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 1.60 (bs, 1H), 2.58 (s,
3H), 2.95 (dd, J=13.9, 7.0, 1H), 3.14 (dd, J=13.9, 4.0, 1H), 3.36
(s, 3H), 3.76 (s, 3H), 4.46 (bm, 1H), 5.65 (s, 2H), 6.90 (s, 1H),
7.31 (s, 1H), 7.99 (s, 1H). Mass spec.: 279.11 (MH).sup.+.
(R)-Methyl
3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)-2-((4-nitropheno-
xy)carbonyloxy)propanoate
[0570] 212
[0571] To a solution of (R)-methyl
2-hydroxy-3-(2-(methoxymethyl)-7-methyl-
-2H-indazol-5-yl)propanoate (1.45 g, 5.21 mmol) and
diisopropylethylamine (2.73 mL, 3.0 equiv) in dichloromethane (27
mL) at 0.degree. C. was added 4-nitrophenyl-chloroformate (1.58 g,
1.5 equiv) and N,N-dimethylaminopyridine (10 mg). The ice bath was
removed and stirring continued for 7 h. The reaction was treated
with an additional portion of diisopropylethylamine (1.5 mL, 1.65
equiv), 4-nitrophenyl-chloroformate (1.6 g, 1.5 equiv), and
N,N-dimethylaminopyridine (10 mg) and stirred overnight. The
reaction was concentrated, dissolved in ethyl acetate, washed with
water, then 1 M potassium bisulfate, then saturated sodium
bicarbonate (5.times.), then brine, dried over magnesium sulfate,
and concentrated to give 6.00 g (quant.) as a light brown oil,
which was used immediately without purification. Mass spec.: 444.10
(MH).sup.+.
(R)-1-Methoxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)-1-oxopropan-2-
-yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0572] 213
[0573] A flask was charged with crude (R)-methyl
3-(2-(methoxymethyl)-7-me-
thyl-2H-indazol-5-yl)-2-((4-nitrophenoxy)carbonyloxy)propanoate
(2.31 g, 5.20 mmol), 3-(piperidin-4-yl)quinolin-2(1H)-one (1.78 g,
1.5 equiv), diisopropylethylamine (1.82 mL, 2.0 equiv), and
dimethylformamide (20 mL). The reaction was stirred at room
temperature for 8 h and concentrated under vacuum. The resulting
residue was dissolved in ethyl acetate and washed with water to
give a suspension which was exhaustively extracted with ethyl
acetate then dichloromethane. The organics were dried over
magnesium sulfate and concentrated. Column chromatography (25%
ethyl acetate/hexanes.fwdarw.10% methanol/ethyl acetate) gave 2.40
g (86%) as a light yellow foam solid. Mass spec.: 533.30
(MH).sup.+.
(R)-1-Hydroxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)propan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0574] 214
[0575]
(R)-1-Methoxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)-1-oxop-
ropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (0.70 g,
1.32 mmol) was dissolved in tetrahydrofuran (10 mL) and cooled to
0.degree. C. To this solution was added lithium borohydride (0.12
g, 4.0 equiv). After 30 min, the ice bath was removed and the
mixture stirred at room temperature for 3 h. The reaction mixture
was diluted with ethyl acetate and carefully quenched with 10%
citric acid. The organic layer was separated and washed with water
(2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated to afford 0.68 g (99%) which was used without
purification. Mass spec.: 505.3 (MH).sup.+.
(R)-3-(2-(Methoxymethyl)-7-methyl-2H-indazol-5-yl)-1-oxopropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0576] 215
[0577]
1-Hydroxy-3-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)propan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (0.65 g,
1.29 mmol) was dissolved in anhydrous dimethyl sulfoxide (5.0 mL).
Triethylamine (0.54 mL, 3.87 mmol) was added and the reaction
mixture cooled to ca. 5.degree. C. using an ice bath. A solution of
sulfur trioxide pyridine complex (0.62 g, 3.87 mmol) in dimethyl
sulfoxide (4.0 mL) was added in one portion. After 1 min, the ice
bath was removed and the reaction mixture stirred at room
temperature for 20 min. The reaction mixture was poured into an ice
slurry and extracted with ethyl acetate (3.times.). The combined
organic extracts were washed with 10% citric acid (2.times.), water
(2.times.), 5% sodium bicarbonate (2.times.), brine (2.times.),
dried over sodium sulfate, and concentrated. Column chromatography
afforded 0.55 g (85%). .sup.1H-NMR (DMSO. d.sub.6, 500 MHz) .delta.
1.90 (s, 3H), 2.48 (s, 3H), 2.51 (m, 2H), 2.71-2.95 (m, 4H), 4.51
(m, 1H), 4.72-4.84 (m, 1H), 6.31-6.46 (m, 1H), 6.91 (d, J=4.0, 1H),
8.36 (s, 1H), 11.74 (s, 1H). Mass spec.: 503.3 (MH).sup.+.
(R)-1-(1H-Imidazol-2-yl)-2-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)eth-
yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0578] 216
[0579]
3-(2-(Methoxymethyl)-7-methyl-2H-indazol-5-yl)-1-oxopropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (0.53 g,
1.06 mmol) and glyoxal trimer (0.22 g, 1.06 mmol) were combined in
a 1,4 dioxane/water mixture (6:1, 7.0 mL). To this was added 28%
ammonia in water (0.12 mL, 3.18 mmol) and the reaction stirred at
80.degree. C. for 16 h. After cooling to room temperature, the
solvents were removed and the crude mixture dissolved in methylene
chloride which was washed with water (2.times.), brine (2.times.),
dried over magnesium sulfate, and concentrated. Column
chromatography afforded 0.22 g (40%). Mass spec.: 541.4
(MH).sup.+.
(R)-1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(2-(methoxymethyl)-7-met-
hyl-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-c- arboxylate
[0580] 217
[0581]
1-(1H-Imidazol-2-yl)-2-(2-(methoxymethyl)-7-methyl-2H-indazol-5-yl)-
ethyl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
(102 mg, 0.19 mmol), 3,5-difluorobenzyl bromide (27.0 .mu.L, 0.21
mmol, 1.1 equiv), and potassium carbonate (54 mg, 3.0 equiv) were
combined in dimethylformamide (2.0 mL). After stirring at room
temperature for 16 h, the reaction mixture was removed in vacuo and
the residue purified by column chromatography to afford 72.0 mg
(57%). Mass spec.: 667.4 (MH).sup.+.
EXAMPLE 78
(R)-1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-y-
l)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0582] 218
[0583]
1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(2-(methoxymethyl)-7--
methyl-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-- 1-carboxylate (72.0
mg, 0.108 mmol) and acetyl chloride (0.18 mL) were combined in
methanol (2.0 mL) and heated at reflux for 1 h. After cooling to
room temperature, the solvents were removed in vacuo. Column
chromatography afforded 47 mg (70%). .sup.1H-NMR (CD.sub.3OD, 500
MHz) .delta. 1.38-2.05 (m, 3H), 2.45 (s, 3H), 2.70-3.05 (m, 3H),
3.24 (dd, J=7.3, 7.3, 1H), 3.45-3.55 (m, 1H), 4.05-4.40 (m, 2H),
5.05-5.45 (m, 2H), 5.50 (s, 1H), 5.95 (bs, 1H), 6.34-6.90 (m, 4H),
7.17 (s, 1H), 7.25 (m, 2H), 7.34 (d, J=8.2, 1H), 7.45-7.75 (m, 3H),
7.90 (s, 1H). Mass spec.: 623.3 (MH).sup.+.
(.+-.)-tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(2-nitrophenyl)-1H-imidazol-2-yl)ethylcarbamate
[0584] 219
[0585]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (25 mg, 0.53 mmol),
1-fluoro-2-nitrobenzene (14 mg, 0.13 mmol), and potassium carbonate
(18.2 mg, 0.13 mmol) were combined in acetonitrile (1.0 mL) and
heated via microwave at 125.degree. C. for 30 h. The reaction was
concentrated, dissolved in methylene chloride, and washed with
water (2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated. Purification by column chromatography afforded 20.4
mg (65%).
EXAMPLE 79
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(2-nitrophenyl)-1H-imidazol-2--
yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0586] 220
[0587] tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(2-nitrophenyl)-1H-imidazol-2-yl)ethylcarbamate
(20.4 mg, 0.034 mmol) was dissolved in a trifluoroacetic
acid/methylene chloride mixture (1:1, 2 mL) and stirred under
nitrogen for 3 h. The solvent was removed in vacuo and the
resulting crude mixture passed through a strong cationic exchange
column. After washing the column with several volumes of methanol,
the desired amine was obtained by washing the column with 2 M
ammonia in methanol which after concentration was immediately
dissolved in dimethylformamide (1.0 mL). The mixture was cooled to
0.degree. C. and treated with carbonyl diimidazole (6.0 mg, 0.036
mmol, 1.1 equiv). The reaction was stirred for 5 min at 0.degree.
C., warmed to room temperature, stirred for 10 min, treated with
3-(piperidin-4-yl)-3,4-dihy- droquinazolin-2(1H)-one (8.3 mg, 0.036
mmol, 1.1 equiv), and stirred at room temperature overnight. The
solvent was evaporated and the residue purified by column
chromatography to afford 4.0 mg (13%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.50-1.78 (m, 5H), 2.50 (s, 3H),
2.70-2.95 (m, 2H), 3.90-4.35 (m, 4H), 4.40-4.60 (m, 1H), 5.50 (s,
1H), 6.71-7.88 (m, 11H), 7.70 (m, 1H), 7.95 (s, 1H), 8.26 (d,
J=8.6, 1H). Mass spec.: 620.48 (MH).sup.+.
(.+-.)-Methyl
2-(4-(8-fluoro-1,2-dihydro-2-oxoquinazolin-3(4H)-yl)piperidi-
ne-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoate
[0588] 221
[0589] A stirred solution of
2-amino-3-(7-methyl-1H-indazol-5-yl)-propioni- c acid methyl ester
(0.36 g, 1.54 mmol) in tetrahydrofuran (15 mL) at 0.degree. C. was
treated with carbonyl diimidazole (0.20, 1.1 equiv). The reaction
was stirred for min at 0.degree. C., warmed to room temperature,
stirred 10 min, and treated with
8-fluoro-3,4-dihydro-3-(piperidin-4-yl)q- uinazolin-2(1H)-one (0.38
g, 1.1 equiv). The mixture was stirred at room temperature
overnight. The solvent was evaporated and the residue purified by
column chromatography to give 0.41 g (53%) as a white powder.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 1.53-1.68 (m, 4H), 2.48
(s, 3H), 2.82 (m, 2H), 3.05 (m, 6H), 3.09 (dd, J.sub.AB=13.7, 6.1,
1H), 3.14 (dd, J.sub.AB=140.0, 6.1, 1H), 3.35 (bs, 1H), 3.68 (s,
3H), 3.88-4.02 (m, 2H), 4.22 (d, J.sub.AB=15.6, 1H), 4.25 (d,
J.sub.AB=15.3, 1H), 4.44 (m, 1H), 4.71 (dd, J=6.1, 6.1, 1H), 6.78
(d, J=7.3, 1H), 6.84 (ddd, J=7.6, 7.6, 4.9, 1H), 6.88-6.95 (m, 2H),
7.28 (s, 1H), 7.91 (s, 1H). Mass spec.: 509.25 (MH).sup.+.
(.+-.)-2-(4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoic
Acid
[0590] 222
[0591] A suspension of (.+-.)-methyl
2-(4-(8-fluoro-1,2-dihydro-2-oxoquina-
zolin-3(4H)-yl)piperidine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propa-
noate (0.4 g, 0.79 mmol) in 1:1 tetrahydrofuran/methanol (30 mL) at
room temperature was treated with a solution of lithium hydroxide
(83 mg, 2.5 equiv) in water (4 mL) and stirred at room temperature
overnight. The solvents were evaporated and the pH was adjusted to
ca. 1 with 1 N hydrochloric acid. The resulting white suspension
was stored at 4.degree. C. overnight and the product was collected
by filtration, washed with a small amount of water, and dried in
vacuo to afford 0.21 g (74%) as a white powder. Mass spec.: 495.06
(MH).sup.+.
[0592] Similarly prepared:
(.+-.)-2-(4-(2-Oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamid-
o)-3-(7-methyl-1H-indazol-5-yl)propanoic Acid
[0593] 223
[0594] Mass spec.: 477.12 (MH).sup.+.
(.+-.)-N-(1-Amino-3-{7-methyl-1H-indazol-5-yl}-1-oxopropan-2-yl)-3-(8-fluo-
ro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)piperidine-1-carboxamide
[0595] 224
[0596] A stirred solution of
2-(4-{8-fluoro-2-oxo-1,2-dihydroquinazolin-3[-
4H]-yl}piperidine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoic
acid (0.30 g, 0.61 mmol) in dimethylformamide (10 mL) was cooled to
0.degree. C. and sequentially treated with methylene chloride (5
mL), 7 N ammonia in methanol (0.18 mL, 2 equiv),
N,N-diisopropylethylamine (0.27 mL, 2.5 equiv), and PyBop.TM. (0.34
g, 0.73 mmol). The solution was stirred for 1.5 h and concentrated.
The product was purified by column chromatography to give 0.25 g
(82%). Mass spec.: 494.08 (MH).sup.+.
(.+-.)-N-(1-Cyano-2-{7-methyl-1H-indazol-5-yl}ethyl)-4-(8-fluoro-2-oxo-1,2-
-dihydroquinazolin-3 [4H]-yl)piperidine-1-carboxamide
[0597] 225
[0598] A stirred solution of
N-(1-amino-3-{7-methyl-1H-indazol-5-yl}-1-oxo-
propan-2-yl)-3-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)piperidine-1-carboxamide (0.25 g, 0.5 mmol) in pyridine (8
mL) at 0.degree. C. was treated with trifluoroacetic anhydride
(0.35 mL, 5.0 equiv). The mixture was stirred for 30 min and
quenched by the addition of excess methanol. The solvents were
evaporated and the crude mixture dissolved in ethyl acetate which
was washed with 5% citric acid (2.times.), water (2.times.), brine
(2.times.), dried over sodium sulfate, and concentrated. The
residue was purified by column chromatography to afford 0.25 g
(100%). Mass spec.: 477.04 (MH).sup.+.
EXAMPLE 80
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)-N-(2{7-methyl-1H-
-indazol-5-yl}-1-{1H-tetrazol-5-yl}ethyl)piperidin-1-carboxamide
[0599] 226
[0600] A stirred solution of
4-N-(1-cyano-2-{7-methyl-1H-indazol-5-yl}ethy-
l)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)piperidine-1-carboxam- ide (0.25 g, 0.5 mmol) in
tetrahydrofuran (6 mL) was treated with azidotrimethyltin (0.16 g,
0.77 mmol). The resulting suspension was heated at reflux
overnight. The solvents were removed. The crude product was
dissolved in ethyl acetate, washed with water (2.times.), brine
(2.times.), dried over sodium sulfate, and concentrated. The
residue was purified by column chromatography to afford 0.19 g
(73%). MS: t.sub.R=1.44 min, 519.10 (MH).sup.+.
(.+-.)-tert-Butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3[4H]--
yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-1H-tetrazo-
l-1-yl}methyl)piperidine-1-carboxylate
[0601] 227
[0602] and
(.+-.)-tert-Butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3[4H]--
10
yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-2H-tetr-
azol-1-yl}methyl)piperidine-1-carboxylate
[0603] 228
[0604] To a stirred solution of
4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3[-
4H]-yl)-N-(2{7-methyl-1H-indazol-5-yl}-1-{1H-tetrazol-5-yl}ethyl)piperidin-
-1-carboxamide (50 mg, 0.1 mmol) and tert-butyl
4-(hydroxymethyl)piperidin- e-1-carboxylate (22 mg, 0.11 mmol) in
dry tetrahydrofuran (3.0 mL) at 0.degree. C. was added in one
portion triphenylphosphine (27.5 mg, 0.11 mmol) followed by a
dropwise addition of diethylazodicarboxylate (10 .mu.L, 0.105
mmol). The resulting mixture was stirred briefly at 0.degree. C.
and then allowed to warm to room temperature. After 16 h, the
solvent was removed and the residue purified by column
chromatography to afford
tert-butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-1H-t-
etrazol-1-yl}methyl)piperidine-1-carboxylate. MS: t.sub.R=1.44 min,
716.17 (MH).sup.+ and
tert-butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazol-
in-3[4H]-yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-2-
H-tetrazol-1-yl}methyl)piperidine-1-carboxylate. MS: t.sub.R=1.45
min, 716.16 (MH).sup.+.
EXAMPLE 81
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-[7-methyl-1H-
-indazol-5-yl]-1-[1-(piperidin-4-ylmethyl)-1H-tetrazol-5-yl]ethyl)piperidi-
n-1-carboxamide
[0605] 229
[0606]
tert-Butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3[4H]--
yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-1H-tetrazo-
l-1-yl}methyl)piperidine-1-carboxylate (10 mg, 0.014 mmol) was
dissolved in a 1:1 mixture of trifluoroacetic acid and methylene
chloride (1.0 mL) and stirred at room temperature for 30 min. The
solvent was removed under reduced pressure and the compound dried
in vacuo for 2 h to afford 5.9 mg (68%). .sup.1H-NMR (CD.sub.3OD,
500 MHz) .delta. 1.20-1.48 (m, 4H), 1.50-1.79 (m, 5H) 2.24 (dd,
J=12.5, 8.6, 1H), 2.50 (s, 3H), 2.57 (dd, J=11.6, 11.3, 1H), 3.18
(bs, 2H), 3.47 (s, 1H), 4.01-4.40 (m, 7H), 5.29 (dd, J=8.2, 7.9,
1H), 6.90-7.15 (m, 4H), 7.37 (s, 1H), 7.98 (s, 1H), 8.00 (s, 1H).
Mass spec.: 616.20 (MH).sup.+.
EXAMPLE 82
(.+-.)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(2-[7-methyl-1H-
-indazol-5-yl]-1-[2-(piperidin-4-ylmethyl)-1H-tetrazol-5-yl]ethyl)piperidi-
n-1-carboxamide
[0607] 230
[0608]
tert-Butyl-4-({5-(1-[4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3
[4H]-yl)piperidine-1-carboxamido]-2-(7-methyl-1H-indazol-5-yl)ethyl)-2H-t-
etrazol-1-yl}methyl)piperidine-1-carboxylate (5.5 mg, 0.008 mmol)
was dissolved in a trifluoroacetic acid/methylene chloride mixture
(1:1, 1.0 mL) and stirred at room temperature for 30 min. The
solvent was removed under reduced pressure and the compound dried
in vacuo for 2 h to afford 2.6 mg (53%). .sup.1H-NMR (CD.sub.3OD,
500 MHz) .delta. 1.27-1.77 (m, 9H), 2.27 (bs, 1H), 2.54 (s, 3H),
2.65 (s, 1H), 2.74-2.95 (m, 4H), 4.06-4.25 (m, 4H), 4.87 (m, 1H),
4.52-4.62 (m, 2H), 5.42 (dd, J=8.5, 7.3, 1H), 6.90-7.03 (m, 3H),
7.12 (s, 1H), 7.36 (s, 1H), 7.96 (s, 1H). Mass spec.:
616.20(MH).sup.+.
(.+-.)-2-(tert-Butoxycarbonyl)-3-(7methyl-1H-indazol-5-yl)propanoic
Acid
[0609] 231
[0610] Methyl-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate (4.8
g, 20.6 mmol) and di-tert-butyl dicarbonate (11.2 g, 51.5 mmol)
were combined in a 1,4-dioxane/water mixture (3:1, 108 mL). To this
solution was added 10 N sodium hydroxide (35 mL) and the mixture
stirred at room temperature overnight. After removing the solvents,
the crude mixture was diluted with water and extracted with diethyl
ether (2.times.). The aqueous phase was carefully acidified to ca.
pH 2.0 by addition of concentrated hydrochloric acid and extracted
with ethyl acetate (3.times.). The organics were pooled together,
washed with brine (2.times.), dried over sodium sulfate, and
concentrated to afford 15.6 g (76%). Mass spec.: 320.10
(MH).sup.+.
(.+-.)-tert-Butyl
1-{2-(pyridin-2-yl)hydrazinyl}-3-(7-methyl-1H-indazol-5--
yl)-1-oxopropan-2-ylcarbamate
[0611] 232
[0612]
2-(tert-Butoxycarbonyl)-3-(7-methyl-1H-indazol-5-yl)propanoic acid
(0.1 g, 0.31 mmol) and iso-butyl chloroformate (49 .mu.L, 0.37
mmol) were combined in dry tetrahydrofuran (4.0 mL) at 0.degree. C.
Triethylamine (0.13 mL, 0.93 mmol) was added to the reaction
mixture which was briefly stirred before addition of
2-hydrazinopyridine dihydrochloride salt (58 mg, 0.31 mmol). The
reaction mixture was allowed to warm to room temperature overnight.
The reaction was concentrated, redissolved in dichloromethane,
washed with water (2.times.), brine (2.times.), dried over sodium
sulfate, and concentrated. Column chromatography afforded 70.0 mg
(55%). Mass spec.: 411.07 (MH).sup.+.
(.+-.)-tert-Butyl-1-([1,2,4]triazolo[4,3-a]pyridine-3-yl)-2-(7-methyl-1H-i-
ndazol-5-yl)ethylcarbamate
[0613] 233
[0614] tert-Butyl
1-{2-(pyridin-2-yl)hydrazinyl}-3-(7-methyl-1H-indazol-5--
yl)-1-oxopropan-2-ylcarbamate (70 mg, 0.17 mmol),
triphenylphosphine (54 mg, 0.2 mmol), and trimethylsilyl azide (25
.mu.L, 0.19 mmol) were combined in dry tetrahydrofuran (2.0 mL) at
0.degree. C. Diethylazodicarbaoxylate (33 .mu.L, 0.2 mmol) was
added to the reaction mixture to afford a brown solution which was
stirred at room temperature for 2 h. The solvents were removed in
vacuo and the crude mixture purified by column chromatography to
afford 45.2 mg (71%). Mass spec.: 393.04 (MH).sup.+.
(.+-.)-1-([1,2,4]Triazolo[4,3-a]pyridine-3-yl)-2-(7-methyl-1H-indazol-5-yl-
)ethanamine
[0615] 234
[0616]
tert-Butyl-1-([1,2,4]triazolo[4,3-a]pyridine-3-yl)-2-(7-methyl-1H-i-
ndazol-5-yl)ethylcarbamate (43.2 mg, 0.11 mmol) was dissolved in a
trifluoroacetic acid/methylene chloride mixture (1:1, 2 mL) and
stirred under nitrogen for 1 h. The solvent was removed in vacuo
and the resulting crude mixture passed through a strong cationic
exchange column. After washing the column with several volumes of
methanol, the desired amine was obtained by washing the column with
2M ammonia in methanol. Concentration afforded 33 mg (93%) of the
crude product which was used without purification. .sup.1H-NMR
(CD.sub.3OD, 300 MHz) .delta. 2.41 (s, 3H), 3.50-3.66 (m, 2H), 5.50
(bs, 2H), 6.63 (dd, J=6.6, 6.2, 1H), 6.95 (s, 1H), 7.11-7.20 (s,
1H), 7.38 (s, 1H), 7.71 (d, J=9.2, 1H), 7.88 (d, J=7.0, 1H), 7.91
(s, 1H). Mass spec.: 293.02 (MH).sup.+.
EXAMPLE 83
(.+-.)-N-(1-([1,2,4]Triazolo
[4,3-a]pyridin-3-yl)-2-(7-methyl-1H-indazol-5-
-yl)ethyl)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-c-
arboxamide
[0617] 235
[0618] A stirred solution of
1-([1,2,4]triazolo[4,3-a]pyridine-3-yl)-2-(7--
methyl-1H-indazol-5-yl)ethanamine (30 mg, 0.1 mmol) in
dimethylformamide (1.0 mL) at 0.degree. C. was treated with
carbonyl diimidazole (17.5 mg, 1.1 equiv). The reaction was stirred
for 5 min at 0.degree. C., warmed to room temperature, stirred for
10 min, and treated with
8-fluoro-3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (26.0
mg, 1.1 equiv). The mixture was then stirred at room temperature
overnight. The solvent was evaporated and the residue purified by
column chromatography to afford 30 mg (53%). .sup.1H-NMR
(CD.sub.3OD, 300 MHz) .delta. 1.25-1.60 (m, 5H), 2.50 (s, 3H),
2.67-2.81 (m, 2H), 3.60 (s, 1H), 3.62 (s, 1H), 3.12-4.18 (m, 4H),
4.25-4.45 (m, 1H), 5.80 (dd, J=8.1, 8.1, 1H), 6.08-7.04 (m, 4H),
7.10 (s, 1H), 7.35-7.44 (s, 1H), 7.49 (s, 1H), 7.70 (m, 1H), 7.96
(s, 1H), 8.41 (d, J=7.0, 1H). Mass spec.: 568.10 (MH).sup.+.
(.+-.)-Benzyl
3-(7-methyl-1H-indazol-5-yl)-1-(neopentylamino)-1-oxopropan--
2-ylcarbamate
[0619] 236
[0620] 2-(Benzyloxycarbonyl)-3-(7-methyl-1H-indazol-5-yl)propanoic
acid (0.2 g, 0.57 mmol), hydroxybenzotriazole (84 mg, 0.62 mmol),
1-(3-dimethyl aminopropyl)-3-ethyl carbodiimide hydrochloride (0.12
g, 0.62 mmol), and 2,2-dimethylpropan-1-amine (74 .mu.L, 0.62 mmol)
were combined in ethyl acetate (6.0 mL). To this solution was added
triethylamine (0.24 mL, 1.7 mmol) and the reaction mixture stirred
at 40.degree. C. for 2 h. After cooling to room temperature, the
mixture was diluted with ethyl acetate, washed with 5% citric acid
(2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated to afford 0.21 g (88%). Mass spec.: 423.06
(MH).sup.+.
(.+-.)-Benzyl
2-(7-methyl-1H-indazol-5-yl)-1-(1-neopentyl-1H-tetrazol-5-yl-
)ethylcarbamate
[0621] 237
[0622] A solution of benzyl
3-(7-methyl-1H-indazol-5-yl)-1-(neopentylamino-
)-1-oxopropan-2-ylcarbamate (0.17 g, 0.402 mmol) in chloroform (0.5
mL) was added to a mixture of phosphorus pentachloride (0.17 g,
0.802 mmol) and quinoline (0.2 mL) in chloroform (1.0 mL). After
stirring at room temperature for 2 h, the solvents were removed in
vacuo. The crude mixture was dissolved in acetonitrile (2.0 mL) and
treated with sodium azide (78 mg, 3.0 equiv). After stirring the
mixture at 40.degree. C. overnight, the solvents were removed and
the crude mixture dissolved in methylene chloride which was washed
with water (2.times.), brine (2.times.), dried over sodium sulfate,
and concentrated. Column chromatography afforded 73 mg (40%, 2
steps). .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 0.82 (s, 9H),
2.46 (s, 3H), 2.30-3.46 (m, 2H), 3.69 (d, J=14.3, 1H), 3.93 (d,
J=14.3, 1H), 4.98-5.13 (m, 2H), 5.30 (m, 1H), 6.02 (d, J=8.9, 1H),
6.86 (s, 1H), 7.25-7.35 (m, 5H), 7.94 (s, 1H). Mass spec.: 448.19
(MH).sup.+.
(.+-.)-2-(7-Methyl-1H-indazol-5-yl)-1-(1-neopentyl-1H-tetrazol-5-yl)ethana-
mine
[0623] 238
[0624] A solution of benzyl
2-(7-methyl-1H-indazol-5-yl)-1-(1-neopentyl-1H-
-tetrazol-5-yl)ethylcarbamate (70.0 mg, 0.156 mmol) in methanol
(2.0 mL) was flushed with nitrogen, and treated with palladium (10%
on charcoal, 7.0 mg). The flask was flushed with hydrogen and
allowed to stir under a balloon of hydrogen overnight. The reaction
was flushed with nitrogen, filtered through celite, and
concentrated. Column chromatography gave 48.0 mg (quant.). Mass
spec.: 314.17 (MH).sup.+.
EXAMPLE 84
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-neopentyl-1H-tetrazol-5-yl)eth-
yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0625] 239
[0626] A stirred solution of
2-(7-methyl-1H-indazol-5-yl)-1-(1-neopentyl-1-
H-tetrazol-5-yl)ethanamine (20.0 mg, 0.06 mmol) in
dimethylformamide (1.0 mL) at 0.degree. C. was treated with
carbonyl diimidazole (11.0 mg, 1.1 equiv). The reaction was stirred
for 5 min at 0.degree. C., warmed to room temperature, stirred for
10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (15.0 mg, 1.1
equiv). The mixture was stirred at room temperature overnight. The
solvent was evaporated and the residue purified by column
chromatography to afford 22.0 mg (64%). .sup.1H-NMR (CD.sub.3OD,
500 MHz) .delta. 0.90 (s, 9H), 1.35-1.60 (m, 4H), 2.53 (s, 3H),
2.71-2.85 (m, 2H), 3.41-3.52 (m, 2H), 3.98-4.14 (m, 5H), 4.24 (d,
J=14.3, 1H), 4.34 (m, 1H), 6.77 (d, J=7.9, 1H), 6.94 (dd, J=7.6,
7.3, 1H), 7.06-7.17 (m, 3H), 7.45 (s, 1H), 7.88 (s, 1H), 7.98 (s,
1H). Mass spec.: 571.28 (MH).sup.+.
Methyl 2-(benzyloxycarbonyl)acrylate
[0627] 240
[0628] To a flame dried three neck round bottom flask, was added
methyl 2-(benzyloxycarbonyl)-3-hydroxypropanoate (129 g, 509 mmol),
anhydrous methylene chloride (2 L), and methanesulfonyl chloride
(49.3 mL, 636 mmol). The mixture was cooled to -15.degree.
C..fwdarw.20.degree. C. for 20 min while stirring with a mechanical
stirrer. Triethylamine (213 mL, 1527 mmol) was added dropwise
ensuring the inner temperature of the reaction mixture did not
exceed 0.degree. C. (the addition of the first equivalent of
triethylamine was exothermic). After the addition of triethylamine,
the mixture was stirred at 0.degree. C. for 30 min, then the
cooling bath was removed and the mixture was stirred at room
temperature for 1.5 h. Methanol (21 mL) was added to quench excess
methanesulfonyl chloride. The mixture was washed portionwise with
0.5% aq. potassium hydrogen sulfate to pH 5, then sat. sodium
bicarbonate/brine (1:2 by volume) and brine. The methylene chloride
solution was dried over anhydrous sodium sulfate. After filtration,
the solvents were removed and the residue was subjected to column
chromatography on silica gel using 1:9 ethyl acetate/hexanes as
eluent to afford the title compound as a colorless very viscous
oil, which recrystalized upon standing at room temperature,
0.degree. C. and -15.degree. C. (111 g, 92% yield). .sup.1H-NMR
(DMSO-d.sub.6) .delta. 8.96 (s, 1H), 7.39-7.35 (m, 5H), 5.76 (s,
1H), 5.60 (s, 1H), 5.10 (s, 2H), 3.71 (s, 3H); .sup.13C-NMR
(DMSO-d.sub.6) .delta. 163.7, 153.5, 136.3, 133.3, 128.8, 128.3,
128.1, 127.8, 65.9, 52.3.
(Z)-Methyl
3-(4-amino-3,5-dimethylphenyl)-2-(benzyloxycarbonyl)acrylate
[0629] 241
[0630] A 2 L round bottom flask, was charged with
4-iodo-2,6-dimethylbenze- namine hydrochloride salt (55 g, 194
mmol), methyl 2-(benzyloxycarbonyl)ac- rylate (59.2 g, 252 mmol),
tetrabutylammonium chloride (59.2 g, 213 mmol), palladium acetate
(4.34 g, 19.4 mmol), and tetrahydrofuran (1.2 L, degassed by a flow
of nitrogen for 30 min). The mixture was stirred to form a
suspension and degassed by a flow of nitrogen for 30 min.
Triethylamine (110 mL, 789 mmol) was then added and the resulting
mixture was heated at reflux for 3 h. After cooling to room
temperature, the reaction mixture was filtered through a pad of
celite and washed twice with tetrahydrofuran (2.times.100 mL). The
solvents were removed and the residue was dissolved in methylene
chloride which was extracted with water (3.times.), brine
(2.times.), dried over sodium sulfate and concentrated. Column
chromatography on silica gel using 1:9 ethyl acetate/methylene
chloride as eluent afforded a tan solid, which was recrystalized
from methanol (210 mL) and water (100 mL). After filtration, the
solid was washed with ice cold 1:1 methanol/water mixture and then
dried under high vacuum overnight at room temperature to afford the
title compound (58.0 g, 65%) as a light tan solid. NMR shows a
2.7:1 ratio of Z and E isomers which were not separated.
.sup.1H-NMR (DMSO-d.sub.6) .delta. 8.79 (s, 0.73H), 8.51 (s,
0.27H), 7.40-7.21 (m, 8H), 5.24 (s, 2H), 5.13 (s, 1.46H), 5.00 (s,
0.54H), 3.68 (s, 2.2H), 3.61 (s, 0.8H), 2.05 (s, 6H); .sup.13C-NMR
(DMSO-d.sub.6) .delta. 166.0, 154.7, 146.9, 137.2, 135.8, 130.9,
128.3, 127.7, 127.3, 120.3, 120.0, 119.4, 65.3, 51.7, 17.8.
(R)-Methyl
3-(4-amino-3,5-dimethylphenyl)-2-(benzyloxycarbonyl)propanoate
[0631] 242
[0632] (Z)-Methyl
3-(4-amino-3,5-dimethylphenyl)-2-(benzyloxycarbonyl)acry- late
(84.5 g, 239 mmol) was weighed into a flame-dried 2 L Parr shaker,
followed by the addition of methylene chloride (300 mL) and
methanol (300 mL). The bottle was swirled to form a light brown
suspension, and this suspension was degassed by a flow of nitrogen
for 30 min. Following addition of
(-)-1,2-bis((2R,5R)-2,5-diethylphospholano)bezene(cyclooctadi-
ene)rhodium(I)tetrafluoroborate ([(2R,5R)-Et-DuPhosRh]BF.sub.4)
(2.11 g, 3.20 mmol), the bottle was put onto a Parr Hydrogenator.
After 5 cycles of purging with hydrogen (60 psi) and vacuum, the
final hydrogen pressure was set at 65 psi and the suspension was
agitated at room temperature for 16 h (after 3 h, the suspension
became a clear solution), and the reaction was complete. Solvents
were removed and the residue was subjected to flash chromatography
on silica gel using ethyl acetate/methylene chloride (1:9) as the
eluent to afford the title compound as a very light tan solid (82.9
g, 98% yield). .sup.1H-NMR (DMSO-d.sub.6) .delta. 7.70 (d, J=7.9
Hz, 1H), 7.37-7.28 (m, 5H), 6.68 (s, 2H), 5.00 (s, 2H), 4.41 (s,
2H), 4.15-4.10 (m, 1H), 3.62 (s, 3H), 2.82 (dd, J=13.7, 5.2 Hz,
1H), 2.65 (dd, J=13.4, 9.8 Hz, 1H), 2.04 (s, 6H); .sup.3C-NMR
(DMSO-d.sub.6) .delta. 172.5, 155.9, 142.6, 136.9, 128.3, 128.2,
127.7, 127.5, 124.0, 120.4, 65.3, 56.1, 51.7, 35.9, 17.7.
(R)-Methyl
2-(benzyloxycarbonyl)-3-(7-methyl-1H-indazol-5-yl)propanoate
[0633] 243
[0634] (R)-Methyl
3-(4-amino-3,5-dimethylphenyl)-2-(benzyloxycarbonyl) propanoate
(50.0 g, 140 mmol) was weighed into a flame-dried 5 L three neck
round bottom flask, followed by the addition of toluene (2.40 L)
and glacial acetic acid (120 mL, 2.1 mol). The mixture was
mechanically stirred at rt for 10 min to form a clear solution and
potassium acetate (103 g, 1.05 mol) was added. To this white
suspension, iso-amylnitrite (20.7 mL, 154 mmol) was added dropwise
at room temperature and the resulting mixture was stirred at room
temperature for 16 h. Saturated sodium bicarbonate (1 L) was added,
followed by careful addition of solid sodium bicarbonate to
neutralize acetic acid. The mixture was extracted with a mixture of
methylene chloride (2 L) and brine (1.5 L). After separation, the
aqueous layer was extracted with methylene chloride (500 mL). The
combined organic layers were dried over sodium sulfate and
filtered. Solvents were removed to afford a tan solid, which was
washed with hexanes (2.0 L) and tolune (150 mL). The solid was
recrystallized from acetone (260 mL) and hexanes (700 mL). The
resulting slight cloudy mixture was cooled to room temperature
slowly, then 0.degree. C. for 1.5 h and -15.degree. C. for 1.5 h.
The solid was filtered and washed with ice-cold acetone/hexanes
(1:1, 200 mL) to afford, after drying overnight under high vacuum,
the title compound as creamy crystals (39.1 g, 76% yield) with
>98% purity (checked by a 20 min analytical HPLC run). The ee
was determined to be 99.8% (conditions: Chiralpak AD column,
4.6.times.250 mm, 10 .mu.m; A=EtOH, B=0.05% DEA/heptane; 85% B @1.0
mL/min. for 55 min. The retention times for R was 44.6 min and for
S was 28.8 min). .sup.1H-NMR (DMSO-d.sub.6) .delta. 13.1 (s, 1H),
7.99 (s, 1H), 7.83 (d, J=8.2 Hz, 1H), 7.41 (s, 1H), 7.29-7.27 (m,
3H), 7.24-7.22 (m, 2H), 7.03 (s, 1H), 4.97 (s, 2H), 4.32-4.27 (m,
1H), 3.63 (s, 3H), 3.10 (dd, J=13.7, 4.9 Hz, 1H), 2.93 (dd, J=13.4,
10.7 Hz, 1H), 2.48 (s, 3H); .sup.13C-NMR (DMSO-d.sub.6) .delta.
172.4, 155.9, 139.2, 136.8, 133.4, 129.3, 128.2, 127.6, 127.4,
127.2, 122.7, 119.6, 117.6, 65.3, 56.0, 51.8, 36.5, 16.7.
(R)-2-(Benzyloxycarbonyl)-3-(7-methyl-1H-indazol-5-yl)propanoic
Acid
[0635] 244
[0636] A suspension of (R)-methyl
2-(benzyloxycarbonyl)-3-(7-methyl-H-inda- zol-5-yl)propanoate (0.66
g, 1.71 mmol) in 1:1 tetrahydrofuran/methanol (60 mL) at room
temperature was treated with a solution of lithium hydroxide
monohydrate (189 mg, 2.5 equiv) in water (10 mL). The solution was
stirred at room temperature for 1 h and the solvents evaporated.
The resultant residue was diluted with water (10 mL) and was
adjusted to ca. pH 1.0 with 1 N hydrochloric acid. The resultant
white suspension was stored at 4.degree. C. overnight. The product
was collected by filtration, washed by a small amount of water, and
dried in vacuo for several hours to give 0.58 g (96%). Mass spec.:
354.30 (MH).sup.+.
(R)-Benzyl
3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(pyridin-2-ylmethylamino)p-
ropan-2-ylcarbamate
[0637] 245
[0638] 2-(Benzyloxycarbonyl)-3-(7-methyl-1H-indazol-5-yl)propanoic
(0.47 g, 1.32 mmol), hydroxybenzotriazole (0.2 g, 1.46 mmol),
1-(3-dimethyl aminopropyl)-3-ethyl carbodiimide hydrochloride (0.28
g, 1.46 mmol), and 2-picolyl amine (0.56 mL, 1.46 mmol) were
combined in ethyl acetate (10.0 mL). To this solution was added
triethylamine (0.56 mL, 4.0 mmol) and the reaction mixture stirred
at 40.degree. C. for 2 h. After cooling to room temperature, the
residue was diluted with ethyl acetate, washed with 5% citric acid
(2.times.), brine (2.times.), dried over sodium sulfate, and
concentrated to afford 0.42 g (72%). Mass spec.: 444.4
(MH).sup.+.
(R)-Benzyl
1-(H-imidazo[1,5-a]pyridin-3-yl)-2-(7-methyl-1H-indazol-5-yl)et-
hylcarbamate
[0639] 246
[0640] To a solution of benzyl
3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(pyrid-
in-2-ylmethylamino)propan-2-ylcarbamate (75 mg, 0.17 mmol) in
1,2-dichloroethane (1.5 mL) was added phosphorus oxychloride (78
.mu.L, 0.85 mmol) and pyridine (0.25 mL, 0.85 mmol). The reaction
mixture was heated at reflux for 1 h, cooled to room temperature,
and concentrated. The resulting residue was partitioned between
ethyl acetate and saturated sodium bicarbonate. The organic layer
was separated, washed with water (2.times.), brine (2.times.),
dried over sodium sulfate, and concentrated to afford 22 mg (30%).
.sup.1H-NMR (CD.sub.3OD, 300 MHz) .delta. 2.42 (s, 3H), 3.44 (s,
1H), 3.46 (s, 1H), 4.82-5.08 (m, 2H), 5.46 (m, 1H), 6.50 (m, 1H),
7.99 (d, J=6.2, 1H). Mass spec.: 426.20 (MH).sup.+.
(R)-1-(H-Imidazo[1,5-a]pyridin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethanamin-
e
[0641] 247
[0642] Benzyl
1-(H-imidazo[1,5-a]pyridin-3-yl)-2-(7-methyl-1H-indazol-5-yl-
)ethylcarbamate (50 mg, 0.11 mmol) was dissolved in methylene
chloride (1.0 mL) and cooled to 0.degree. C. Iodotrimethylsilane
(67 .mu.L, 4.0 equiv) was added and the reaction mixture allowed to
warm to room temperature. After stirring for 1 h, triethylamine (57
.mu.L, 3.0 equiv) was added to the reaction mixture and stirring
continued for 30 min. The reaction was diluted with methylene
chloride, washed with water (2.times.), brine (2.times.), dried
over sodium sulfate, and concentrated to afford 26.0 mg (66%) which
was used without purification. Mass spec.: 292.3 (MH).sup.+.
EXAMPLE 85
(R)-N-(1-(H-Imidazo[1,5-a]pyridin-3-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-
-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0643] 248
[0644] A stirred solution of
1-(H-imidazo[1,5-a]pyridin-3-yl)-2-(7-methyl--
1H-indazol-5-yl)ethanamine (38.0 mg, 0.12 mmol) in
dimethylformamide (1.0 mL) at 0.degree. C. was treated with
carbonyl diimidazole (21.0 mg, 1.1 equiv). The reaction was stirred
for 5 min at 0.degree. C., warmed to room temperature, stirred for
10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (29.8 mg, 1.1
equiv). The mixture was stirred at room temperature overnight. The
solvent was evaporated and the residue purified by column
chromatography to afford 29.4 mg (45%). .sup.1H-NMR (CD.sub.3OD,
500 MHz) .delta. 1.35-1.60 (m, 4H), 2.50 (s, 3H), 2.72-2.86 (m,
2H), 3.44-3.56 (m, 2H), 4.10 (s, 2H), 4.17 (dd, J=15.0, 13.1, 1H),
4.30-4.42 (m, 1H), 5.72 (dd, J=7.6, 7.3, 1H), 7.01 (s, 1H),
7.10-7.20 (m, 2H), 7.42 (s, 1H), 7.50 (d, J=9.5, 1H), 7.96 (s, 1H),
8.13 (d, J=7.3, 1H). Mass spec.: 549.68 (MH).sup.+.
(.+-.)-tert-Butyl
1-(4-bromo-1H-imidazol-2-yl)-2-(7-methyl-2-((2(trimethyl-
silyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate and
(.+-.)-tert-Butyl
1-(4,5-dibromo-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trim-
ethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0645] 249
[0646]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (73 mg, 0.16 mmol) was
dissolved in methylene chloride and cooled to -78.degree. C. To
this was added N-bromosuccinimide (24.8 mg, 0.14 mmol) and the
mixture allowed to stir at -78.degree. C. for 30 min. After warming
to room temperature, the solvent was removed and the residue
purified by column chromatography to afford 19 mg (22%) of the
monobrominated product and 25 mg (26%) of the bis-brominated
product. tert-butyl 1-(4-bromo-1H-imidazol-2-yl)-2-(7-meth-
yl-2-((2(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate:
.sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. -0.10 (s, 9H), 0.86-0.95
(m, 2H), 1.33 (s, 9H), 2.51 (s, 3H), 3.26 (m, 2H), 4.79-4.93 (m,
1H), 5.67 (s, 2H), 6.80 (m, 2H), 7.18 (s, 1H), 7.94 (s, 1H). Mass
spec.: 551.99 (MH).sup.+. tert-Butyl
1-(4,5-dibromo-1H-imidazol-2-yl)-2-(7-methyl-2-((2-
-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate:
.sup.1H-NMR (CDCl.sub.3, 300 MHz) .delta. 0.00 (s, 9H), 0.90 (m,
2H), 1.33 (s, 9H), 2.50 (s, 3H), 3.06-3.27 (m, 2H), 3.59 (m, 2H),
4.86 (m, 1H), 5.89 (m, 1H), 5.66 (s, 2H), 6.73 (s, 1H), 7.14 (s,
1H), 7.92 (s, 1H). Mass spec.: 630.59 (MH).sup.+.
EXAMPLE 86
(.+-.)-N-(1-(4-Bromo-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)--
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0647] 250
[0648] tert-Butyl
1-(4-bromo-1H-imidazol-2-yl)-2-(7-methyl-2-((2(trimethyl-
silyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate (19.0 mg, 0.035
mmol) was dissolved in a minimum amount of ethyl acetate, and
treated with hydrochloric acid (4 N in dioxane, 1.0 mL) (1.0 mL).
The mixture was stirred under nitrogen for 3 days. After removal of
the solvents, the crude mixture was treated with diethyl ether to
give a precipitate which was filtered. The resulting solid was
dissolved in dimethylformamide (1.0 mL), cooled to 0.degree. C.,
and treated with carbonyl diimidazole (6.2 mg, 0.038 mmol, 1.1
equiv) and N'N-diisopropylethylamine (25.0 .mu.L, 4.0 equiv). The
reaction was stirred for 5 min at 0.degree. C., warmed to room
temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (10.1 mg, 0.038,
1.1 equiv). The mixture was stirred at room temperature overnight.
The solvent was evaporated and the residue purified by column
chromatography to afford 7.3 mg, (36%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.50-1.71 (m, 4H), 2.55 (s, 3H),
2.74-2.93 (m, 2H), 3.16-3.25 (m, 2H), 4.03-4.20 (m, 4H), 4.78 (m,
1H), 5.12-5.19 (m, 1H), 6.63 (d, J=7.9, 1H), 6.94 (d, J=7.9, 1H),
6.94-7.00 (m, 2H), 7.04 (s, 1H), 7.12 (s, 1H), 7.12 (d, J=7.3, 1H),
7.16 (dd, J=7.6, 7.6, 1H), 7.40 (s, 1H), 7.99 (s, 1H). Mass spec.:
577.67 (MH).sup.+.
[0649] Similarly prepared:
EXAMPLE 87
(.+-.)-N-(1-(4,5-Dibromo-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)eth-
yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0650] 251
[0651] .sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.29-1.70 (m, 4H),
2.55 (s, 3H), 2.73-2.93 (m, 3H), 4.02-4.21 (m, 4H), 4.88 (m, 1H),
5.10-5.19 (m, 1H), 6.79 (d, J=7.9, 1H), 6.97 (dd, J=7.6, 7.6, 1H),
7.01 (s, 1H), 7.12 (d, J=7.3, 1H), 7.16 (dd, J=7.9, 7.3, 1H), 7.42
(s, 1H), 8.00 (s, 1H). Mass spec.: 657.68 (MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(3,5-difluorobenzyl)-5-bromo-1H-imidazol-2-yl)-2-(7-
-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamat-
e
[0652] 252
[0653] tert-Butyl
1-(1-(3,5-difluorobenzyl)-1H-imidazol-2-yl)-2-(7-methyl--
2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
(72.0 mg, 0.12 mmol) was dissolved in methylene chloride (3.0 mL)
and cooled to -78.degree. C. To this was added N-bromosuccinimide
(18.3 mg, 0.11 mmol) and the mixture allowed to stir at -78.degree.
C. for 30 min. After warming to room temperature, the solvent was
removed and the residue purified by column chromatography to afford
30 mg (40%). .sup.1H-NMR (CD.sub.3OD, 300 MHz) .delta. -0.06 (s,
9H), 0.89 (m, 2H), 1.33 (s, 9H), 2.44 (s, 3H), 3.15-3.25 (m, 1H),
3.57-3.66 (m, 2H), 4.80-5.09 (m, 2H), 6.26 (m, 2H), 6.47-6.66 (m,
2H), 7.12 (s, 1H), 7.20 (s, 1H), 7.91 (s, 1H). Mass spec.: 678.3
(MH).sup.+.
EXAMPLE 88
(.+-.)-N-(1-(1-(3,5-Difluorobenzyl)-5-bromo-1H-imidazol-2-yl)-2-(7-methyl--
2H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine--
1-carboxamide
[0654] 253
[0655] tert-Butyl
1-(1-(3,5-difluorobenzyl)-5-bromo-1H-imidazol-2-yl)-2-(7-
-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamat-
e (16.0 mg, 0.024 mmol) was dissolved in a minimum amount of ethyl
acetate, and treated with hydrochloric acid (4 N in dioxane, 1.0
mL). The mixture was stirred under nitrogen for 3 days. After
removal of the solvents, the crude mixture was treated with diethyl
ether to give a precipitate which was filtered. The resulting solid
was dissolved in dimethylformamide (1.0 mL), cooled to 0.degree.
C., and treated with carbonyl diimidazole (4.0 mg, 0.025 mmol, 1.1
equiv) and N'N-diisopropylethylamine (16.7 .mu.L, 3 equiv). The
reaction was stirred for 5 min at 0.degree. C., warmed to room
temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (5.8 mg, 0.025,
1.1 equiv). The mixture was stirred at room temperature overnight.
The solvent was evaporated and the residue purified by column
chromatography to afford 7.5 mg (52%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.40-1.58 (m, 4H), 2.42 (s, 3H),
2.61-2.72 (m, 2H), 3.14-3.24 (m, 2H), 3.92-4.06 (m, 2H), 4.15 (s,
2H), 4.25-4.38 (m, 1H), 4.10-5.24 (m, 2H), 5.42 (m, 1H), 6.32 (s,
1H), 6.33 (s, 1H), 6.61-6.78 (m, 3H), 6.82 (s, 1H), 6.90-6.99 (m,
1H), 7.08-7.13 (m, 2H), 7.86 (s, 1H). Mass spec.: 705.2
(MH).sup.+.
(.+-.)-tert-Butyl
1-(4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimeth-
ylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0656] 254
[0657]
tert-Butyl-3-(7-methyl-2-[{2-[trimethylsilyl]ethoxy}methyl]-2H-inda-
zol-5-yl)-1-oxopropan-2-ylcarbamate (0.14 g, 0.32 mmol) and pyruvic
aldehyde (40.0 .mu.L, 0.64 mmol, 2.0 equiv) were combined in a
dioxane/water mixture (6:1, 4 mL). To this was added 28% ammonia in
water (37.0 .mu.L, 0.97 mmol) and the reaction was allowed to stir
at 80.degree. C. for 16 h. After cooling to room temperature, the
solvents were removed and the crude mixture dissolved in methylene
chloride which was washed with water (2.times.), brine (2.times.),
dried over magnesium sulfate, and concentrated. Column
chromatography afforded 65.0 mg (42%). Mass spec.: 486.30
(MH).sup.+.
(.+-.)-tert-Butyl
1-(1-(3-fluorobenzyl)-4-methyl-1H-imidazol-2-yl)-2-(7-me-
thyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
[0658] 255
[0659] tert-Butyl
1-(4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimeth-
ylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate (38.4 mg,
0.079 mmol), 3-fluoro benzylbromide (10.8 .mu.L, 0.083 mmol, 1.05
equiv), and potassium carbonate (22.0 mg, 0.16 mmol) were combined
in dimethylformamide (1.0 mL). After stirring at room temperature
for 16 h, the solvents were removed and the residue purified by
column chromatography to afford 31.0 mg (64%). .sup.1H-NMR
(CD.sub.3OD, 300 MHz) .delta. -0.02 (s, 9H), 0.87-0.98 (m, 2H),
1.31 (s, 9H), 2.23 (s, 3H), 2.47 (s, 3H), 3.08-3.18 (m, 2H),
3.56-3.71 (m, 2H), 4.89-5.13 (m, 3H), 5.72 (s, 1H), 6.83-7.14 (m,
2H), 7.21 (s, 1H), 8.20 (s, 1H). Mass spec.: 594.47 (MH).sup.+.
EXAMPLE 89
(.+-.)-N-(1-(1-(3-Fluorobenzyl)-4-methyl-1H-imidazol-2-yl)-2-(7-methyl-1H--
indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-c-
arboxamide
[0660] 256
[0661] tert-Butyl
1-(1-(3-fluorobenzyl)-4-methyl-1H-imidazol-2-yl)-2-(7-me-
thyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate
(20.0 mg, 0.034 mmol) was dissolved in a minimum amount of ethyl
acetate, and treated with hydrochloric acid (4 N in dioxane, 1.0
mL). The mixture was stirred under nitrogen for 3 days. After
removal of the solvents, the crude mixture was treated with diethyl
ether to give a precipitate which was filtered. The resulting solid
was dissolved in dimethylformamide (1.0 mL), cooled to 0.degree.
C., and treated with carbonyl diimidazole (6.0 mg, 0.037 mmol, 1.1
equiv) and N'N-diisopropylethylamine (24.3 .mu.L, 3 equiv). The
reaction was stirred for 5 min at 0.degree. C., warmed to room
temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (8.5 mg, 0.037
mmol, 1.1 equiv). The mixture was stirred at room temperature
overnight. The solvent was evaporated and the residue purified by
column chromatography to afford 16.1 mg (74%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.50-1.68 (m, 4H), 2.27 (s, 3H), 2.46
(s, 3H), 2.77 (m, 2H), 3.20 (m, 2H), 4.01-4.16 (m, 2H), 4.20 (s,
2H), 4.32-4.43 (m, 1H), 5.13-5.22 (m, 2H), 6.60-6.67 (m, 2H), 6.70
(s, 1H), 6.76-6.86 (m, 2H), 6.87-6.94 (m, 1H), 6.96 (dd, J=8.3,
6.7, 1H), 7.07-7.14 (m, 2H), 7.16 (dd, J=7.9, 7.6, 1H), 7.25 (s,
1H), 7.92 (s, 1H). Mass spec.: 621.4 (MH).sup.+.
EXAMPLE 90
(.+-.)-N-(1-(4-Methyl-1H-imidazol-2-yl)-2-(7-methyl-1H-indazol-5-yl)ethyl)-
-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide
[0662] 257
[0663] tert-Butyl
1-(4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimeth-
ylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate (25.2 mg,
0.052 mmol) was dissolved in a minimum amount of ethyl acetate, and
treated with hydrochloric acid (4 N in dioxane, 1.5 mL). The
mixture was stirred under nitrogen for 3 days. After removal of the
solvents, the crude mixture was treated with diethyl ether to give
a precipitate which was filtered. The resulting solid was dissolved
in dimethylformamide (1.0 mL), cooled to 0.degree. C., and treated
with carbonyl diimidazole (10.0 mg, 0.055 mmol, 1.1 equiv) and
diisopropylethylamine (36.2 .mu.L, 4.0 equiv). The reaction was
stirred for 5 min at 0.degree. C., warmed to room temperature,
stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (13.0 mg, 0.055,
1.1 equiv). The mixture was stirred at room temperature overnight.
The solvent was evaporated and the residue purified by column
chromatography to afford 10.1 mg (38%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.39-1.66 (m, 4H), 2.20 (s, 3H), 2.55
(s, 3H), 2.73-2.95 (m, 2H), 3.14-3.22 (m, 1H), 4.01-4.20 (m, 4H),
4.32-4.43 (m, 1H), 5.13-5.19 (m, 1H), 6.65 (s, 1H), 6.79 (d, J=7.6,
1H), 6.97 (dd, J=7.6, 7.3, 1H), 7.02 (s, 1H), 7.12 (d, J=7.3, 1H),
7.17 (dd, J=7.9, 7.3, 1H), 7.40 (s, 1H), 7.99 (s, 1H). Mass spec.:
513.3 (MH).sup.+.
2-Acetoxy-2-(diethoxyphosphoryl)acetic Acid
[0664] 258
[0665] Glyoxylic acid monohydrate (4.00 g, 43.45 mmol) was
suspended in diethyl phosphite (5.59 mL, 1.0 equiv) and warmed to
60.degree. C. for 5 h. The reaction was cooled, diluted with
dichloromethane (40 mL), and treated with pyridine (3.51 mL, 1.0
equiv) and acetyl chloride (3.09 mL, 1.0 equiv). A significant
exotherm was noted. The reaction was stirred at room temperature
for 2 h. The reaction was washed with 1 M hydrochloric acid
(2.times.20 mL), then saturated sodium bicarbonate. The organics
were dried over magnesium sulfate, and concentrated to give <2 g
as an oil. The aqueous washes were combined and extracted with
dichloromethane (4.times.). The organics were dried over magnesium
sulfate and concentrated to give 5.85 g (53%) as an oil which
solidified upon standing. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta.
1.36 (t, J=7.0, 6H), 2.21 (s, 3H), 4.28 (m, 4H), 5.54 (d, J=17.7,
1H), 8.90 (bs, 1H). Mass spec.: 255.10 (MH).sup.+.
Methyl 2-acetoxy-2-(diethylphosphoryl)acetate
[0666] 259
[0667] To a mixture of 5M sodium hydroxide (50 mL) and diethyl
ether (100 mL) at 0.degree. C. was added
N-methyl-N'-nitro-N-nitrosoguanidine (6.37 g, 43.3 mmol) in small
portions with swirling. After addition was complete, the mixture
was allowed to stand at 0.degree. C. for 15 min with occasional
swirling. The ethereal layer was transferred in portions to a
suspension of 2-acetoxy-2-(diethoxyphosphoryl)acetic acid (5.50 g,
21.6 mmol) in ether (ca. 50 mL) until the solid had completely
dissolved and a yellow color persisted. The reaction was allowed to
stand at 0.degree. C. for 15 min before bubbling nitrogen through
the solution to remove unreacted diazomethane. The reaction was
concentrated to give 5.90 g (quant.) as a faint yellow oil.
.sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 1.36 (td, J=7.0, 2.4,
6H), 2.21 (s, 3H), 3.82 (s, 3H), 4.23 (m, 4H), 5.43 (d, J=16.8,
1H). Mass spec.: 269.17 (MH).sup.+.
(.+-.)-tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-yl)ethylcarbamate
[0668] 260
[0669]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (48 mg, 0.101 mmol),
3-(chloromethyl)pyridine (18.3 mg, 0.11 mmol, 1.05 equiv), and
cesium carbonate (99.0 mg, 0.303 mmol) were combined in
dimethylformamide (1.5 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 51.0 mg (92%). Mass spec.: 563.3
(MH).sup.+.
EXAMPLE 91
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(pyridin-3-ylmethyl)-1H-imidaz-
ol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
amide
[0670] 261
[0671] tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-yl)ethylcarbamate
(51.0 mg, 0.091 mmol) was dissolved in a minimum amount of ethyl
acetate, and treated with hydrochloric acid (4 N in dioxane, 1.5
mL). The mixture was stirred under nitrogen for 3 days. After
removal of the solvents, the crude mixture was treated with diethyl
ether to give a precipitate which was filtered. The resulting solid
was dissolved in dimethylformamide (1.0 mL), cooled to 0.degree.
C., and treated with carbonyl diimidazole (17.2 mg, 0.106 mmol,
1.05 equiv) and N'N-diisopropylethylamine (53.0 .mu.L, 3 equiv).
The reaction was stirred for 5 min at 0.degree. C., warmed to room
temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (28.3 mg, 0.106
mmol, 1.05 equiv). The mixture was stirred at room temperature
overnight. The solvent was evaporated and the residue purified by
column chromatography to afford 23.2 mg (43%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.50-1.67 (m, 4H), 2.45 (s, 3H),
2.68-2.72 (m, 2H), 3.71-3.79 (m, 3H), 4.01-4.15 (m, 2H), 4.20 (s,
2H), 4.31-4.43 (m, 1H), 5.16-5.35 (m, 3H), 6.80 (d, J=7.9, 1H),
6.84 (s, 1H), 6.93-7.21 (m, 8H), 7.26 (s, 1H), 7.92 (s, 1H), 8.27
(s, 1H), 8.32 (s, 1H). Mass spec.: 590.3 (MH).sup.+.
(.+-.)-tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-yl)ethylcarbamate
[0672] 262
[0673]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (35.0 mg, 0.074 mmol),
2-(chloromethyl)pyridine (13.3 mg, 0.082 mmol, 1.05 equiv), and
cesium carbonate (72.3 mg, 0.22 mmol) were combined in
dimethylformamide (1.5 mL). After stirring at room temperature for
16 h, the solvents were removed and the residue purified by column
chromatography to afford 35.2 mg (77%). Mass spec.: 563.3
(MH).sup.+.
EXAMPLE 92
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-(pyridin-2-ylmethyl)-1H-imidaz-
ol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carbox-
amide
[0674] 263
[0675] tert-Butyl
2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-inda-
zol-5-yl)-1-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-yl)ethylcarbamate
(35.2 mg, 0.063 mmol) was dissolved in a minimum amount of ethyl
acetate, and treated with hydrochloric acid (4 N in dioxane, 1.0
mL). The mixture was stirred under nitrogen overnight. After
removal of the solvents, the crude mixture was treated with diethyl
ether to give a precipitate which was filtered. The resulting solid
was dissolved in dimethylformamide (1.0 mL), cooled to 0.degree.
C., and treated with carbonyl diimidazole (11.0 mg, 0.066 mmol,
1.05 equiv) and diisopropylethylamine (44.0 .mu.L, 4.0 equiv). The
reaction was stirred for 5 min at 0.degree. C., warmed to room
temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (17.6 mg, 0.066
mmol, 1.05 equiv). The mixture was stirred at room temperature
overnight. The solvent was evaporated and the residue purified by
column chromatography to afford 4.6 mg (12%, 2 steps). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.48-1.65 (m, 4H), 2.03 (s, 1H), 2.45
(s, 3H), 2.69-2.82 (m, 2H), 3.99-4.16 (m, 2H), 4.19 (s, 2H), 5.24
(d, J=16.5, 1H), 6.67 (d, J=7.6, 1H), 6.80 (d, J=7.9, 1H), 6.89 (s,
1H), 6.97 (dd, J=8.2, 7.6, 1H), 7.10-7.23 (m, 5H), 7.30 (s, 1H),
7.37-7.42 (m, 1H), 7.94 (s, 1H). Mass spec.: 590.3 (MH).sup.+.
(2-Chloro-6-methylpyridin-4-yl)methanol
[0676] 264
[0677] 2-Chloro-6-methylpyridine-4-carboxylic acid (0.52 g, 3.04
mmol) and borane-tetrahydrofuran complex (6.08 mL, 6.08 mmol) were
combined in tetrahydrofuran (10.0 mL) at 0.degree. C. After 15 min,
the ice bath was removed and mixture stirred at room temperature
for 4 h. The mixture was cooled to 0.degree. C., and treated with
methanol until no bubbles were observed. The solvents were removed
and the crude mixture dissolved in ethyl acetate which was washed
with water (2.times.), brine (2.times.), dried over sodium sulfate,
and concentrated to afford 0.25 g (53%) which was used without
purification. .sup.1H-NMR (CDCl.sub.3, 500 MHz) .delta. 2.53 (s,
3H), 4.7 (s, 2H), 7.06 (s, 1H), 7.15 (s, 1H). Mass spec.: 158.0
(MH).sup.+.
2-Chloro-4-(chloromethyl)-6-methylpyridine
[0678] 265
[0679] (2-Chloro-6-methylpyridin-4-yl)methanol (0.212 g, 1.35 mmol)
and thionyl chloride (0.12 mL, 1.62 mmol) were combined in
methylene chloride (4 mL) and stirred at room temperature for 4 h.
The solvents were removed and the product dried under vacuum for
several hours to afford 0.24 g (quant.) as a clear oil which was
used without purification. Mass spec.: 176.0 (MH).sup.+.
(.+-.)-tert-Butyl
1-(1-((2-chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-
-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)et-
hylcarbamate
[0680] 266
[0681]
tert-Butyl-1-(1H-imidazol-2-yl)-2-(7-methyl-2-[{2-[trimethylsilyl]e-
thoxy}methyl]-2H-indazol-5-yl)ethylcarbamate (0.1 g, 0.212 mmol),
2-chloro-4-(chloromethyl)-6-methylpyridine (39.0 mg, 0.222 mmol,
1.05 equiv), and cesium carbonate (0.21 g, 0.64 mmol) were combined
in dimethylformamide (2.0 mL). After stirring at room temperature
for 16 h, the solvents were removed and the residue purified by
column chromatography to afford 0.1 g (77%). Mass spec.: 611.21
(MH).sup.+.
EXAMPLE 93
(.+-.)-N-(1-(1-((2-Chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-
-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-
piperidine-1-carboxamide
[0682] 267
[0683] tert-Butyl
1-(1-((2-chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-
-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)et-
hylcarbamate (100 mg, 0.16 mmol) was dissolved in a minimum amount
of ethyl acetate, and treated with hydrochloric acid (4 N in
dioxane, 2.0 mL). The mixture was stirred under nitrogen overnight.
After removal of the solvents, the crude mixture was treated with
diethyl ether to give a precipitate which was filtered. The
resulting solid was dissolved in dimethylformamide (1.0 mL), cooled
to 0.degree. C., and treated with carbonyl diimidazole (27.0 mg,
0.165 mmol, 1.05 equiv) and N'N-diisopropylethylamine (66.0 .mu.L,
3.0 equiv). The reaction was stirred for 5 min at 0.degree. C.,
warmed to room temperature, stirred for 10 min, and treated with
3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1- H)-one (44.0 mg,
0.165 mmol, 1.05 equiv). The mixture was stirred at room
temperature overnight. The solvent was evaporated and the residue
purified by column chromatography to afford 67.1 mg (65%, 2 steps).
.sup.1H-NMR (CD.sub.3OD, 500 MHz) .delta. 1.43-1.62 (m, 4H), 2.27
(s, 3H), 2.46 (s, 3H), 2.65-2.77 (m, 3H), 3.22-3.30 (m, 1H),
3.95-4.07 (m, 2H), 4.19 (s, 2H), 4.30-4.38 (m, 1H), 5.14-5.37 (m,
3H), 6.61 (s, 1H), 6.70 (s, 1H), 6.80 (d, J=7.9, 1H), 6.88 (s, 1H),
6.96 (dd, J=7.6, 7.3, 1H), 7.10 (s, 1H), 7.13 (s, 1H), 7.14-7.20
(m, 2H), 7.28 (s, 1H). Mass spec.: 638.1 (MH).sup.+.
EXAMPLE 94
(.+-.)-N-(2-(7-Methyl-1H-indazol-5-yl)-1-(1-((2-methylpyridin-4-yl)methyl)-
-1H-imidazol-2-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-
e-1-carboxamide
[0684] 268
[0685]
N-(1-(1-((2-Chloro-6-methylpyridin-4-yl)methyl)-1H-imidazol-2-yl)-2-
-(7-methyl-1H-indazol-5-yl)ethyl)-4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidine-1-carboxamide (15.0 mg, 0.024 mmol) in methanol
(1.0 mL) was flushed with nitrogen, and treated with palladium (10%
on charcoal, 1.5 mg). The flask was flushed with hydrogen and
allowed to stir under an atmosphere of hydrogen overnight. After 24
h, the reaction was charged with additional palladium (10% on
charcoal, 1.5 mg). The flask was flushed with hydrogen and allowed
to stir under an atmosphere of hydrogen overnight. The reaction was
flushed with nitrogen, filtered through celite, and concentrated in
vacuo. Column chromatography gave 2.4 mg (17%). .sup.1H-NMR
(CD.sub.3OD, 500 MHz) .delta. 1.49-1.63 (m, 4H), 2.32 (s, 3H), 2.43
(s, 3H), 2.69-2.78 (m, 2H), 3.98-4.12 (m, 2H), 5.11-5.24 (m, 3H),
5.39 (d, J=17.1, 1H), 6.55 (d, J=0.9, 1H), 6.72 (s, 1H), 6.80 (d,
J=7.9, 1H), 6.85 (s, 1H), 6.97 (dd, J=7.6, 7.3, 1H), 7.06 (s, 1H),
7.10-7.76 (m, 6H), 8.03 (d, J=5.2, 1H). Mass spec.: 604.96
(MH).sup.+.
4-Tert-Butyl 1-methyl
2-((7-methyl-1H-indazol-5-yl)methyl)succinate
[0686] 269
[0687] To a solution of
4-methoxy-3-((7-methyl-1H-indazol-5-yl)methyl)-4-o- xobutanoic acid
(0.9764 g, 3.54 mmol) and t-butyl-2,2,2-trichloroacetoimid- ate
(3.78 mL, 21.22 mmol) in tetrahydrofuran (25 mL) was added 1M boron
trifluoride etherate (0.2 mL) at room temperature. Heat generation
was observed and the reaction was stirred for 3.5 h before passing
it through a pad of silica gel. Evaporation of the filtrate gave a
white solid. Methylene chloride (20 mL) was added and the resulting
white solid was removed by filtration. The filtrate was
concentrated and the final product was obtained via silica gel
chromatography eluting with 0% to 50% ethyl acetate/hexane. (0.605
g, 52%) HPLC t.sub.R=1.51 min, MS(ESI)[M+H].sup.+=332.77.
4-tert-Butyl 1-methyl
2-((7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-
-indazol-5-yl)methyl)succinate
[0688] 270
[0689] To a solution of 4-tert-butyl 1-methyl
2-((7-methyl-1H-indazol-5-yl- )methyl)succinate (0.6053 g, 1.82
mmol) and N-cyclohexyl-N-methylcyclohexa- namine (0.4686 mL, 2.19
mmol) in tetrahydrofuran (10 mL) was added
trimethylsilylethoxymethyl chloride (0.3859 mL, 2.19 mmol) at room
temperature under nitrogen. The reaction was stirred overnight and
the solvent was removed in vacuo. The crude product was taken up in
ethyl acetate (10 mL) and washed with water (3.times.5 mL). The
ethyl acetate layer was dried, filtered and concentrated. The final
product was obtained by flash chromatography, eluting with 0% to
20% ethyl acetate/hexane. (0.5873 g, 70%) HPLC t.sub.R=1.89 min,
MS(ESI)[M+H].sup.+=462.94.
Tert-Butyl
3-(hydroxymethyl)-4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)meth-
yl)-2H-indazol-5-yl)butanoate
[0690] 271
[0691] 4-tert-butyl 1-methyl
2-((7-methyl-2-((2-(trimethylsilyl)ethoxy)met-
hyl)-2H-indazol-5-yl)methyl)succinate (0.5873 g, 1.27 mmol) was
dissolved in tetrahydrofuran (4 mL) and water (1 mL). Lithium
hydroxide (0.1750 g, 5.08 mmol) was added and the reaction was
stirred at room temperature overnight. The tetrahydrofuran was
evaporated and 1 N HCl (2 mL) was added. The acid was extracted
with ethyl acetate (3.times.10 mL) and the ethyl acetate layer was
dried, filtered and concentrated to give the corresponding acid
(0.5214 g, 92%).
[0692] To a solution of the above acid (0.5214 g, 1.16 mmol) in
tetrahydrofuran (10 mL) and triethylamine (0.1942 mL, 1.40 mmol) at
0.degree. C. under nitrogen was added isobutylchloroformate (0.1810
mL, 1.40 mmol). After 1 h, the reaction was allowed to warm to room
temperature and stirred for 4 h. A solution of sodium borohydride
(14 mmol in 5 mL water) was added slowly to the reaction mixture at
room temperature and stirring was continued for a further 2 h.
After concentration in vacuo, the residue was taken up in ethyl
acetate (35 mL) and washed by water (3.times.10 mL). The ethyl
acetate layer was dried, filtered and concentrated. The final
product was obtained by flash chromatography eluting with 0% to 50%
ethyl acetate/hexane (95%). HPLC t.sub.R=1.89 min,
MS(ESI)[M+H].sup.+=434.93. .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta. 7.94 (1H, s), 7.23 (1H, s), 6.89 (1H, s), 5.66 (2H, s),
3.59 (2H, t, J=8.0 Hz), 3.52 (1H, m), 2.69 (1H, m), 2.58 (1H, m),
2.57 (1H, m), 2.56 (3H, s), 2.33-2.23 (3H, m), 1.39 (9H, s), 0.90
(2H, t, J=8.0 Hz), 0.07 (9H, s).
Tert-Butyl
3-formyl-4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-in-
dazol-5-yl)butanoate
[0693] 272
[0694] To a solution of tert-butyl
3-(hydroxymethyl)-4-(7-methyl-2-((2-(tr-
imethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoate (0.5500 g,
1.27 mmol) in methylene chloride (25 mL) was added Dess-Martin
reagent (0.6449 g, 1.52 mmol) at room temperature. The reaction was
stirredo vernight before washing with 1 N sodium hydroxide (10 mL)
and water (2.times.10 mL). The organic layer was dried, filtered
and concentrated. The final product was obtained by flash
chromatography using 0% to 50% ethyl acetate/hexane (0.2773 g, 51%)
HPLC t.sub.R=2.02 min, .sup.1H-NMR (400 MHz, CDCl.sub.3)
.delta.9.42 (1H, s), 7.94 (1H, s), 7.19 (1H, s), 6.82 (1H, s), 5.64
(2H, s), 3.57 (2H, t, J=8.40 Hz), 3.02 (2H, m), 2.58 (1H, m), 2.54
(3H, s), 2.49 (1H, m), 2.30 (1H, m), 1.33 (9H, s), 0.87 (2H, t,
J=8.40 Hz), -0.01 (9H, s).
Tert-butyl
3-(1H-Imidazol-2-yl)-4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)m-
ethyl)-2H-indazol-5-yl)butanoate
[0695] 273
[0696] A solution of tert-butyl
3-formyl-4-(7-methyl-2-((2-(trimethylsilyl-
)ethoxy)methyl)-2H-indazol-5-yl)butanoate (0.64 mmol), glyoxal (1.3
mmol) and ammonium hydroxide (1.3 mmol) in dioxane (10 mL) was
heated at 70.degree. C. for 4 h. The crude product was extracted
with ethyl acetate (3.times.20 mL). The ethyl acetate portions were
combined, dried and filtered. Flash chromatography using 0% to 100%
ethyl acetate/hexane gave the desired product (65%). .sup.1H-NMR
(400 MHz, CDCl.sub.3) .delta. 7.93 (1H, s), 7.15 (1H, s), 6.89 (2H,
s), 6.79 (1H, s), 5.66 (2H, s), 3.60 (2H, t, J=8.40 Hz), 3.55 (1H,
m), 3.16 (1H, dd), 2.97 (1H, dd), 2.70 (1H, dd), 2.60 (1H, dd),
2.52 (3H, s), 1.34 (9H, s), 0.91 (2H, t, J=8.40 Hz), 0.05 (9H, s).
MS(ESI)[M+H].sup.+=471.
Tert-Butyl
3-(1-(4-tert-butylbenzyl)-1H-imidazol-2-yl)-4-(7-methyl-2-((2-(-
trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoate
[0697] 274
[0698] A mixture of tert-butyl
3-(1H-imidazol-2-yl)-4-(7-methyl-2-((2-(tri-
methylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoate (0.16 mmol),
4-tert-butylbenzyl bromide (1.0 equiv), and potassium carbonate
(1.0 equiv) in dimethylformamide (2 mL) was stirred at room
temperature overnight. The mixture was diluted with ethyl acetate
(20 mL) and washed with water (3.times.5 mL). The ethyl acetate
layer was dried, filtered and concentrated in vacuo. The product
was obtained by flash chromatography using 0% to 50% ethyl
acetate/hexane (65%). .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.
7.93 (1H, s), 7.23 (2H, m), 7.03 (2H, m), 6.82 (2H, m), 6.63 (1H,
s), 6.49 (1H,s), 5.68 (2H, s), 4.82 (2H, d, J=4.0 Hz), 3.60 (2H, t,
8.0 Hz), 3.41 (1H, m), 2.86 (2H, d, J=8.0 Hz), 2.79 (1H, dd, J1=8.0
Hz, J2=16 Hz), 2.61 (1H, dd, J1=8.0 Hz, J2=16 Hz), 2.49 (3H, s),
1.31 (9H, s), 1.25 (9H, s), 0.91 (2H, t, J=8.0 Hz), -0.06 (9H,s).
MS(ESI)[M+H]+=617.
EXAMPLE 95
3-(1-(3-(1-(4-tert-Butylbenzyl)-1H-imidazol-2-yl)-4-(7-methyl-3a,7a-dihydr-
o-1H-indazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0699] 275
[0700] A solution of tert-butyl
3-(1-(4-tert-butylbenzyl)-1H-imidazol-2-yl-
)-4-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)butanoa-
te (0.10 mmol) in methylene chloride (1 mL) and trifluoroacetic
acid (1 mL) was stirred at room temperature overnight. The solvents
were removed in vacuo. The crude carboxylic acid was immediately
coupled to 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one as
described above for Example 89 (51%). .sup.1H-NMR (400 MHz,
CDCl.sub.3) .delta. 7.93 (1H, d, J=2.8 Hz), 7.31-6.61 (13H, m),
4.90 (2H, m), 4.64 (1H, m); 4.50 (1H, m); 4.22-3.89 (3H, m), 3.65
(1H, m), 3.26 (1H, m), 2.98 (3H, m), 2.70-2.30 (6H, m), 1.74-1.32
(3H, m), 1.23 (9H, s). MS (ESI)[M+H].sup.+=644.36.
[0701] Similarly prepared:
EXAMPLE 96
3-(1-(3-(1-(4-tert-Butylbenzyl)-1H-imidazol-2-yl)-4-(7-methyl-3a,7a-dihydr-
o-1H-indazol-5-yl)butanoyl)piperidin-4-yl)-8-fluoro-3,4-dihydroquinazolin--
2(1H)-one
[0702] 276
[0703] Yield: 71% .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 7.93
(1H, d, J=2.8 Hz), 7.31-6.61 (12H, m), 4.90 (2H, m), 4.64 (1H, m);
4.50 (1H, m); 4.22-3.89 (3H, m), 3.65 (1H, m), 3.26 (1H, m), 2.98
(3H, m), 2.70-2.30 (6H, m), 1.74-1.32 (3H, m), 1.23 (9H, s).
MS(ESI)[M+H].sup.+=662.34.
EXAMPLE 97
3-(1-(4-(7-Methyl-3a,7a-dihydro-1H-indazol-5-yl)-3-(1-(pyridin-4-ylmethyl)-
-1H-imidazol-2-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0704] 277
[0705] Yield: 81%. .sup.1H-NMR (400 MHz, CDCl.sub.3) .delta. 8.09
(1H, m), 7.93 (1H, s), 7.38-6.90 (6H, m), 6.67-6490 (5H, m), 5.27
(1H, m), 4.82 (1H, m), 4.66-4.52 (2H, m), 4.27-3.99 (3H, m);
3.61-2.51 (7H, m), 2.26 (3H, s), 1.78-1.23 (4H, m). MS
(ESI)[M+H].sup.+=589.16.
N-(2-Aminophenyl)-2-((7-methyl-3a,7a-dihydro-1H-indazol-5-yl)methyl)-4-oxo-
-4-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-1-yl)butanamide
[0706] 278
[0707] A solution of
(.+-.)-2-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)pip-
eridine-1-carboxamido)-3-(7-methyl-1H-indazol-5-yl)propanoic acid
(98.9 mg, 0.21 mmol), benzene-1,2-diamine (46.7 mg, 0.43 mmol) and
triethylamine (0.1 mL, 0.72 mmol) in 1:1 methylene
chloride/dimethylformamide (4 mL) was stirred at room temperature
for 4 h. The solvents were removed in vacuo and the residue was
purified using a 20 g SCX cartridge. The cartridge was washed with
methanol and methylene chloride and the product was eluted using 2M
ammonia in methanol (68%).
EXAMPLE 98
3-(1-(3-(1H-Benzo[d]imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-indazol-5--
yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0708] 279
[0709] A solution of
N-(2-aminophenyl)-2-((7-methyl-3a,7a-dihydro-1H-indaz-
ol-5-yl)methyl)-4-oxo-4-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-
-1-yl)butanamide in 1,2-dichloroethane (8 mL) and acetic acid (1
mL) was heated under nitrogen at 65.degree. C. for 5 h. The solvent
was evaporated and the residue taken up in ethyl acetate (20 mL).
The ethyl acetate layer was washed with 1M sodium hydroxide (5 mL)
and water (2.times.5 mL), dried, filtered and concentrated. The
final product was obtained by flash chromatography using 0% to 10%
2 M ammonia in methanol/methylene chloride.
MS(ESI)[M+H].sup.+=550.
N-(2-(Ethylamino)phenyl)-2-((7-methyl-3a,7a-dihydro-1H-indazol-5-yl)methyl-
)-4-oxo-4-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidin-1-yl)butanami-
de
[0710] 280
[0711] A solution of
N-(2-aminophenyl)-2-((7-methyl-3a,7a-dihydro-1H-indaz-
ol-5-yl)methyl)-4-oxo-4-(4-(2-oxo-1,2-dihydroquinazolin-3
(4H)-yl)piperidin-1-yl)butanamide (0.24 mmol) in methanol (5 mL)
was treated with acetaldehyde (1 mL) at room temperature. The
mixture was stirred for 2 h at room temperature before the solvent
was removed in vacuo. The residue was taken up in methanol (5 mL)
and then sodium borohydride (0.48 mmol) was added. After 30 min,
the methanol was removed in vacuo and the residue was taken up in
methylene chloride (15 mL). The final product was obtained by
filtration through a pad of celite and concentration of the
filtrate. (95%) MS(ESI)[M+H].sup.+=594.
EXAMPLE 99
3-(1-(3-(1-Ethyl-1H-benzo
[d]imidazol-2-yl)-4-(7-methyl-3a,7a-dihydro-1H-i-
ndazol-5-yl)butanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
[0712] 281
[0713] Prepared as described above for Example 93. HPLC
t.sub.R=1.18 min, MS(ESI)[M+H].sup.+=576.16.
Tert-Butyl
(Z)-1-(methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethoxy)methyl)-
-7-methyl-2H-indazol-5-yl)vinylcarbamate
[0714] 282
[0715] To a solution of
2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-i-
ndazole-5-carbaldehyde (4.46 g, 15.4 mmol) and
N-(tert-butoxycarbonyl)-met- hyl-2-(dimethylphosphono)glycinate
(4.80 g, 1.0 equiv) in tetrahydrofuran (40 mL) at room temperature
was added N,N,N'N'-tetramethylguanidine (3.29 mL, 1.7 equiv). The
reaction was allowed to stir at room temperature for 3 days. The
reaction was diluted with ethyl acetate and water, and then poured
into diethyl ether. The organic phase was washed with water
(2.times.), then brine, dried over magnesium sulfate and
concentrated. Column chromatography (30% ethyl
acetate/hexanes->40% ethyl acetate/hexanes) gave 5.90 g (83%) as
a foam. Mass spec.: 462.40 (MH).sup.+.
Methyl
3-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-indazol-5-yl)-2-
-hydroxypropanoate
[0716] 283
[0717] To a solution of tert-butyl
(Z)-1-(methoxycarbonyl)-2-(2-((2-(trime-
thylsilyl)ethoxy)methyl)-7-methyl-2H-indazol-5-yl)vinylcarbamate
(200 mg, 0.43 mmol) in dichloromethane (2 mL) at 0.degree. C. was
added trifluoroacetic acid (1 mL). The ice bath was removed. After
30 min, the reaction was poured into a separatory funnel containing
ethyl acetate and water, neutralized with solid sodium bicarbonate,
and the layers were separated. The organic phase was washed with
saturated sodium bicarbonate, then brine, dried over magnesium
sulfate, and concentrated. The yellow residue was treated with
sodium cyanoborohydride (200 mg, 7.4 equiv) and tetrahydrofuran (2
mL). The reaction was stirred at room temperature overnight,
diluted with ethyl acetate, washed with water (2.times.), then
brine, dried over magnesium sulfate, and concentrated. Column
chromatography on silica gel (25% ethyl acetate/hexanes) gave 20.4
mg (13%) as a light yellow oil. Mass spec.: 365.40 (MH).sup.+.
1-(Methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-in-
dazol-5-yl)ethyl 4-nitrophenyl Carbonate
[0718] 284
[0719] To a solution of methyl
3-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-m-
ethyl-2H-indazol-5-yl)-2-hydroxypropanoate (20 mg, 55 .mu.moles) in
pyridine (1 mL) was added 4-nitrophenylchloroformate (55 mg, 5
equiv). The reaction was stirred at room temperature overnight. The
reaction was treated with an additional portion of
4-nitrophenylchloroformate (30 mg, 2.7 equiv) and stirred at room
temperature for 8 h. The reaction was poured into diethyl ether,
washed with 1M potassium bisulfate, saturated bicarbonate, and 1M
sodium hydroxide until most of the p-nitrophenyl had been removed.
The solution was then washed with brine, dried over sodium sulfate,
and concentrated to give 50 mg (quant.) of a pale yellow solid
which was used immediately in the next reaction. Mass spec.: 530.30
(MH).sup.+.
1-(Methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-in-
dazol-5-yl)ethyl 4-(1,2-dihydro-2-oxoquinazolin-3
(4H)-yl)piperidine-1-car- boxylate
[0720] 285
[0721] A flask was charged with
1-(methoxycarbonyl)-2-(2-((2-(trimethylsil-
yl)ethoxy)methyl)-7-methyl-2H-indazol-5-yl)ethyl 4-nitrophenyl
carbonate (27 mg, 51 mmoles) and
3,4-dihydro-3-(piperidin-4-yl)quinazolin-2(1H)-one (34 mg, 2.8
equiv). The solids were dissolved in dimethylformamide (1 mL) and
treated with diisopropylethylamine (0.1 mL, 11 equiv). The reaction
was stirred at room temperature for 2 d. The reaction was
concentrated, dissolved in ethyl acetate, washed with 20% potassium
hydroxide (3.times.), then brine, dried over magnesium sulfate, and
concentrated. Column chromatography (100% ethyl acetate) removed
baseline material to give 50 mg (quant.). Mass spec.: 622.50
(MH).sup.+.
(R)-1-Methoxy-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol--
5-yl)-1-oxopropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carb- oxylate
[0722] 286
[0723] To a solution of
1-(methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethox-
y)methyl)-7-methyl-2H-indazol-5-yl)ethyl 4-nitrophenyl carbonate
(0.859 mmol) was added
3-(piperidin-4-yl)quinolin-2(1H)-one-hydrochloride (682 mg, 2.58
mmol), in one portion, followed by dropwise addition of
diisopropylethylamine (0.37 mL, 2.15 mmol) at room temperature. The
resulting yellow suspension was stirred at room temperature
overnight. The mixture was extracted with ethyl acetate (2.times.2
mL) and the organic phase was washed with brine and dried over
sodium sulfate. The crude product was purified using preparative
HPLC to afford
(R)-1-methoxy-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-
-5-yl)-1-oxopropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-car- boxylate (157
mg, 30%). Mass spec. 619.24 (MH.sup.+). .sup.1H-NMR (CDCl.sub.3,
400 MHz) .delta. 8.0 (s, 1H), 7.53 (br s, 2H), 7.47-7.43 (m, 1H),
7.34-7.31 (m, 1H), 7.21-7.18 (m, 1H), 6.96 (s, 1H), 5.7 (s, 2H),
5.23 (dd, J=8.6, 4.6 Hz, 1H), 4.28 (br s, 2H), 3.74 (s, 3H), 3.61
(m, 2H), 3.13 (m, 3H), 2.93 (m, 2H), 2.59 (s, 3H), 1.94 (m, 2H),
0.92 (m, 2H), -0.064 (s, 9H).
(R)-3-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-2-(4-
-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carbonyloxy)propanoic
acid
[0724] 287
[0725] Aqueous lithium hydroxide (1M, 130 mL, 0.13 mmol) was added
dropwise to a stirred solution of
(R)-1-methoxy-3-(7-methyl-2-((2-(trimet-
hylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-oxopropan-2-yl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (40 mg,
0.0646 mmol) in dioxane (2 mL) at 0.degree. C., and the mixture was
stirred for 2 h. The reaction was quenched with 1N hydrochloric
acid, poured into ethyl acetate (30 mL), washed with brine (10 mL),
dried over magnesium sulfate and concentrated in vacuo to afford a
tan foamy solid (32 mg, 82%), which was used without further
purification. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 8.02
(s,1H), 7.60 (s,1H), 7.52-7.32 (m, 3H), 7.29-7.13 (m, 2H), 7.05
(s,1H), 5.71 (s,2H), 5.29 (dd, J=9.0, 3.8 Hz, 1H), 4.28 (br, 2H),
3.34 (br, 2H), 3.34 (dd, J=14.1, 3.9 Hz, 2H), 3.21 (dd, J=14.4, 9.2
Hz, 2H) 3.13-2.75 (m, 4H), 2.60 (s, 3H), 1.95-1.72 (m, 4H),
0.95-1.85 (m, 2H), 0.051 (s, 9H). Mass spec. 605.34 (MH.sup.+).
(R)-1-(3-(Ethoxycarbonyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-2-((2-(trimeth-
ylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-- 3-yl)piperidine-1-carboxylate
[0726] 288
[0727] A stirred solution of
(R)-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)-
methyl)-2H-indazol-5-yl)-2-(4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-
-carbonyloxy)propanoic acid (28.5 mg, 0.0471 mmol) in anhydrous
diglyme (2.5 mL) was treated with ethyl
2-amino-2-(hydroxyimino)acetate (6.54 mg, 0.0495 mmol) and
1-[3-(dimethylamino)propyl]3-ethylcarbodiimide hydrochloride (0.49
mg, 0.0495 mmol) at room temperature. The mixture was stirred
overnight at room temperature and then overnight at 110.degree. C.
After cooling to room temperature and removal of the solvent in
vacuo, the crude compound was purified using preparative HPLC to
afford a tan gum (11.2 mg, 34%). .sup.1H-NMR (CDCl.sub.3, 400 MHz)
.delta. 8.0 (s,1H), 7.58 (s, 1H), 7.57 (s, 1H), 7.46 (m, 1H), 7.30
(s,1H), 7.24-7.20 (m, 2H), 6.93 (s,1H), 6.17-6.15 (m, 1H), 5.71 (s,
2H), 4.50-4.48 (m, 2H), 4.29-4.20 (m, 2H), 3.65-3.55 (m, 2H),
3.40-3.38 (m, 2H), 3.20-2.81 (m, 4H), 2.59 (s, 3 h), 2.03-1.72 (m,
4H), 1.44-1.38 (m, 3H), 0.95-0.86 (m, 2H), -0.045 (s, 9H). Mass
spec. 701.22 (MH.sup.+).
(R)-1-(3-(Hydroxymethyl)-2,3-dihydro-1,2,4-oxadiazol-5-yl)-2-(7-methyl-2-(-
(2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0728] 289
[0729] Solid lithium borohydride (1.5 mg, 0.0689 mmol) was added to
a stirred solution of
(R)-1-(3-(ethoxycarbonyl)-1,2,4-oxadiazol-5-yl)-2-(7--
methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (2.3 mg,
0.00328 mmol) in ethanol (2 mL) at room temperature. The mixture
was stirred for 3 h, and then quenched with saturated ammonium
chloride and extracted with methylene chloride (15 mL). The organic
layer was washed with brine (5 mL), dried over magnesium sulfate,
and concentrated in vacuo to afford the expected product (2.02 mg,
94%). Mass spec. 661.45(MH.sup.+).
(R)-1-(3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-2-((2-(trimeth-
ylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-- 3-yl)piperidine-1-carboxylate
[0730] 290
[0731] A stirred solution of
(R)-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)-
methyl)-2H-indazol-5-yl)-2-(4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-
-carbonyloxy)propanoic acid (22.4 mg, 0.0370 mmol) in anhydrous
diglyme (2 mL) was treated with 4-fluorobenzamidoxime (5.3 mg,
0.0389 mmol) and 1-[3-(dimethylamino)propyl]3-ethylcarbodiimide
hydrochloride (7.5 mg, 0.0389 mmol) to at room temperature. The
mixture was stirred overnight. The stirred mixture was then heated
to 110.degree. C. overnight. After cooling to room temperature, the
solvent was removed in vacuo and the crude product was purified
using preparative HPLC to afford a tan gum (16.2 mg, 61%).
.sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 8.8.06 (bs, 2H), 7.88 (s,
1H), 7.69-7.46 (m, 2H), 7.40 (s, 1H), 7.35-7.20 (m,2H), 7.18-7.07
(m, 2H), 7.07 (s, 1H), 6.19-6.15 (m, 1H), 5.79 (s, 2H), 4.40-4.20
(m, 2H), 3.55-3.40 (m, 4H), 3.20-2.83 (m, 4H), 2.70 (s, 3H),
2.72-2.35 (m, 2H), 2.08-1.9 (m, 2H), 0.90-0.77 (m, 2H), -0.11 (s,
9H). Mass spec. 723.3 (MH.sup.+).
[0732] The following intermediates were similarly prepared:
(R)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(3-
-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinazolin-- 3
(4H)-yl)piperidine-1-carboxylate
[0733] 291
[0734] Yield: 58%. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 8.95
(d, J=3.2 Hz, 2H), 8.48 (s, 1H), 8.38 (d, J=5.6 Hz, 2H), 7.92
(s,1H), 7.39 (d, J=6.8 Hz, 1H), 7.22-7.18 (m,1H), 7.10-6.96 (m,
2H), 6.76 (d, J=7.6 Hz, 1H), 6.16 (overlaping dd, J=6.8, 6.8 Hz,
1H), 5.79 (s, 2H), 4.50-4.20 (m, 5H), 3.65-3.55 (m, 2H), 3.40-3.38
(m, 2H), 3.20-2.81 (m, 4H), 2.59 (s, 3H), 2.03-1.72 (m, 4H),
0.90-0.82 (m, 2H), -0.112 (s, 9H). Mass spec. 709.34
(MH.sup.+).
(R)-2-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-(3-
-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-- yl)piperidine-1-carboxylate
[0735] 292
[0736] Yield: 43%. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 9.65
(s,1H), 9.42 (s, 1H), 9.02 (s, 1H), 8.85-8.70 (m, 2H), 7.93 (s,
1H), 7.88-7.70 (m, 2H), 7.65-7.50 (m, 2H), 7.40 (s, 1H), 7.09
(s,1H), 6.22-6.15 (m, 1H), 5.81 (s, 2H), 4.40-4.22 (m, 2H),
3.56-3.42 (m, 4H), 3.17-2.85 (m, 4H), 2.72 (s, 3H), 2.05-1.75 (m,
4H), 0.88-0.76 (m, 2H), -0.12 (s, 9H). Mass spec. 706.33
(MH.sup.+).
EXAMPLE 100
(R)-1-(3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-1H-indazol-5-y-
l)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0737] 293
[0738] A stirred solution of
(R)-1-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-y-
l)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (16.2
mg, 0.0224 mmol) in 1:1 trifluoroacetic acid/methylene chloride 91
mL) was stirred at room temperature for 2 h. Removal of the
solvents in vacuo followed by purification using preparative HPLC
afforded a tan gum (8.6 mg, 65%). .sup.1H-NMR (CDCl.sub.3, 400 MHz)
.delta. 8.22 (s, 1H), 8.12-8.01 (m,2H), 7.80 (s, 1H), 7.76-7.45 (m,
5H), 7.35-7.45 (m, 2H), 7.30 (s,1H), 7.20-7.07 (m,2H), 6.28-6.15
(m,1H), 4.42-4.25 (m,2H), 3.57-3.45 (m,2H) 3.31-2.85 (m, 4H), 2.60
(s,3H), 2.09-1.88 (m,2H), 1.70-1.53 (m,2H). Mass spec. 593.28
(MH.sup.+).
[0739] The following Examples were similarly prepared:
EXAMPLE 101
(R)-2-(7-Methyl-1H-indazol-5-yl)-1-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)-
ethyl
4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxylate
[0740] 294
[0741] Yield: 56%. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 8.97
(bs, 2H), 8.61 (bs,2H), 7.49-7.42 (m, 1H), 7.35-7.15 (m, 2H), 7.20
(s,1H), 7.06-6.97 (m,2H), 6.80-6.73 (m,1H), 6.32-6.12 (m,1H),
4.42-4.17 (m, 5H), 3.57-3.40 (m,2H), 3.15-2.85 (m, 2H), 2.60
(s,3H), 1.95-1.68 (m,2H). Mass spec. 579.13 (MH.sup.+).
EXAMPLE 102
(R)-2-(7-Methyl-1H-indazol-5-yl)-1-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-
ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0742] 295
[0743] Yield: 56%. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 9.45
(s,1H), 9.27 (s,1H), 8.96 (d, J=9.6 Hz, 1H), 8.81 (d, J=7.6 Hz,
1H), 8.17 (s, 1H), 7.87 (dd, J=7.6, 5.6 Hz, 1H), 7.72-7.42 (m, 5H),
7.37 (d, J=7.6 Hz, 1H), 6.20 (m, 1H), 4.42-4.18 (m, 2H), 3.53-3.42
(m, 2H), 3.15-2.82 (m, 3H), 2.58 (s, 3H), 2.08-1.90 (m, 2H),
1.85-1.35 (m, 2H). Mass spec. 576.29 (MH.sup.+).
EXAMPLE 103
(R)-1-(3-(Ethoxycarbonyl)-1,2,4-oxadiazol-5-yl)-2-(7-methyl-1H-indazol-5-y-
l)ethyl
4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate
[0744] 296
[0745] Yield: 100%. .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 8.22
(s, 1H), 7.91 (s, 1H), 7.72-7.59 (m, 2H), 7.54-7.38 (m, 4H),
6.27-6.13 (m, 1H), 4.56-4.45 (m, 2H), 4.26 (q, J=12.4 Hz, 2H),
3.56-3.42 9 m, 2H), 3.20-2.83 (m, 3H), 2.74 (s, 1H), 2.68-2.54 (m,
3H), 2.03-1.88 (m, 2H), 1.75-1.52 (m, 2H), 1.44 (t, J=11.6 Hz).
Mass spec. 571.19 (MH.sup.+).
[0746] CGRP Binding Assay
[0747] Tissue Culture. SK-N-MC cells were grown at 37.degree. C. in
5% CO.sub.2 as a monolayer in medium consisting of MEM with Earle's
salts and L-glutamine (Gibco) supplemented with 10% fetal bovine
serum (Gibco).
[0748] Cell Pellets. The cells were rinsed twice with
phosphate-buffered saline (155 mM NaCl, 3.3 mM Na.sub.2HPO.sub.4,
1.1 mM KH.sub.2PO.sub.4, pH 7.4), and incubated for 5-10 min. at
4.degree. C. in hypotonic lysis buffer consisting of 10 mM Tris (pH
7.4) and 5 mM EDTA. The cells were transferred from plates to
polypropylene tubes (16.times.100 mm) and homogenized using a
polytron. Homogenates were centrifuged at 32,000.times.g for 30
min. The pellets were resuspended in cold hypotonic lysis buffer
with 0.1% mammalian protease inhibitor cocktail (Sigma) and assayed
for protein concentration. The SK-N-MC homogenate was then
aliquoted and stored at -80.degree. C. until needed.
[0749] Radioligand Binding Assay. The compounds of invention were
solubilized and carried through serial dilutions using 100% DMSO.
Aliquots from the compound serial dilutions were further diluted 25
fold into assay buffer (50 mM Tris-Cl pH 7.5, 5 mM MgCl.sub.2,
0.005% Triton X-100) and transferred (volume 50 .mu.l) into 96 well
assay plates. [.sup.125I]-CGRP (Amersham Biosciences) was diluted
to 60 pM in assay buffer and a volume of 50 .mu.l was added to each
well. SK-N-MC pellets were thawed, diluted in assay buffer with
fresh 0.1% mammalian protease inhibitor cocktail (Sigma), and
homogenized again. SK-N-MC homogenate (5 .mu.g/well) was added in a
volume of 100 .mu.l. The assay plates were then incubated at room
temperature for 2 h. Assays were stopped by addition of excess cold
wash buffer (20 mM Tris-Cl pH 7.5, 0.1% BSA) immediately followed
by filtration over glass fiber filters (Whatman GF/B) previously
soaked in 0.5% PEI. Non-specific binding was defined with 1 .mu.M
beta-CGRP. Protein bound radioactivity was determined using a gamma
or scintillation counter. The IC.sub.50 was defined as the
concentration of a compound of invention required to displace 50%
of radioligand binding.
1TABLE 1 A < 10 nm, B 10 nM < 100 nm, C 100 nM < 1,000 nM
Example Human CGRP1 Number Receptor IC.sub.50, nM 1 A 2 A 3 B 4 B 5
B 6 B 7 B 8 B 9 C 10 A 11 B 12 B 13 C 14 C 15 A 16 B 17 B 18 A 19 A
20 B 21 B 22 B 23 B 24 B 25 A 26 B 27 A 28 A 29 A 30 A 31 A 32 A 33
A 34 A 35 A 36 A 37 B 38 A 39 A 40 A 41 C 42 C 43 B 44 A 45 A 46 A
47 A 48 B 49 A 50 A 51 A 52 A 53 A 54 A 55 A 56 B 57 C 58 C 59 C 60
B 61 A 62 C 63 C 64 B 65 B 66 A 67 A 68 A 69 A 70 A 71 A 72 A 73 A
74 A 75 A 76 A 77 A 78 A 79 A 80 C 81 A 82 B 83 A 84 A 85 A 86 A 87
A 88 A 89 A 90 C 91 A 92 A 93 A 94 A 95 A 96 A 97 A 98 A 99 A 100 C
101 B 102 B 103 B
* * * * *